sampleid	submitted_name	run_prefix	experimental_strategy	cgc_base_name	filename	analyte_amount	analyte_A260A280Ratio	aliquot_concentration	cgc_id	cgc_filename	vital_status	gender	race	ethnicity	disease_type	data_subtype	tcga_sample_id	cgc_case_uuid	sample_type	cgc_platform	gdc_file_uuid	primary_site	age_at_diagnosis	cgc_sample_uuid	cgc_aliquot_uuid	tcga_aliquot_id	reference_genome	tcga_case_id	investigation	days_to_death	knightlabID	data_submitting_center_label	tissue_source_site_label	country_of_sample_procurement	portion_is_ffpe	pathologic_t_label	pathologic_n_label	histological_diagnosis_label	pathologic_stage_label	PlateCenter	PlateCenterFlag
13722.58cfa82fe4b0c9d6adf6b8f4	58cfa82fe4b0c9d6adf6b8f4	TCGA-A7-A0DC-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A7-A0DC-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_2_rg.sorted	TCGA-A7-A0DC-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_2_rg.sorted.bam	6.58	NA	0.15	58cfa82fe4b0c9d6adf6b8f4	TCGA-A7-A0DC-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A7-A0DC-01B	CB9F5E50-F49D-4899-8895-9367AFCC1015	Primary Tumor	Illumina HiSeq	b8f1a569-bcd5-4da4-a1ea-ae76c98a5d91	Breast	63	00B54C99-C26D-423A-9871-2552C1603A9C	A253B105-73B8-4E33-8870-B31CCFB02847	TCGA-A7-A0DC-01B-04D-A22S-26	HG19_Broad_variant	TCGA-A7-A0DC	TCGA-BRCA	NA	s6121	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	None	YES	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A22S-26	FALSE
13722.58cfa830e4b0c9d6adf6be66	58cfa830e4b0c9d6adf6be66	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted.bam	17.47	NA	0.15	58cfa830e4b0c9d6adf6be66	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A3PT-01A	29C4319C-3EAD-42B1-810D-418DA8D515C4	Primary Tumor	Illumina HiSeq	0d7263bd-8ffa-4ba1-93c4-0444afd9b56e	Thyroid	51	8C112A5F-AE83-4B13-8E00-802382729344	EC6A8D75-A25A-4179-BAF4-53607841AC09	TCGA-BJ-A3PT-01A-12D-A221-26	HG19_Broad_variant	TCGA-BJ-A3PT	TCGA-THCA	NA	s12747	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	TRUE
13722.58cfa831e4b0c9d6adf6c7cb	58cfa831e4b0c9d6adf6c7cb	TCGA-CX-7085-01A-21D-2317_120710_SN590_0166_AC0VNFACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CX-7085-01A-21D-2317_120710_SN590_0166_AC0VNFACXX_s_3_rg.sorted	TCGA-CX-7085-01A-21D-2317_120710_SN590_0166_AC0VNFACXX_s_3_rg.sorted.bam	262.73	NA	0.15	58cfa831e4b0c9d6adf6c7cb	TCGA-CX-7085-01A-21D-2317_120710_SN590_0166_AC0VNFACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CX-7085-01A	2A7B4613-F908-4E78-98ED-857DCD7ED774	Primary Tumor	Illumina HiSeq	2a118e3e-c8f9-43b4-b1d7-4659e37a96ce	Head and Neck	77	A07E086C-1D2D-4D92-A663-ECD7EA4DBD73	57FA3BBB-D571-475C-95A2-AAEDFF4835FC	TCGA-CX-7085-01A-21D-2317-26	HG19_Broad_variant	TCGA-CX-7085	TCGA-HNSC	NA	s16056	MD Anderson - Institute for Applied Cancer Science	Medical College of Georgia	United States	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c8ea	58cfa831e4b0c9d6adf6c8ea	TCGA-CV-7411-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CV-7411-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_5_rg.sorted	TCGA-CV-7411-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_5_rg.sorted.bam	80.73	NA	0.16	58cfa831e4b0c9d6adf6c8ea	TCGA-CV-7411-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7411-01A	600FC87B-A177-4BF9-9084-457F7E7E102C	Primary Tumor	Illumina HiSeq	7db9b308-952d-4c12-98c4-9de1f4b9fbd2	Head and Neck	64	24876E1A-E07E-4F74-86BF-3395A88CE4A1	221E7B51-6E05-45A9-99AC-EB705D3B2AD8	TCGA-CV-7411-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7411	TCGA-HNSC	2717	s15526	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6cb00	58cfa831e4b0c9d6adf6cb00	TCGA-EA-A3QE-01A-21D-A245_140124_SN1440_0178_AC2PL6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EA-A3QE-01A-21D-A245_140124_SN1440_0178_AC2PL6ACXX_s_5_rg.sorted	TCGA-EA-A3QE-01A-21D-A245_140124_SN1440_0178_AC2PL6ACXX_s_5_rg.sorted.bam	67	NA	0.14	58cfa831e4b0c9d6adf6cb00	TCGA-EA-A3QE-01A-21D-A245_140124_SN1440_0178_AC2PL6ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3QE-01A	A4E444B5-BBCA-4EF0-B92F-908D608CBB91	Primary Tumor	Illumina HiSeq	14055776-9bfb-42c1-a760-39fb0c8dba92	Cervix	45	36FFA53D-1404-49C0-B9C1-A3EB1ECBC6B9	80A263E0-9F91-48FD-B53C-7E2A25710BF3	TCGA-EA-A3QE-01A-21D-A245-26	HG19_Broad_variant	TCGA-EA-A3QE	TCGA-CESC	NA	s1524	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1b	N0	Cervical Squamous Cell Carcinoma	Not available	A245-26	TRUE
13722.58cfa831e4b0c9d6adf6cb04	58cfa831e4b0c9d6adf6cb04	TCGA-EA-A3HT-01A-61D-A245_140124_SN1440_0178_AC2PL6ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EA-A3HT-01A-61D-A245_140124_SN1440_0178_AC2PL6ACXX_s_2_rg.sorted	TCGA-EA-A3HT-01A-61D-A245_140124_SN1440_0178_AC2PL6ACXX_s_2_rg.sorted.bam	54.34	NA	0.15	58cfa831e4b0c9d6adf6cb04	TCGA-EA-A3HT-01A-61D-A245_140124_SN1440_0178_AC2PL6ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HT-01A	3C5B2452-014B-495F-B86A-F522ED84BC3B	Primary Tumor	Illumina HiSeq	e0e70b08-26f3-48d5-80c3-4836e9faa569	Cervix	68	8460C1E5-0029-4D66-AF11-373324347800	CE1A5984-E350-46A3-BF53-B32DEC8F8AF0	TCGA-EA-A3HT-01A-61D-A245-26	HG19_Broad_variant	TCGA-EA-A3HT	TCGA-CESC	NA	s1182	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1b	N0	Cervical Squamous Cell Carcinoma	Not available	A245-26	TRUE
13722.58cfa831e4b0c9d6adf6cc4c	58cfa831e4b0c9d6adf6cc4c	TCGA-EA-A1QS-01A-61D-A232_140124_SN208_0506_BC2PD5ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EA-A1QS-01A-61D-A232_140124_SN208_0506_BC2PD5ACXX_s_2_rg.sorted	TCGA-EA-A1QS-01A-61D-A232_140124_SN208_0506_BC2PD5ACXX_s_2_rg.sorted.bam	36.95	NA	0.15	58cfa831e4b0c9d6adf6cc4c	TCGA-EA-A1QS-01A-61D-A232_140124_SN208_0506_BC2PD5ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A1QS-01A	6F9D21C0-3B88-450D-A249-3E9BAFBA2DFA	Primary Tumor	Illumina HiSeq	c7f62ea9-e05f-40ea-9e4c-1771bd722b74	Cervix	46	8389C79E-164E-4462-ADCD-364DB3AFB463	109962B4-F4A5-4C72-B902-92516110FE7E	TCGA-EA-A1QS-01A-61D-A232-26	HG19_Broad_variant	TCGA-EA-A1QS	TCGA-CESC	NA	s1361	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1b1	N0	Cervical Squamous Cell Carcinoma	Not available	A232-26	TRUE
13722.58cfa831e4b0c9d6adf6cd09	58cfa831e4b0c9d6adf6cd09	TCGA-EX-A3L1-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EX-A3L1-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_6_rg.sorted	TCGA-EX-A3L1-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_6_rg.sorted.bam	44.57	NA	0.14	58cfa831e4b0c9d6adf6cd09	TCGA-EX-A3L1-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EX-A3L1-01A	F5D90810-8C4B-4CED-9360-383E42CB54B3	Primary Tumor	Illumina HiSeq	73141d26-4c6a-46e1-ab5f-b431f2f35c23	Cervix	32	89AD6395-973B-4011-BFBD-6759209406BE	6F24A0BE-76D7-4388-B73A-32BE2E902470	TCGA-EX-A3L1-01A-11D-A245-26	HG19_Broad_variant	TCGA-EX-A3L1	TCGA-CESC	NA	s1530	MD Anderson - Institute for Applied Cancer Science	University of North Carolina	United States	NO	T2a1	N0	Cervical Squamous Cell Carcinoma	Not available	A245-26	TRUE
13722.58cfa831e4b0c9d6adf6ccdf	58cfa831e4b0c9d6adf6ccdf	TCGA-EM-A3O7-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EM-A3O7-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_1_rg.sorted	TCGA-EM-A3O7-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_1_rg.sorted.bam	34.81	NA	0.15	58cfa831e4b0c9d6adf6ccdf	TCGA-EM-A3O7-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A3O7-01A	3A211D5A-085F-4902-86B6-50E4EB36B897	Primary Tumor	Illumina HiSeq	c3515173-4e8f-4198-a9de-0bf2232c3fbd	Thyroid	46	362F0CC2-B884-404B-8DF1-2BFC2A75E9C3	AF35D79C-4F32-4B6E-8FDE-BDA9D715A542	TCGA-EM-A3O7-01A-11D-A221-26	HG19_Broad_variant	TCGA-EM-A3O7	TCGA-THCA	NA	s12383	MD Anderson - Institute for Applied Cancer Science	University Health Network	Canada	NO	T3	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	TRUE
13722.58cfa831e4b0c9d6adf6cd9c	58cfa831e4b0c9d6adf6cd9c	TCGA-FD-A3SR-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FD-A3SR-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_7_rg.sorted	TCGA-FD-A3SR-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_7_rg.sorted.bam	39.24	NA	0.14	58cfa831e4b0c9d6adf6cd9c	TCGA-FD-A3SR-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SR-01A	72D6E9AA-4A99-4FC9-A67B-4631E95FB043	Primary Tumor	Illumina HiSeq	e8c95d25-27f4-4cba-b644-eb39019c6cc0	Bladder	68	8E9683F4-52B4-4646-921E-7BF89F56774A	93A2B3C4-915C-46BE-9D36-C244036B7A0C	TCGA-FD-A3SR-01A-11D-A233-26	HG19_Broad_variant	TCGA-FD-A3SR	TCGA-BLCA	602	s3116	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T4a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	TRUE
13722.58cfa832e4b0c9d6adf6ce58	58cfa832e4b0c9d6adf6ce58	TCGA-FU-A3HY-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FU-A3HY-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_7_rg.sorted	TCGA-FU-A3HY-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_7_rg.sorted.bam	37.56	NA	0.16	58cfa832e4b0c9d6adf6ce58	TCGA-FU-A3HY-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3HY-01A	674E010C-7AD4-4DC2-86B0-284CD4560633	Primary Tumor	Illumina HiSeq	30d23ada-985e-43b1-9cc5-9e3931905b07	Cervix	47	A5879A60-AA8B-4DA0-904A-9FFE2968418C	0FD6C08E-8B41-422F-A6BA-1234E6596ADA	TCGA-FU-A3HY-01A-11D-A245-26	HG19_Broad_variant	TCGA-FU-A3HY	TCGA-CESC	NA	s1531	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T1b2	N1	Cervical Squamous Cell Carcinoma	Not available	A245-26	TRUE
13722.58cfa832e4b0c9d6adf6ceac	58cfa832e4b0c9d6adf6ceac	TCGA-FD-A3NA-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FD-A3NA-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_1_rg.sorted	TCGA-FD-A3NA-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_1_rg.sorted.bam	63.16	NA	0.16	58cfa832e4b0c9d6adf6ceac	TCGA-FD-A3NA-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3NA-01A	14917461-DAE4-44CB-909D-42AC45AEF450	Primary Tumor	Illumina HiSeq	8c4c1672-fea7-4c17-a6d0-d4a0f3c04558	Bladder	60	7BD000AB-6F48-4A9E-98A4-EAF47D6E3C05	37789FCA-0C64-49B7-A704-572A19BD2645	TCGA-FD-A3NA-01A-11D-A21C-26	HG19_Broad_variant	TCGA-FD-A3NA	TCGA-BLCA	NA	s3114	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A21C-26	TRUE
13722.58cfa832e4b0c9d6adf6cf7f	58cfa832e4b0c9d6adf6cf7f	TCGA-GD-A3OP-01A-21D-A221_120902_SN1222_0147_AC195DACXX_s_1_rg.sorted.filtered.	WGS	TCGA-GD-A3OP-01A-21D-A221_120902_SN1222_0147_AC195DACXX_s_1_rg.sorted	TCGA-GD-A3OP-01A-21D-A221_120902_SN1222_0147_AC195DACXX_s_1_rg.sorted.bam	15.89	NA	0.17	58cfa832e4b0c9d6adf6cf7f	TCGA-GD-A3OP-01A-21D-A221_120902_SN1222_0147_AC195DACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GD-A3OP-01A	31DA07BB-6752-49A3-A7EA-5427C04A9458	Primary Tumor	Illumina HiSeq	e01f55a8-4fbe-4f9a-8617-ce0e6900f177	Bladder	84	C0773229-5A20-4451-9DB5-F757E34921AE	AB6D114E-DF58-4912-85F4-3C385CAA3749	TCGA-GD-A3OP-01A-21D-A221-26	HG19_Broad_variant	TCGA-GD-A3OP	TCGA-BLCA	NA	s3125	MD Anderson - Institute for Applied Cancer Science	ABS - IUPUI	United States	NO	T4a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6cfb8	58cfa832e4b0c9d6adf6cfb8	TCGA-GC-A3I6-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-GC-A3I6-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_5_rg.sorted	TCGA-GC-A3I6-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_5_rg.sorted.bam	65	NA	0.16	58cfa832e4b0c9d6adf6cfb8	TCGA-GC-A3I6-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3I6-01A	74CBB078-9AAE-422A-A7AF-DD29EBCA949E	Primary Tumor	Illumina HiSeq	ec0a1f1d-c6e7-4b4a-a296-02087e0b6586	Bladder	45	DB9442F6-38F2-4092-9E85-F5EC0C924025	8B23B777-2BF2-422A-8AB3-1DF94EE61690	TCGA-GC-A3I6-01A-11D-A210-26	HG19_Broad_variant	TCGA-GC-A3I6	TCGA-BLCA	NA	s2733	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	TRUE
13722.58cfa832e4b0c9d6adf6d0d4	58cfa832e4b0c9d6adf6d0d4	TCGA-FY-A3I5-01B-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FY-A3I5-01B-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_1_rg.sorted	TCGA-FY-A3I5-01B-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_1_rg.sorted.bam	41.37	NA	0.14	58cfa832e4b0c9d6adf6d0d4	TCGA-FY-A3I5-01B-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3I5-01B	52203FF5-57B2-4D56-8935-2FF1EB61D7B8	Primary Tumor	Illumina HiSeq	ed0cff3d-a985-40a9-b0df-ec57b3bcdd50	Thyroid	64	7AEC7C70-6A5A-48D5-A863-A8DB40D93097	C32A9B9D-B381-4492-9BBC-8F25B09D18C1	TCGA-FY-A3I5-01B-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3I5	TCGA-THCA	NA	s12119	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage III	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6d128	58cfa832e4b0c9d6adf6d128	TCGA-G2-A3IE-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G2-A3IE-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_3_rg.sorted	TCGA-G2-A3IE-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_3_rg.sorted.bam	48.07	NA	0.15	58cfa832e4b0c9d6adf6d128	TCGA-G2-A3IE-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A3IE-01A	C65BA2B8-E867-42E8-BBD0-C2CDF5130CFB	Primary Tumor	Illumina HiSeq	171a2a97-43d5-41cc-a9ae-2f685c3ed80f	Bladder	51	FC529667-D055-4FC3-806D-C0431D9A6CFF	5C93720D-56AA-4324-8543-9B37351BC9B6	TCGA-G2-A3IE-01A-11D-A210-26	HG19_Broad_variant	TCGA-G2-A3IE	TCGA-BLCA	612	s2917	MD Anderson - Institute for Applied Cancer Science	MD Anderson	United States	NO	Not available	NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	TRUE
13722.58cfa832e4b0c9d6adf6d1a4	58cfa832e4b0c9d6adf6d1a4	TCGA-IG-A50L-01A-11D-A267_131120_SN1222_0230_BC29YPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-IG-A50L-01A-11D-A267_131120_SN1222_0230_BC29YPACXX_s_1_rg.sorted	TCGA-IG-A50L-01A-11D-A267_131120_SN1222_0230_BC29YPACXX_s_1_rg.sorted.bam	22.45	NA	0.17	58cfa832e4b0c9d6adf6d1a4	TCGA-IG-A50L-01A-11D-A267_131120_SN1222_0230_BC29YPACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A50L-01A	9E54A27F-D0FA-4A5B-91BC-13E27FED2A3D	Primary Tumor	Illumina HiSeq	3e7102a5-f6cf-4918-83d4-8bc4a36d6eda	Esophagus	58	5B30B4D1-4FC6-4712-92B4-E3BE5131551E	62296F7F-6BE0-41E3-A2AA-27B3D1ACE0C7	TCGA-IG-A50L-01A-11D-A267-26	HG19_Broad_variant	TCGA-IG-A50L	TCGA-ESCA	NA	s1815	MD Anderson - Institute for Applied Cancer Science	Asterand	Vietnam	NO	T3	N1	Not available	Stage IIIA	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d3d0	58cfa832e4b0c9d6adf6d3d0	TCGA-L5-A43J-01A-12D-A248_121211_SN208_0443_BC1H55ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-L5-A43J-01A-12D-A248_121211_SN208_0443_BC1H55ACXX_s_5_rg.sorted	TCGA-L5-A43J-01A-12D-A248_121211_SN208_0443_BC1H55ACXX_s_5_rg.sorted.bam	17.75	NA	0.17	58cfa832e4b0c9d6adf6d3d0	TCGA-L5-A43J-01A-12D-A248_121211_SN208_0443_BC1H55ACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A43J-01A	209E2E16-CB88-4A8F-9CDB-10E152CAA26C	Primary Tumor	Illumina HiSeq	ed639604-bac1-4406-ad55-5a821261a54a	Esophagus	90	EEA7BE16-BAF9-4101-A712-CFAF5349476E	9BDD056B-DEC2-4856-9093-94FD133CF06B	TCGA-L5-A43J-01A-12D-A248-26	HG19_Broad_variant	TCGA-L5-A43J	TCGA-ESCA	131	s1739	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T3	N0	Not available	Stage IIB	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d5b2	58cfa832e4b0c9d6adf6d5b2	TCGA-LN-A49R-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-LN-A49R-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_3_rg.sorted	TCGA-LN-A49R-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_3_rg.sorted.bam	25.76	NA	0.16	58cfa832e4b0c9d6adf6d5b2	TCGA-LN-A49R-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49R-01A	4C9FB311-0860-4A04-A2F6-79558AC1D98F	Primary Tumor	Illumina HiSeq	94a0c801-3854-49af-babc-dbd07042752e	Esophagus	46	74585CFD-4536-4EF9-89E6-B2D133BB6A0C	219B22EF-9A05-4BA2-AB14-DD88A395615E	TCGA-LN-A49R-01A-11D-A248-26	HG19_Broad_variant	TCGA-LN-A49R	TCGA-ESCA	NA	s1852	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1	Not available	Stage III	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d578	58cfa832e4b0c9d6adf6d578	TCGA-V4-A9EM-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9EM-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_2_rg.sorted	TCGA-V4-A9EM-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_2_rg.sorted.bam	31.67	NA	0.15	58cfa832e4b0c9d6adf6d578	TCGA-V4-A9EM-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EM-01A	711EB720-4CB7-48DE-9350-5C729BF9F0DA	Primary Tumor	Illumina HiSeq	f3dd06ee-2d71-4310-b226-e94b83da83f7	Eye	53	79658DC3-F2B6-4C5E-9BF7-2C0E440BA3BF	2A1955C2-F55D-48EF-A013-AA69288C3A0C	TCGA-V4-A9EM-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EM	TCGA-UVM	NA	s233	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d57a	58cfa832e4b0c9d6adf6d57a	TCGA-LN-A4MQ-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_4_rg.sorted.filtered.	WGS	TCGA-LN-A4MQ-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_4_rg.sorted	TCGA-LN-A4MQ-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_4_rg.sorted.bam	35.61	NA	0.16	58cfa832e4b0c9d6adf6d57a	TCGA-LN-A4MQ-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_4_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4MQ-01A	33C0199A-BE0C-46D1-BB1E-889BFAEDF20B	Primary Tumor	Illumina HiSeq	beb51eaa-d60f-4bae-a401-293cb0ff9121	Esophagus	46	23CF07BE-97E6-4F55-A8F2-FF03CDBBA74E	4B6D7228-2E11-44F6-A1F4-DABF2085BB05	TCGA-LN-A4MQ-01A-11D-A28P-26	HG19_Broad_variant	TCGA-LN-A4MQ	TCGA-ESCA	NA	s1868	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1	Not available	Stage III	A28P-26	TRUE
13722.58cfa832e4b0c9d6adf6d5b4	58cfa832e4b0c9d6adf6d5b4	TCGA-LN-A49P-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-LN-A49P-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_3_rg.sorted	TCGA-LN-A49P-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_3_rg.sorted.bam	26.81	NA	0.16	58cfa832e4b0c9d6adf6d5b4	TCGA-LN-A49P-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49P-01A	B64A5F5A-5913-432E-9D08-0FF67A8C6B64	Primary Tumor	Illumina HiSeq	bc96d005-85da-45f9-924a-a168644b49c0	Esophagus	71	4B768A42-B383-40A9-9A6F-511974E9E4C8	044EA190-FCC0-41BE-99F7-274A1DDA540B	TCGA-LN-A49P-01A-11D-A248-26	HG19_Broad_variant	TCGA-LN-A49P	TCGA-ESCA	NA	s1760	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0	Not available	Stage IIA	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d618	58cfa832e4b0c9d6adf6d618	TCGA-LN-A4MR-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_8_rg.sorted.filtered.	WGS	TCGA-LN-A4MR-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_8_rg.sorted	TCGA-LN-A4MR-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_8_rg.sorted.bam	38.53	NA	0.17	58cfa832e4b0c9d6adf6d618	TCGA-LN-A4MR-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_8_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4MR-01A	CC14603B-E32C-43F3-8218-B6ED7EE2EC18	Primary Tumor	Illumina HiSeq	6c329173-3100-4df0-ad53-2f0bdffd2143	Esophagus	57	CB5E48F2-2803-4F25-9D6C-4A812722E900	65B1AB3A-A807-44D1-A734-DE9A6821151C	TCGA-LN-A4MR-01A-11D-A28P-26	HG19_Broad_variant	TCGA-LN-A4MR	TCGA-ESCA	NA	s1774	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0	Not available	Stage IIA	A28P-26	TRUE
13722.58cfa831e4b0c9d6adf6c710	58cfa831e4b0c9d6adf6c710	TCGA-CV-7428-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CV-7428-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_2_rg.sorted	TCGA-CV-7428-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_2_rg.sorted.bam	325.73	NA	0.16	58cfa831e4b0c9d6adf6c710	TCGA-CV-7428-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7428-01A	90D3C240-5CB6-4601-A852-B5CDFBCD6483	Primary Tumor	Illumina HiSeq	234197c5-8479-49c1-9f04-5e9171364a3d	Head and Neck	47	F3CFC60B-ADA9-4549-8CDB-6CEBABB1E6B3	BA021325-B1CC-4C81-99B7-7B7349CFFFB6	TCGA-CV-7428-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7428	TCGA-HNSC	1671	s15784	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c737	58cfa831e4b0c9d6adf6c737	TCGA-CV-7263-01A-11D-2317_120623_SN1222_0118_AD13T1ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-7263-01A-11D-2317_120623_SN1222_0118_AD13T1ACXX_s_8_rg.sorted	TCGA-CV-7263-01A-11D-2317_120623_SN1222_0118_AD13T1ACXX_s_8_rg.sorted.bam	170.73	NA	0.14	58cfa831e4b0c9d6adf6c737	TCGA-CV-7263-01A-11D-2317_120623_SN1222_0118_AD13T1ACXX_s_8_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	Not available	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7263-01A	93B742EB-5FC3-4CE2-B7F6-C89F97E0DCC9	Primary Tumor	Illumina HiSeq	d8d79518-dd53-49b5-850c-3af45043e30c	Head and Neck	64	54DCB9AC-FD35-49C2-A790-B1F016160183	32435F1B-5D36-4335-B25E-43B89202F1B2	TCGA-CV-7263-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7263	TCGA-HNSC	560	s15776	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c76c	58cfa831e4b0c9d6adf6c76c	TCGA-CV-7178-01A-21D-2317_120623_SN1222_0118_AD13T1ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CV-7178-01A-21D-2317_120623_SN1222_0118_AD13T1ACXX_s_7_rg.sorted	TCGA-CV-7178-01A-21D-2317_120623_SN1222_0118_AD13T1ACXX_s_7_rg.sorted.bam	199.73	NA	0.16	58cfa831e4b0c9d6adf6c76c	TCGA-CV-7178-01A-21D-2317_120623_SN1222_0118_AD13T1ACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7178-01A	8F044599-3FBE-4B69-B67D-49AEE9168545	Primary Tumor	Illumina HiSeq	f76f830b-a361-4cf5-a60f-69d4d574723f	Head and Neck	64	CAAB8E84-3225-4543-949E-7B7EB11244A2	A139820A-0B76-4A95-A3EE-DDDDF514A9C3	TCGA-CV-7178-01A-21D-2317-26	HG19_Broad_variant	TCGA-CV-7178	TCGA-HNSC	2166	s15900	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T4a	N2	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c757	58cfa831e4b0c9d6adf6c757	TCGA-CV-7183-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CV-7183-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_7_rg.sorted	TCGA-CV-7183-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_7_rg.sorted.bam	7.43	NA	0.14	58cfa831e4b0c9d6adf6c757	TCGA-CV-7183-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7183-01A	DE206681-3E27-4D4F-8669-AEFB12B5B1E3	Primary Tumor	Illumina HiSeq	f449ea84-f7cf-4a26-bc43-707ac56f0038	Head and Neck	53	0BFD11FD-B227-41EF-BD54-7BE877BCE5A2	C2030338-EFEF-48CD-B893-BBDB8D85456E	TCGA-CV-7183-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7183	TCGA-HNSC	NA	s15652	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6cb0e	58cfa831e4b0c9d6adf6cb0e	TCGA-EA-A3Y4-01A-51D-A245_140124_SN1440_0178_AC2PL6ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EA-A3Y4-01A-51D-A245_140124_SN1440_0178_AC2PL6ACXX_s_1_rg.sorted	TCGA-EA-A3Y4-01A-51D-A245_140124_SN1440_0178_AC2PL6ACXX_s_1_rg.sorted.bam	30.33	NA	0.15	58cfa831e4b0c9d6adf6cb0e	TCGA-EA-A3Y4-01A-51D-A245_140124_SN1440_0178_AC2PL6ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3Y4-01A	3AC62513-B5F4-4063-AABD-DAD08A1F56FB	Primary Tumor	Illumina HiSeq	32cd0b72-100c-4e6c-81f1-6be30738cafb	Cervix	40	FF97C148-76BA-480E-9456-5DD7D7238373	A7529CB6-2386-410F-B09A-62E10BAFF8CB	TCGA-EA-A3Y4-01A-51D-A245-26	HG19_Broad_variant	TCGA-EA-A3Y4	TCGA-CESC	NA	s1362	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO	T1b	N0	Cervical Squamous Cell Carcinoma	Not available	A245-26	TRUE
13722.58cfa831e4b0c9d6adf6ccf8	58cfa831e4b0c9d6adf6ccf8	TCGA-FD-A3SP-01A-31D-A233_120830_SN208_0424_BD1DKLACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FD-A3SP-01A-31D-A233_120830_SN208_0424_BD1DKLACXX_s_3_rg.sorted	TCGA-FD-A3SP-01A-31D-A233_120830_SN208_0424_BD1DKLACXX_s_3_rg.sorted.bam	26.79	NA	0.15	58cfa831e4b0c9d6adf6ccf8	TCGA-FD-A3SP-01A-31D-A233_120830_SN208_0424_BD1DKLACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SP-01A	5F99DCFF-D809-4C87-8024-C9B30BD565E9	Primary Tumor	Illumina HiSeq	2da38f98-8b94-404e-99e7-7a8d58aa25c1	Bladder	60	3592A9C5-124E-428F-B1F9-40429C591429	9BE9B27C-A33C-450E-806D-7C791472DAE6	TCGA-FD-A3SP-01A-31D-A233-26	HG19_Broad_variant	TCGA-FD-A3SP	TCGA-BLCA	NA	s3112	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	TRUE
13722.58cfa832e4b0c9d6adf6ce60	58cfa832e4b0c9d6adf6ce60	TCGA-GV-A3QF-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-GV-A3QF-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_4_rg.sorted	TCGA-GV-A3QF-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_4_rg.sorted.bam	21.58	NA	0.16	58cfa832e4b0c9d6adf6ce60	TCGA-GV-A3QF-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3QF-01A	47990D5E-A0E1-4752-86F5-4F5B84E219DF	Primary Tumor	Illumina HiSeq	bcac19c7-1e8c-40ba-a577-39fce12db063	Bladder	79	6647C98E-7AA1-49E4-A067-D53AEBACFF9C	F7B433D0-F5DA-4E9C-9C32-A614FB4F614C	TCGA-GV-A3QF-01A-31D-A233-26	HG19_Broad_variant	TCGA-GV-A3QF	TCGA-BLCA	NA	s2931	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T3b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	TRUE
13722.58cfa832e4b0c9d6adf6ceed	58cfa832e4b0c9d6adf6ceed	TCGA-FY-A3R7-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FY-A3R7-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_3_rg.sorted	TCGA-FY-A3R7-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_3_rg.sorted.bam	10.86	NA	0.15	58cfa832e4b0c9d6adf6ceed	TCGA-FY-A3R7-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3R7-01A	B983A678-B0AE-42C2-8F37-D6ECAF07413B	Primary Tumor	Illumina HiSeq	8f5f6e5a-6274-4d57-8dbd-2dc9d5bc3544	Thyroid	50	E85B6BC8-C182-4483-8F53-F312D5A545CB	5F86B67F-ECBC-477C-B72A-F41F104E03A2	TCGA-FY-A3R7-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3R7	TCGA-THCA	NA	s12009	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6cfd8	58cfa832e4b0c9d6adf6cfd8	TCGA-FU-A3TQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FU-A3TQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_3_rg.sorted	TCGA-FU-A3TQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_3_rg.sorted.bam	59.29	NA	0.15	58cfa832e4b0c9d6adf6cfd8	TCGA-FU-A3TQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3TQ-01A	7218AA6F-3345-484F-A329-A3B6169A67C7	Primary Tumor	Illumina HiSeq	87ede4e6-17e6-4287-8ee3-cde27de3aa7d	Cervix	55	2F3BFFB4-2C85-4B72-9AF5-4DB9DC358AE6	7018744F-49FF-4F47-AEE5-07F0DEA5D7D3	TCGA-FU-A3TQ-01A-11D-A232-26	HG19_Broad_variant	TCGA-FU-A3TQ	TCGA-CESC	NA	s1199	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2b	N1	Cervical Squamous Cell Carcinoma	Not available	A232-26	TRUE
13722.58cfa832e4b0c9d6adf6cff0	58cfa832e4b0c9d6adf6cff0	TCGA-GD-A3OS-01A-12D-A221_120906_SN208_0426_BC194HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-GD-A3OS-01A-12D-A221_120906_SN208_0426_BC194HACXX_s_7_rg.sorted	TCGA-GD-A3OS-01A-12D-A221_120906_SN208_0426_BC194HACXX_s_7_rg.sorted.bam	37.3	NA	0.14	58cfa832e4b0c9d6adf6cff0	TCGA-GD-A3OS-01A-12D-A221_120906_SN208_0426_BC194HACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GD-A3OS-01A	2A41B7D4-132F-4FB6-87B5-487C445379C7	Primary Tumor	Illumina HiSeq	2a801113-8404-4c17-9d60-508761ec1659	Bladder	54	C629CD55-54D7-4E31-AB90-955EBFF0B20A	80DBF776-1B0B-454C-9DA6-9688816A294D	TCGA-GD-A3OS-01A-12D-A221-26	HG19_Broad_variant	TCGA-GD-A3OS	TCGA-BLCA	NA	s2922	MD Anderson - Institute for Applied Cancer Science	ABS - IUPUI	United States	NO	Not available	NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6d058	58cfa832e4b0c9d6adf6d058	TCGA-IG-A4QT-01A-21D-A267_131120_SN1222_0229_AD2FDGACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IG-A4QT-01A-21D-A267_131120_SN1222_0229_AD2FDGACXX_s_3_rg.sorted	TCGA-IG-A4QT-01A-21D-A267_131120_SN1222_0229_AD2FDGACXX_s_3_rg.sorted.bam	23.35	NA	0.14	58cfa832e4b0c9d6adf6d058	TCGA-IG-A4QT-01A-21D-A267_131120_SN1222_0229_AD2FDGACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A4QT-01A	3F7B600B-282E-4F35-9FD8-567B3FCA8273	Primary Tumor	Illumina HiSeq	4bffb791-ea4d-4a2e-86dd-ac9a6dd727e6	Esophagus	56	49B4F5ED-93E8-41B5-971E-7C6454C8554D	79A37247-ACFA-4DE0-A904-027707CACE87	TCGA-IG-A4QT-01A-21D-A267-26	HG19_Broad_variant	TCGA-IG-A4QT	TCGA-ESCA	NA	s1909	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO	T3	N0	Not available	Stage IIA	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d0d2	58cfa832e4b0c9d6adf6d0d2	TCGA-IG-A3Y9-01A-12D-A248_121211_SN208_0443_BC1H55ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-IG-A3Y9-01A-12D-A248_121211_SN208_0443_BC1H55ACXX_s_7_rg.sorted	TCGA-IG-A3Y9-01A-12D-A248_121211_SN208_0443_BC1H55ACXX_s_7_rg.sorted.bam	28.44	NA	0.16	58cfa832e4b0c9d6adf6d0d2	TCGA-IG-A3Y9-01A-12D-A248_121211_SN208_0443_BC1H55ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3Y9-01A	4B8809A6-4AB3-4567-8623-37CE3FAA978C	Primary Tumor	Illumina HiSeq	c2ef3740-4373-4315-812a-aec2bc6fde24	Esophagus	72	ACABEB3D-A6C0-46E8-ABB5-5FA9373D98AB	4320D40E-6CE1-4C13-A260-751281314AED	TCGA-IG-A3Y9-01A-12D-A248-26	HG19_Broad_variant	TCGA-IG-A3Y9	TCGA-ESCA	NA	s1627	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T4	N0	Not available	Stage IIIA	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d116	58cfa832e4b0c9d6adf6d116	TCGA-JX-A3Q0-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-JX-A3Q0-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_3_rg.sorted	TCGA-JX-A3Q0-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_3_rg.sorted.bam	42.52	NA	0.14	58cfa832e4b0c9d6adf6d116	TCGA-JX-A3Q0-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_3_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-JX-A3Q0-01A	20280122-A66A-4C83-8F25-0B9D97558DC2	Primary Tumor	Illumina HiSeq	20d5be50-f8a2-406a-9415-bc65cdff0cad	Cervix	63	04FFDFC0-A73F-47AE-9014-73870B69AD91	A7EE4E31-77DF-470B-A748-87BB4DF76FD5	TCGA-JX-A3Q0-01A-11D-A245-26	HG19_Broad_variant	TCGA-JX-A3Q0	TCGA-CESC	NA	s1218	MD Anderson - Institute for Applied Cancer Science	Washington University	United States	NO	T3	N0	Cervical Squamous Cell Carcinoma	Not available	A245-26	TRUE
13722.58cfa832e4b0c9d6adf6d153	58cfa832e4b0c9d6adf6d153	TCGA-FU-A3YQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FU-A3YQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_6_rg.sorted	TCGA-FU-A3YQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_6_rg.sorted.bam	36.15	NA	0.15	58cfa832e4b0c9d6adf6d153	TCGA-FU-A3YQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3YQ-01A	6E01248B-C551-4F52-8066-CB2D26EB6394	Primary Tumor	Illumina HiSeq	104b02af-20c0-4d30-ba14-f5028b3a3ee4	Cervix	35	84A97589-63AE-4151-89F3-40F5AA9DE72E	5C95B361-B203-400F-B18A-8375849F5B84	TCGA-FU-A3YQ-01A-11D-A232-26	HG19_Broad_variant	TCGA-FU-A3YQ	TCGA-CESC	NA	s1205	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma	Not available	A232-26	TRUE
13722.58cfa832e4b0c9d6adf6d16e	58cfa832e4b0c9d6adf6d16e	TCGA-IG-A5S3-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-IG-A5S3-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_7_rg.sorted	TCGA-IG-A5S3-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_7_rg.sorted.bam	45.06	NA	0.15	58cfa832e4b0c9d6adf6d16e	TCGA-IG-A5S3-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A5S3-01A	DF0125B2-5278-4DED-B3B7-9FC829FE9F63	Primary Tumor	Illumina HiSeq	736bee98-6905-4aea-a839-1157081fd524	Esophagus	69	9595654D-B5F8-4571-A80A-BDD179881D91	AC4D24CB-89FC-4744-9227-4F65D8893F90	TCGA-IG-A5S3-01A-11D-A28P-26	HG19_Broad_variant	TCGA-IG-A5S3	TCGA-ESCA	NA	s1827	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T3	N0	Not available	Stage IIB	A28P-26	TRUE
13722.58cfa832e4b0c9d6adf6d1c9	58cfa832e4b0c9d6adf6d1c9	TCGA-HM-A3JK-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-HM-A3JK-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_1_rg.sorted	TCGA-HM-A3JK-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_1_rg.sorted.bam	58.55	NA	0.15	58cfa832e4b0c9d6adf6d1c9	TCGA-HM-A3JK-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-HM-A3JK-01A	7C4CD55F-750E-4941-A9F3-0632A75D6531	Primary Tumor	Illumina HiSeq	cc4a29a9-d389-4d17-b8c7-53fcc5731b22	Cervix	64	88C6E5CB-D33E-4042-BE7B-12A081ACDAFB	EDAC7C77-CA42-461B-9006-F65E3EB6B7AB	TCGA-HM-A3JK-01A-11D-A245-26	HG19_Broad_variant	TCGA-HM-A3JK	TCGA-CESC	NA	s1208	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	NO	T2b	N1	Cervical Squamous Cell Carcinoma	Not available	A245-26	TRUE
13722.58cfa832e4b0c9d6adf6d25c	58cfa832e4b0c9d6adf6d25c	TCGA-JX-A3PZ-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_2_rg.sorted.filtered.	WGS	TCGA-JX-A3PZ-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_2_rg.sorted	TCGA-JX-A3PZ-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_2_rg.sorted.bam	19.49	NA	0.14	58cfa832e4b0c9d6adf6d25c	TCGA-JX-A3PZ-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-JX-A3PZ-01A	3DF6ABE2-2123-4BFA-A4E4-88DF5F940C04	Primary Tumor	Illumina HiSeq	ecad03c2-29cd-48c4-8c37-7eade85970f7	Cervix	25	BD39C4C4-A4DD-4B2D-9F3C-608CA8708958	1B04D621-E036-4D1E-9D57-6CCCD0C020D8	TCGA-JX-A3PZ-01A-11D-A245-26	HG19_Broad_variant	TCGA-JX-A3PZ	TCGA-CESC	642	s1540	MD Anderson - Institute for Applied Cancer Science	Washington University	United States	NO	T1b	N0	Cervical Squamous Cell Carcinoma	Not available	A245-26	TRUE
13722.58cfa832e4b0c9d6adf6d3b6	58cfa832e4b0c9d6adf6d3b6	TCGA-L5-A4ON-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_7_rg.sorted.filtered.	WGS	TCGA-L5-A4ON-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_7_rg.sorted	TCGA-L5-A4ON-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_7_rg.sorted.bam	47.01	NA	0.17	58cfa832e4b0c9d6adf6d3b6	TCGA-L5-A4ON-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A4ON-01A	CABA34F2-3877-48CA-9FBC-665C3960F574	Primary Tumor	Illumina HiSeq	9bb22695-702d-410d-98a3-d4adcf022a94	Esophagus	65	B801A0D7-09E8-48D8-9C8E-C6D52767F7C1	469616E0-7C5B-491E-8D25-E71CCDB27D18	TCGA-L5-A4ON-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4ON	TCGA-ESCA	558	s1843	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N1	Not available	Stage IIB	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d3cd	58cfa832e4b0c9d6adf6d3cd	TCGA-L5-A43H-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_3_rg.sorted.filtered.	WGS	TCGA-L5-A43H-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_3_rg.sorted	TCGA-L5-A43H-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_3_rg.sorted.bam	36.23	NA	0.16	58cfa832e4b0c9d6adf6d3cd	TCGA-L5-A43H-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A43H-01A	06CA7FC4-4AE0-47D5-9E83-F92BA42A957B	Primary Tumor	Illumina HiSeq	f8c7d908-f915-4b1b-9947-4b6eadf4e914	Esophagus	75	C144B311-B50C-4CB1-89B3-0B056871F54B	E2B4C9E3-0346-40A8-A700-4D5DAB592085	TCGA-L5-A43H-01A-11D-A248-26	HG19_Broad_variant	TCGA-L5-A43H	TCGA-ESCA	9	s1915	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T3	N1	Not available	Stage III	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d35e	58cfa832e4b0c9d6adf6d35e	TCGA-L5-A43I-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-L5-A43I-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_5_rg.sorted	TCGA-L5-A43I-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_5_rg.sorted.bam	27.04	NA	0.15	58cfa832e4b0c9d6adf6d35e	TCGA-L5-A43I-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A43I-01A	22EE75E0-5D61-41F4-AACD-B4E09C70D2C3	Primary Tumor	Illumina HiSeq	deef8598-1109-476b-b3f7-ca8bd62bf710	Esophagus	77	210B53EB-2664-4E0E-A00B-A24838804726	4E5B2FFE-BCF1-485A-B507-2B332BE6DF98	TCGA-L5-A43I-01A-11D-A248-26	HG19_Broad_variant	TCGA-L5-A43I	TCGA-ESCA	556	s1836	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T3	N1	Not available	Stage IIIA	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d407	58cfa832e4b0c9d6adf6d407	TCGA-VD-A8KJ-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-VD-A8KJ-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_6_rg.sorted	TCGA-VD-A8KJ-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_6_rg.sorted.bam	45.14	NA	0.16	58cfa832e4b0c9d6adf6d407	TCGA-VD-A8KJ-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_6_rg.sorted.bam	Alive	MALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-A8KJ-01A	7289BC25-2551-4C6D-B2FA-C7E13859B9B3	Primary Tumor	Illumina HiSeq	fc31e7c7-1135-4bd9-b27a-14853ce2751f	Eye	53	81194B66-EBA6-4AD8-A745-6CABD69218F0	EB63AF0F-8072-47F0-8CC6-02A5B28126C7	TCGA-VD-A8KJ-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KJ	TCGA-UVM	NA	s274	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T3a	NX	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d558	58cfa832e4b0c9d6adf6d558	TCGA-L5-A4OM-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OM-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_1_rg.sorted	TCGA-L5-A4OM-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_1_rg.sorted.bam	36.8	NA	0.17	58cfa832e4b0c9d6adf6d558	TCGA-L5-A4OM-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OM-01A	1A578AE7-5C0B-48EF-8BAF-7189DF703A93	Primary Tumor	Illumina HiSeq	2069622c-925f-4886-8005-9b8680ecc584	Esophagus	54	01EF1408-F028-4F6C-B09E-9BBB8D738704	081DEE66-D2A2-4FF2-94A1-6E3219D878D7	TCGA-L5-A4OM-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OM	TCGA-ESCA	NA	s1842	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0	Not available	Stage IA	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d630	58cfa832e4b0c9d6adf6d630	TCGA-LN-A49Y-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A49Y-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_5_rg.sorted	TCGA-LN-A49Y-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_5_rg.sorted.bam	41.86	NA	0.16	58cfa832e4b0c9d6adf6d630	TCGA-LN-A49Y-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49Y-01A	87FABA0E-28E7-4A7E-A7E1-12582EC68FAC	Primary Tumor	Illumina HiSeq	61d40e9e-a5c9-4e35-8e7f-5e08661da9b6	Esophagus	77	E443EA94-586E-4A0B-8330-55336AAE9A15	9AAF77BB-57CB-4073-BA2E-380B80303B0B	TCGA-LN-A49Y-01A-11D-A267-26	HG19_Broad_variant	TCGA-LN-A49Y	TCGA-ESCA	NA	s1870	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0	Not available	Stage IIA	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d545	58cfa832e4b0c9d6adf6d545	TCGA-L5-A43E-01A-11D-A248_130115_SN590_0207_AC1H8PACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A43E-01A-11D-A248_130115_SN590_0207_AC1H8PACXX_s_1_rg.sorted	TCGA-L5-A43E-01A-11D-A248_130115_SN590_0207_AC1H8PACXX_s_1_rg.sorted.bam	40.6	NA	0.15	58cfa832e4b0c9d6adf6d545	TCGA-L5-A43E-01A-11D-A248_130115_SN590_0207_AC1H8PACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A43E-01A	6969FE5A-5993-48E5-95C5-C5C7D3D08205	Primary Tumor	Illumina HiSeq	70d7fe7a-b9ff-4651-94bd-cc39c64b3657	Esophagus	74	5C8F603A-B8D3-407C-8E74-559C5F8C4D0E	2BDCF492-4741-430F-B1C3-ED029AD05FD6	TCGA-L5-A43E-01A-11D-A248-26	HG19_Broad_variant	TCGA-L5-A43E	TCGA-ESCA	NA	s1916	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0	Not available	Stage I	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d602	58cfa832e4b0c9d6adf6d602	TCGA-LN-A49N-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_7_rg.sorted.filtered.	WGS	TCGA-LN-A49N-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_7_rg.sorted	TCGA-LN-A49N-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_7_rg.sorted.bam	23.88	NA	0.15	58cfa832e4b0c9d6adf6d602	TCGA-LN-A49N-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49N-01A	AE404398-6544-4F3A-8830-44A4A227F8D5	Primary Tumor	Illumina HiSeq	cc2923b6-4e0b-4a1c-ad36-baa7b55f96ac	Esophagus	50	79EDB231-5534-4EB8-9B67-2BF628C19FB4	092A4F76-1526-48FA-932B-5FFA9AC1FAF5	TCGA-LN-A49N-01A-11D-A248-26	HG19_Broad_variant	TCGA-LN-A49N	TCGA-ESCA	NA	s1668	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N1	Not available	Stage IIB	A248-26	TRUE
13722.58cfa830e4b0c9d6adf6c2d8	58cfa830e4b0c9d6adf6c2d8	TCGA-BT-A3PH-01A-11D-A221_120902_SN1222_0147_AC195DACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BT-A3PH-01A-11D-A221_120902_SN1222_0147_AC195DACXX_s_7_rg.sorted	TCGA-BT-A3PH-01A-11D-A221_120902_SN1222_0147_AC195DACXX_s_7_rg.sorted.bam	56.18	NA	0.16	58cfa830e4b0c9d6adf6c2d8	TCGA-BT-A3PH-01A-11D-A221_120902_SN1222_0147_AC195DACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A3PH-01A	932BCDD4-5145-49E8-9A95-8A546396F572	Primary Tumor	Illumina HiSeq	9096dde9-2391-4c22-b816-2057b8adb483	Bladder	76	33A83E54-3BE5-4A68-8AB0-D31D0BCD3B67	4C010558-360B-44AF-A980-A1CCDF3AB9C7	TCGA-BT-A3PH-01A-11D-A221-26	HG19_Broad_variant	TCGA-BT-A3PH	TCGA-BLCA	142	s2699	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A221-26	TRUE
13722.58cfa831e4b0c9d6adf6c406	58cfa831e4b0c9d6adf6c406	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted.filtered.	WGS	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted.bam	43.33	NA	0.15	58cfa831e4b0c9d6adf6c406	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HE-01A	BC63DD2A-B8F6-4B30-A8D7-CE193BCD17F1	Primary Tumor	Illumina HiSeq	1d64c1f3-438b-4576-b2bc-74c1a26a2aca	Cervix	44	506D8B22-EE8D-4FB3-BB57-5CA79D6F5637	D0321E82-FF46-450C-AAF2-9FDCA2FF2590	TCGA-C5-A3HE-01A-21D-A232-26	HG19_Broad_variant	TCGA-C5-A3HE	TCGA-CESC	NA	s1514	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma	Not available	A232-26	TRUE
13722.58cfa831e4b0c9d6adf6c50c	58cfa831e4b0c9d6adf6c50c	TCGA-CF-A3MI-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CF-A3MI-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_1_rg.sorted	TCGA-CF-A3MI-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_1_rg.sorted.bam	46.48	NA	0.14	58cfa831e4b0c9d6adf6c50c	TCGA-CF-A3MI-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A3MI-01A	F1EBF96B-8DF9-4E59-ACEF-7AD433E40214	Primary Tumor	Illumina HiSeq	6559c325-d368-4f95-a2c0-df5efa895e3d	Bladder	62	A373568A-BBD3-4D67-92D6-96E8378065CF	86D4A4FB-47BB-4CD4-B481-CE9F815D38E6	TCGA-CF-A3MI-01A-11D-A210-26	HG19_Broad_variant	TCGA-CF-A3MI	TCGA-BLCA	NA	s3273	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	TRUE
13722.58cfa831e4b0c9d6adf6c610	58cfa831e4b0c9d6adf6c610	TCGA-CQ-6221-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CQ-6221-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_6_rg.sorted	TCGA-CQ-6221-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_6_rg.sorted.bam	12.33	NA	0.15	58cfa831e4b0c9d6adf6c610	TCGA-CQ-6221-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6221-01A	839B660C-98FE-4468-A2B3-408594350250	Primary Tumor	Illumina HiSeq	16de682b-970e-4857-821f-5a32d6b74f71	Head and Neck	79	65BAAE80-7FD5-40B1-B5FB-BDD013B70931	C90134BD-6F38-45B9-B82D-E84ACEB2E90F	TCGA-CQ-6221-01A-11D-2317-26	HG19_Broad_variant	TCGA-CQ-6221	TCGA-HNSC	NA	s15637	MD Anderson - Institute for Applied Cancer Science	University Health Network, Toronto	Canada	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Not available	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c819	58cfa831e4b0c9d6adf6c819	TCGA-CN-6998-01A-23D-2317_120623_SN1222_0118_AD13T1ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-6998-01A-23D-2317_120623_SN1222_0118_AD13T1ACXX_s_5_rg.sorted	TCGA-CN-6998-01A-23D-2317_120623_SN1222_0118_AD13T1ACXX_s_5_rg.sorted.bam	9.03	NA	0.13	58cfa831e4b0c9d6adf6c819	TCGA-CN-6998-01A-23D-2317_120623_SN1222_0118_AD13T1ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6998-01A	039788EC-1364-40C7-9E9D-13DC305674E9	Primary Tumor	Illumina HiSeq	d281a462-58dd-4303-9419-617fec3fcf35	Head and Neck	53	64C8DB8B-5D5C-4FBE-8996-4A7CB161D4A0	88B8B48D-51B8-4D46-9C36-E565A2582D94	TCGA-CN-6998-01A-23D-2317-26	HG19_Broad_variant	TCGA-CN-6998	TCGA-HNSC	NA	s16333	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c8bc	58cfa831e4b0c9d6adf6c8bc	TCGA-DK-A3IT-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DK-A3IT-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_5_rg.sorted	TCGA-DK-A3IT-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_5_rg.sorted.bam	24.31	NA	0.16	58cfa831e4b0c9d6adf6c8bc	TCGA-DK-A3IT-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IT-01A	58520C66-7688-435A-B09F-653B18768C41	Primary Tumor	Illumina HiSeq	276fd52d-8d51-4e03-85a5-a7f02ee03b71	Bladder	62	6B48DAE5-B757-450A-8248-65C2434A7AFC	CDBAE634-52F3-4165-A214-BB60BEC5D6C4	TCGA-DK-A3IT-01A-31D-A210-26	HG19_Broad_variant	TCGA-DK-A3IT	TCGA-BLCA	NA	s2715	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	TRUE
13722.58cfa831e4b0c9d6adf6c8c2	58cfa831e4b0c9d6adf6c8c2	TCGA-DK-A3IL-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A3IL-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_3_rg.sorted	TCGA-DK-A3IL-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_3_rg.sorted.bam	32.38	NA	0.16	58cfa831e4b0c9d6adf6c8c2	TCGA-DK-A3IL-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IL-01A	178B28CD-99C3-48DC-8D09-1EF71B4CEE80	Primary Tumor	Illumina HiSeq	56a85daa-804e-4c68-b2be-c58cf3d5153e	Bladder	79	59D6683F-5EB7-493D-8E8E-78B88BE2CD70	F666A681-CA0D-4281-8E8A-156A24BBB63A	TCGA-DK-A3IL-01A-11D-A210-26	HG19_Broad_variant	TCGA-DK-A3IL	TCGA-BLCA	NA	s3282	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A210-26	TRUE
13722.58cfa831e4b0c9d6adf6c9b5	58cfa831e4b0c9d6adf6c9b5	TCGA-DK-A3IU-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A3IU-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_7_rg.sorted	TCGA-DK-A3IU-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_7_rg.sorted.bam	34.01	NA	0.15	58cfa831e4b0c9d6adf6c9b5	TCGA-DK-A3IU-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IU-01A	F093F043-EFD4-4CBA-A87F-8CBB5C1ACD9E	Primary Tumor	Illumina HiSeq	346b87a3-0c3a-455c-b3c1-0fb96acd0f2f	Bladder	58	B9C39E8B-D689-499A-BC06-CE3BFFC9996C	8E8E8966-582A-45FF-96C2-EC0C1718C4F2	TCGA-DK-A3IU-01A-11D-A210-26	HG19_Broad_variant	TCGA-DK-A3IU	TCGA-BLCA	NA	s3285	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	TRUE
13722.58cfa831e4b0c9d6adf6c9d5	58cfa831e4b0c9d6adf6c9d5	TCGA-DK-A3IQ-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A3IQ-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_3_rg.sorted	TCGA-DK-A3IQ-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_3_rg.sorted.bam	22.29	NA	0.16	58cfa831e4b0c9d6adf6c9d5	TCGA-DK-A3IQ-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IQ-01A	E44F60EC-66C4-45A2-A003-0A1FAF1D6E03	Primary Tumor	Illumina HiSeq	edc43d06-7118-46e7-894e-d40138b6d69c	Bladder	74	1E375786-DB8F-4A8C-BA1C-C6DD7DE1A9BE	DB940CE0-2357-4E83-AA19-AEA672A121D9	TCGA-DK-A3IQ-01A-31D-A210-26	HG19_Broad_variant	TCGA-DK-A3IQ	TCGA-BLCA	NA	s2894	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	TRUE
13722.58cfa831e4b0c9d6adf6cb17	58cfa831e4b0c9d6adf6cb17	TCGA-EA-A3QD-01A-32D-A232_140124_SN1120_0291_AC2PHAACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EA-A3QD-01A-32D-A232_140124_SN1120_0291_AC2PHAACXX_s_2_rg.sorted	TCGA-EA-A3QD-01A-32D-A232_140124_SN1120_0291_AC2PHAACXX_s_2_rg.sorted.bam	58.49	NA	0.15	58cfa831e4b0c9d6adf6cb17	TCGA-EA-A3QD-01A-32D-A232_140124_SN1120_0291_AC2PHAACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3QD-01A	9E2E29E8-D94A-499F-A98A-5B53B2C38F3B	Primary Tumor	Illumina HiSeq	d97f385a-fc08-43a1-9481-35f9ffdfcc05	Cervix	59	987E1913-A506-4A06-B247-9FF778CE552B	677FE002-1736-4263-B2CE-D93983F0BF95	TCGA-EA-A3QD-01A-32D-A232-26	HG19_Broad_variant	TCGA-EA-A3QD	TCGA-CESC	NA	s1185	MD Anderson - Institute for Applied Cancer Science	Asterand	United States	NO	T1b1	N1	Cervical Squamous Cell Carcinoma	Not available	A232-26	TRUE
13722.58cfa831e4b0c9d6adf6cd50	58cfa831e4b0c9d6adf6cd50	TCGA-FD-A3SQ-01A-21D-A233_120830_SN208_0424_BD1DKLACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FD-A3SQ-01A-21D-A233_120830_SN208_0424_BD1DKLACXX_s_5_rg.sorted	TCGA-FD-A3SQ-01A-21D-A233_120830_SN208_0424_BD1DKLACXX_s_5_rg.sorted.bam	35.93	NA	0.14	58cfa831e4b0c9d6adf6cd50	TCGA-FD-A3SQ-01A-21D-A233_120830_SN208_0424_BD1DKLACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SQ-01A	3071CB51-DCF5-41F7-B047-AFC2DCBF0AAF	Primary Tumor	Illumina HiSeq	104a1ca4-a3b6-42e6-b6ba-1b0916160573	Bladder	62	A78A8C62-06ED-4562-B529-D30A5D1508E7	749C6741-66D9-4BEE-B5D6-7F6C4F9F0F88	TCGA-FD-A3SQ-01A-21D-A233-26	HG19_Broad_variant	TCGA-FD-A3SQ	TCGA-BLCA	1423	s3295	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	TRUE
13722.58cfa831e4b0c9d6adf6cdc5	58cfa831e4b0c9d6adf6cdc5	TCGA-FD-A3SO-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FD-A3SO-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_1_rg.sorted	TCGA-FD-A3SO-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_1_rg.sorted.bam	39.92	NA	0.14	58cfa831e4b0c9d6adf6cdc5	TCGA-FD-A3SO-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SO-01A	94809FBF-4895-42C0-A7C6-F39EE1A41F1A	Primary Tumor	Illumina HiSeq	6b296020-484a-4cc2-a114-6c8a34ed5712	Bladder	68	869E3D55-CAD8-436E-B6A8-7ED90AD0A535	3D37A593-EFD7-4250-961D-D914E0AB8C13	TCGA-FD-A3SO-01A-11D-A233-26	HG19_Broad_variant	TCGA-FD-A3SO	TCGA-BLCA	168	s2911	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3a	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	TRUE
13722.58cfa832e4b0c9d6adf6ce0f	58cfa832e4b0c9d6adf6ce0f	TCGA-FD-A3B8-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FD-A3B8-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_7_rg.sorted	TCGA-FD-A3B8-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_7_rg.sorted.bam	26.04	NA	0.16	58cfa832e4b0c9d6adf6ce0f	TCGA-FD-A3B8-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B8-01A	537CA5D1-5B26-496F-B7B4-05FEA7B46353	Primary Tumor	Illumina HiSeq	c0aadcb9-2d54-45c7-9585-575ed21ea52f	Bladder	56	9A27AA84-D541-4FA3-A798-D7559A5AE70C	582B2439-02F1-4E2A-9A4E-771603658FB5	TCGA-FD-A3B8-01A-31D-A210-26	HG19_Broad_variant	TCGA-FD-A3B8	TCGA-BLCA	NA	s3296	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	TRUE
13722.58cfa832e4b0c9d6adf6ce18	58cfa832e4b0c9d6adf6ce18	TCGA-FD-A3B5-01A-11D-A210_120912_SN1120_0192_AC18ALACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FD-A3B5-01A-11D-A210_120912_SN1120_0192_AC18ALACXX_s_1_rg.sorted	TCGA-FD-A3B5-01A-11D-A210_120912_SN1120_0192_AC18ALACXX_s_1_rg.sorted.bam	33.2	NA	0.17	58cfa832e4b0c9d6adf6ce18	TCGA-FD-A3B5-01A-11D-A210_120912_SN1120_0192_AC18ALACXX_s_1_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B5-01A	462D5A6B-9F39-4AAE-A35B-D06A7811D053	Primary Tumor	Illumina HiSeq	d7af6a65-2c95-4a83-8e6f-756aef5309bd	Bladder	86	F9DEDC8C-327D-456A-9C0B-E1EC58AE3169	0D51FF4C-41D7-4296-BDDC-F9DB7F41276A	TCGA-FD-A3B5-01A-11D-A210-26	HG19_Broad_variant	TCGA-FD-A3B5	TCGA-BLCA	272	s2721	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A210-26	TRUE
13722.58cfa832e4b0c9d6adf6cf1a	58cfa832e4b0c9d6adf6cf1a	TCGA-H7-7774-01A-21D-2317_120623_SN1222_0119_BC0WLLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-H7-7774-01A-21D-2317_120623_SN1222_0119_BC0WLLACXX_s_4_rg.sorted	TCGA-H7-7774-01A-21D-2317_120623_SN1222_0119_BC0WLLACXX_s_4_rg.sorted.bam	52.73	NA	0.15	58cfa832e4b0c9d6adf6cf1a	TCGA-H7-7774-01A-21D-2317_120623_SN1222_0119_BC0WLLACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-H7-7774-01A	EEAE67AC-C9E0-468D-AAD6-052501F7B982	Primary Tumor	Illumina HiSeq	ab347312-e135-4dd6-9be3-fa5fdebbcd68	Head and Neck	75	50F6615A-49CC-4E14-B5DD-54784B66C27B	B9B2B6F5-57EB-4DD6-8FE2-1E8669840DAB	TCGA-H7-7774-01A-21D-2317-26	HG19_Broad_variant	TCGA-H7-7774	TCGA-HNSC	NA	s16209	MD Anderson - Institute for Applied Cancer Science	ABS - IUPUI	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	TRUE
13722.58cfa832e4b0c9d6adf6d01c	58cfa832e4b0c9d6adf6d01c	TCGA-FU-A3TX-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FU-A3TX-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_4_rg.sorted	TCGA-FU-A3TX-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_4_rg.sorted.bam	57.65	NA	0.16	58cfa832e4b0c9d6adf6d01c	TCGA-FU-A3TX-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3TX-01A	B75644C2-B515-41CE-9B03-842EF5208A17	Primary Tumor	Illumina HiSeq	3692ce0d-daf2-4076-a86f-4d8e9ea25745	Cervix	78	D9146847-1E6A-4963-9BC2-C2041B36A84C	14CDA56B-E939-4F52-8F22-00F3E5EA0DA6	TCGA-FU-A3TX-01A-11D-A232-26	HG19_Broad_variant	TCGA-FU-A3TX	TCGA-CESC	NA	s1371	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma	Not available	A232-26	TRUE
13722.58cfa832e4b0c9d6adf6d036	58cfa832e4b0c9d6adf6d036	TCGA-FU-A3WB-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FU-A3WB-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_5_rg.sorted	TCGA-FU-A3WB-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_5_rg.sorted.bam	44.44	NA	0.16	58cfa832e4b0c9d6adf6d036	TCGA-FU-A3WB-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3WB-01A	6868BA1D-B612-454C-8146-74AF2F573D76	Primary Tumor	Illumina HiSeq	39124a1d-9323-40ae-aee5-6fb32cf4a565	Cervix	43	0334B0B7-115E-40A0-960B-6A3365CDA3AD	52C1B6D6-A160-4FFB-945C-6FB3B29EFEF9	TCGA-FU-A3WB-01A-11D-A232-26	HG19_Broad_variant	TCGA-FU-A3WB	TCGA-CESC	NA	s1203	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2a2	N0	Cervical Squamous Cell Carcinoma	Not available	A232-26	TRUE
13722.58cfa832e4b0c9d6adf6d0ac	58cfa832e4b0c9d6adf6d0ac	TCGA-IG-A3I8-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_5_rg.sorted.filtered.	WGS	TCGA-IG-A3I8-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_5_rg.sorted	TCGA-IG-A3I8-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_5_rg.sorted.bam	64.11	NA	0.16	58cfa832e4b0c9d6adf6d0ac	TCGA-IG-A3I8-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3I8-01A	7BF3F18B-A013-48D2-A743-26A57FDBE4C4	Primary Tumor	Illumina HiSeq	d45e0e39-36b5-4628-9dae-7a185f129e6b	Esophagus	51	944A68B7-51D4-4831-88D4-D647BE17BC13	3A1FBCCE-BAB6-466C-AE4C-AADC4E5D357F	TCGA-IG-A3I8-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3I8	TCGA-ESCA	NA	s1621	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T3	N0	Not available	Stage IIA	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d0d0	58cfa832e4b0c9d6adf6d0d0	TCGA-IG-A3YA-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-IG-A3YA-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_1_rg.sorted	TCGA-IG-A3YA-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_1_rg.sorted.bam	41.16	NA	0.16	58cfa832e4b0c9d6adf6d0d0	TCGA-IG-A3YA-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3YA-01A	7AB6DE57-D659-47F1-A70F-1B67650E99D7	Primary Tumor	Illumina HiSeq	d20d3af7-3c79-446f-834f-9be861dc1490	Esophagus	53	AAADB48E-3C60-4AE4-B6EB-7B5F9C9D6544	A389CF30-6460-43E5-A895-6EBFC9555AF2	TCGA-IG-A3YA-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3YA	TCGA-ESCA	NA	s1819	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T4	N0	Not available	Stage IIIA	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d12e	58cfa832e4b0c9d6adf6d12e	TCGA-G2-A3IB-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G2-A3IB-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_1_rg.sorted	TCGA-G2-A3IB-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_1_rg.sorted.bam	39.31	NA	0.15	58cfa832e4b0c9d6adf6d12e	TCGA-G2-A3IB-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_1_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A3IB-01A	AF53D51E-0B5C-437F-A1C0-EC5F55C49364	Primary Tumor	Illumina HiSeq	f78443a3-8c1b-429a-93c3-fcd93f3c6d55	Bladder	66	791E4058-E872-4AF8-A431-F5782811F02A	80F634F1-C34C-40CD-9F9B-BBFC18E9DE6E	TCGA-G2-A3IB-01A-11D-A210-26	HG19_Broad_variant	TCGA-G2-A3IB	TCGA-BLCA	NA	s2726	MD Anderson - Institute for Applied Cancer Science	MD Anderson	United States	NO	Not available	NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	TRUE
13722.58cfa832e4b0c9d6adf6d158	58cfa832e4b0c9d6adf6d158	TCGA-IR-A3LF-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-IR-A3LF-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_7_rg.sorted	TCGA-IR-A3LF-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_7_rg.sorted.bam	36.63	NA	0.15	58cfa832e4b0c9d6adf6d158	TCGA-IR-A3LF-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LF-01A	785DDEA1-399D-47D8-B2B0-39E95EAA24B5	Primary Tumor	Illumina HiSeq	aba44461-5b2e-40f7-9e8e-262aee825e6c	Cervix	64	B6A74A02-CD3B-4F0A-BB2F-F90C1D3F6D14	02D65CAC-E751-493F-A4FB-3DDB1400EFAC	TCGA-IR-A3LF-01A-21D-A232-26	HG19_Broad_variant	TCGA-IR-A3LF	TCGA-CESC	NA	s1216	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Endocervical Adenocarcinoma of the Usual Type	Not available	A232-26	TRUE
13722.58cfa832e4b0c9d6adf6d034	58cfa832e4b0c9d6adf6d034	TCGA-GC-A3RD-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_7_rg.sorted.filtered.	WGS	TCGA-GC-A3RD-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_7_rg.sorted	TCGA-GC-A3RD-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_7_rg.sorted.bam	46.83	NA	0.16	58cfa832e4b0c9d6adf6d034	TCGA-GC-A3RD-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3RD-01A	6A2155B3-915C-41B1-B730-32E55E0C1FBD	Primary Tumor	Illumina HiSeq	27573bf6-b72d-47e6-93f7-38d2887d8b32	Bladder	83	1C60F60E-A3C6-43A1-A56E-BA68801D2D90	C9E9DC46-2917-47BE-92DA-9C40C6F13500	TCGA-GC-A3RD-01A-12D-A233-26	HG19_Broad_variant	TCGA-GC-A3RD	TCGA-BLCA	NA	s2731	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	TRUE
13722.58cfa832e4b0c9d6adf6d170	58cfa832e4b0c9d6adf6d170	TCGA-J8-A3YH-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_3_rg.sorted.filtered.	WGS	TCGA-J8-A3YH-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_3_rg.sorted	TCGA-J8-A3YH-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_3_rg.sorted.bam	48.6	NA	0.15	58cfa832e4b0c9d6adf6d170	TCGA-J8-A3YH-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	Not available	Thyroid Carcinoma	Aligned reads	TCGA-J8-A3YH-01A	A09B20B5-C187-4632-B996-0D5314A9885C	Primary Tumor	Illumina HiSeq	f6ec340c-1c9c-4c8d-9266-4728709a90e6	Thyroid	39	EFDAD0C2-A44D-48F8-A908-E8C9747E78B8	BF118D4C-A2DF-4617-92E2-3475E07D9BE7	TCGA-J8-A3YH-01A-11D-A23Q-26	HG19_Broad_variant	TCGA-J8-A3YH	TCGA-THCA	NA	s12535	MD Anderson - Institute for Applied Cancer Science	Mayo Clinic	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A23Q-26	TRUE
13722.58cfa832e4b0c9d6adf6d655	58cfa832e4b0c9d6adf6d655	TCGA-LN-A49O-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-LN-A49O-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_1_rg.sorted	TCGA-LN-A49O-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_1_rg.sorted.bam	20.64	NA	0.16	58cfa832e4b0c9d6adf6d655	TCGA-LN-A49O-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49O-01A	3DF1B9DB-D900-47D2-839D-3900829CB2A9	Primary Tumor	Illumina HiSeq	e460c5ae-4179-406e-a1fd-fb7b1c7403ae	Esophagus	47	37A1045E-A566-4BC0-88CA-A54C5426A96D	C5253C04-01D3-40D9-85A2-155F9D0360C3	TCGA-LN-A49O-01A-11D-A248-26	HG19_Broad_variant	TCGA-LN-A49O	TCGA-ESCA	NA	s1863	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0	Not available	Stage IIA	A248-26	TRUE
13722.58cfa82fe4b0c9d6adf6b8e2	58cfa82fe4b0c9d6adf6b8e2	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted.bam	8.32	NA	0.14	58cfa82fe4b0c9d6adf6b8e2	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A7-A26F-01B	3B7B9C1E-A84C-47ED-983C-9E4B00CBF01A	Primary Tumor	Illumina HiSeq	4925c013-4605-47d0-9c97-2e8a69233aa4	Breast	55	29619D1E-E8B4-411E-BBBA-07F2CFB69E8A	A723DE1E-A9E0-487D-8D86-7AA4A062A1C2	TCGA-A7-A26F-01B-04D-A22S-26	HG19_Broad_variant	TCGA-A7-A26F	TCGA-BRCA	NA	s6916	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	YES	T1	N0	Other  specify	Stage IA	A22S-26	FALSE
13722.58cfa830e4b0c9d6adf6be78	58cfa830e4b0c9d6adf6be78	TCGA-BL-A3JM-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BL-A3JM-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_3_rg.sorted	TCGA-BL-A3JM-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_3_rg.sorted.bam	24.07	NA	0.16	58cfa830e4b0c9d6adf6be78	TCGA-BL-A3JM-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A3JM-01A	0F4FB205-B13C-4A85-97B3-779429E6CCDD	Primary Tumor	Illumina HiSeq	5cd881b7-caa0-43ad-9ba8-f9696fdf7403	Bladder	62	110ACEE1-915F-43A2-B382-5D0AF1FC167F	6ABBBA00-C322-4EDE-91A4-85D0D3E886F9	TCGA-BL-A3JM-01A-12D-A21C-26	HG19_Broad_variant	TCGA-BL-A3JM	TCGA-BLCA	205	s2691	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A21C-26	TRUE
13722.58cfa831e4b0c9d6adf6c3cb	58cfa831e4b0c9d6adf6c3cb	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted.filtered.	WGS	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted.bam	60.19	NA	0.16	58cfa831e4b0c9d6adf6c3cb	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HD-01B	12427B02-6E3F-461C-B271-6AB230F628E7	Primary Tumor	Illumina HiSeq	475d850b-49e8-4f15-9f59-8d65bf9cf22d	Cervix	51	56AA88C8-AF6D-42BE-8672-074476F6575A	03576AE9-4222-48C3-A428-D85AEC400BD6	TCGA-C5-A3HD-01B-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A3HD	TCGA-CESC	NA	s1171	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	Not available	Not available	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa831e4b0c9d6adf6c4d0	58cfa831e4b0c9d6adf6c4d0	TCGA-BT-A3PJ-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BT-A3PJ-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_1_rg.sorted	TCGA-BT-A3PJ-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_1_rg.sorted.bam	55.89	NA	0.15	58cfa831e4b0c9d6adf6c4d0	TCGA-BT-A3PJ-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A3PJ-01A	CB664EEF-BE6F-44EF-AA90-6F6DA0E6440A	Primary Tumor	Illumina HiSeq	cac436d2-b3cb-4351-953e-084c7a431f0f	Bladder	76	29D79B83-FA80-490E-A8A1-C51C9AD061FE	4BAD319F-9A5F-4257-863A-BCD8ED983EFE	TCGA-BT-A3PJ-01A-21D-A221-26	HG19_Broad_variant	TCGA-BT-A3PJ	TCGA-BLCA	NA	s2698	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3a	N3	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A221-26	TRUE
13722.58cfa831e4b0c9d6adf6c87c	58cfa831e4b0c9d6adf6c87c	TCGA-CV-7414-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-7414-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_8_rg.sorted	TCGA-CV-7414-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_8_rg.sorted.bam	79.73	NA	0.16	58cfa831e4b0c9d6adf6c87c	TCGA-CV-7414-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7414-01A	C3B2C38D-81A3-42FD-A41E-6F6DE3934007	Primary Tumor	Illumina HiSeq	d2264558-e25d-4169-9e22-8f3c23b50ad9	Head and Neck	78	7BE274D5-D5A0-4EF9-A65A-4127ED864F0C	A78CD28C-EDAF-4439-905B-44B4616DF078	TCGA-CV-7414-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7414	TCGA-HNSC	14	s15523	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c8b0	58cfa831e4b0c9d6adf6c8b0	TCGA-CV-7432-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CV-7432-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_1_rg.sorted	TCGA-CV-7432-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_1_rg.sorted.bam	222.73	NA	0.15	58cfa831e4b0c9d6adf6c8b0	TCGA-CV-7432-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7432-01A	EAF674DD-9909-4879-B9A3-74253169EDDD	Primary Tumor	Illumina HiSeq	d1f8d81a-4553-4c26-9d59-534aa2475dca	Head and Neck	79	9213AB13-AFC6-40B9-B278-98DD05C92934	541FB07A-7568-4CFC-9FCD-C5B403C619BA	TCGA-CV-7432-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7432	TCGA-HNSC	2570	s15783	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6cb1a	58cfa831e4b0c9d6adf6cb1a	TCGA-E7-A3X6-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-E7-A3X6-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_5_rg.sorted	TCGA-E7-A3X6-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_5_rg.sorted.bam	39.5	NA	0.15	58cfa831e4b0c9d6adf6cb1a	TCGA-E7-A3X6-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-E7-A3X6-01A	C871EA6B-FBD2-4E6F-AB29-F43F6E3DDCBB	Primary Tumor	Illumina HiSeq	548e206a-eaec-49d3-a405-664cf76d0e16	Bladder	70	554AE735-9991-4CB3-AFE8-4951490BD709	AE6DC0A6-7405-44C2-886F-E10BAD336295	TCGA-E7-A3X6-01A-12D-A233-26	HG19_Broad_variant	TCGA-E7-A3X6	TCGA-BLCA	NA	s3291	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO	T2	NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A233-26	TRUE
13722.58cfa831e4b0c9d6adf6cc87	58cfa831e4b0c9d6adf6cc87	TCGA-EM-A3O6-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EM-A3O6-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_1_rg.sorted	TCGA-EM-A3O6-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_1_rg.sorted.bam	44.88	NA	0.15	58cfa831e4b0c9d6adf6cc87	TCGA-EM-A3O6-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A3O6-01A	398D5C2E-F877-4BBF-A10C-486B8523C9CE	Primary Tumor	Illumina HiSeq	efd1fae6-df5c-4d7d-9579-296f0077b186	Thyroid	54	B3E6F726-256B-450B-B3F5-A1BB9AAB9C15	FA63C656-1DD5-4A92-9AE8-36B3408E00C7	TCGA-EM-A3O6-01A-11D-A221-26	HG19_Broad_variant	TCGA-EM-A3O6	TCGA-THCA	NA	s12114	MD Anderson - Institute for Applied Cancer Science	University Health Network	Canada	NO	T2	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A221-26	TRUE
13722.58cfa831e4b0c9d6adf6cd12	58cfa831e4b0c9d6adf6cd12	TCGA-FD-A3SJ-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FD-A3SJ-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_1_rg.sorted	TCGA-FD-A3SJ-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_1_rg.sorted.bam	30.78	NA	0.17	58cfa831e4b0c9d6adf6cd12	TCGA-FD-A3SJ-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SJ-01A	6D8D8169-0C1A-4CDB-BE6F-9761C981A369	Primary Tumor	Illumina HiSeq	2635ae0a-878a-4237-ad5c-5f0092134ee3	Bladder	59	491A8898-7CC5-45D9-9502-FD24399C239D	E9F8EE08-E951-41A8-88AB-E7A98618EECC	TCGA-FD-A3SJ-01A-12D-A233-26	HG19_Broad_variant	TCGA-FD-A3SJ	TCGA-BLCA	739	s2909	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	TRUE
13722.58cfa831e4b0c9d6adf6ccc8	58cfa831e4b0c9d6adf6ccc8	TCGA-EK-A2RD-01A-12D-A20X_140117_SN590_0245_AC371LACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EK-A2RD-01A-12D-A20X_140117_SN590_0245_AC371LACXX_s_2_rg.sorted	TCGA-EK-A2RD-01A-12D-A20X_140117_SN590_0245_AC371LACXX_s_2_rg.sorted.bam	50.11	NA	0.15	58cfa831e4b0c9d6adf6ccc8	TCGA-EK-A2RD-01A-12D-A20X_140117_SN590_0245_AC371LACXX_s_2_rg.sorted.bam	Alive	FEMALE	AMERICAN INDIAN OR ALASKA NATIVE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2RD-01A	16363EF7-899D-4927-A74B-E7C03B3D8AF1	Primary Tumor	Illumina HiSeq	2f14caa1-7594-45db-b8dc-69e3659c129d	Cervix	47	5690A425-BA49-4BCA-B5EC-461BD5660BE0	D14F932D-58AF-4648-93DD-75F8F8A539BC	TCGA-EK-A2RD-01A-12D-A20X-26	HG19_Broad_variant	TCGA-EK-A2RD	TCGA-CESC	NA	s1366	MD Anderson - Institute for Applied Cancer Science	Gynecologic Oncology Group	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa831e4b0c9d6adf6cd1e	58cfa831e4b0c9d6adf6cd1e	TCGA-EX-A1H6-01B-11D-A232_140124_SN208_0506_BC2PD5ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EX-A1H6-01B-11D-A232_140124_SN208_0506_BC2PD5ACXX_s_3_rg.sorted	TCGA-EX-A1H6-01B-11D-A232_140124_SN208_0506_BC2PD5ACXX_s_3_rg.sorted.bam	47.39	NA	0.16	58cfa831e4b0c9d6adf6cd1e	TCGA-EX-A1H6-01B-11D-A232_140124_SN208_0506_BC2PD5ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EX-A1H6-01B	1FE594D9-4240-49EE-8AFD-C7D16A377181	Primary Tumor	Illumina HiSeq	32948425-770d-4a87-8c3d-ade77ab0391d	Cervix	38	FE018D31-EEE8-4335-96A1-95ECEABFADF1	DD730721-CEC0-4034-B18D-588A200D4D76	TCGA-EX-A1H6-01B-11D-A232-26	HG19_Broad_variant	TCGA-EX-A1H6	TCGA-CESC	NA	s1197	MD Anderson - Institute for Applied Cancer Science	University of North Carolina	United States	NO	T1b1	N0	Endocervical Type of Adenocarcinoma	Not available	A232-26	TRUE
13722.58cfa831e4b0c9d6adf6cd64	58cfa831e4b0c9d6adf6cd64	TCGA-FD-A3SS-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FD-A3SS-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_1_rg.sorted	TCGA-FD-A3SS-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_1_rg.sorted.bam	37.16	NA	0.15	58cfa831e4b0c9d6adf6cd64	TCGA-FD-A3SS-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SS-01A	7B98B829-FDC7-4719-BEE9-C83F6154019C	Primary Tumor	Illumina HiSeq	23aab0ed-a2ae-43db-9050-527db1729aa5	Bladder	66	015E6B08-AB3C-4D1D-99E4-77B5E10BD7FC	315B09D3-D014-4EF1-9CAC-AD5F63F6024A	TCGA-FD-A3SS-01A-12D-A233-26	HG19_Broad_variant	TCGA-FD-A3SS	TCGA-BLCA	NA	s3302	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T4	N3	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	TRUE
13722.58cfa831e4b0c9d6adf6cd7e	58cfa831e4b0c9d6adf6cd7e	TCGA-FE-A3PD-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FE-A3PD-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_7_rg.sorted	TCGA-FE-A3PD-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_7_rg.sorted.bam	59.24	NA	0.15	58cfa831e4b0c9d6adf6cd7e	TCGA-FE-A3PD-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A3PD-01A	39D90499-8549-4DA5-B391-C421F18FACF1	Primary Tumor	Illumina HiSeq	66155739-2eb1-4230-8b24-645dca4e0c0d	Thyroid	17	A6C23CA9-E6F4-4A2C-BB86-25EF76076381	3F63EB17-5F71-4EEC-AEF5-1D4FF328043C	TCGA-FE-A3PD-01A-11D-A221-26	HG19_Broad_variant	TCGA-FE-A3PD	TCGA-THCA	NA	s12390	MD Anderson - Institute for Applied Cancer Science	Ohio State University	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A221-26	TRUE
13722.58cfa831e4b0c9d6adf6cd90	58cfa831e4b0c9d6adf6cd90	TCGA-FE-A3PA-01A-12D-A221_120611_SN1222_0114_AC0WL3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FE-A3PA-01A-12D-A221_120611_SN1222_0114_AC0WL3ACXX_s_1_rg.sorted	TCGA-FE-A3PA-01A-12D-A221_120611_SN1222_0114_AC0WL3ACXX_s_1_rg.sorted.bam	44.72	NA	0.15	58cfa831e4b0c9d6adf6cd90	TCGA-FE-A3PA-01A-12D-A221_120611_SN1222_0114_AC0WL3ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A3PA-01A	10BDAFBB-831D-48B5-B9A3-AD374FC50235	Primary Tumor	Illumina HiSeq	0d67cded-ff5a-4b7c-bc1e-2bda8ee44700	Thyroid	16	D37BED2A-BF63-43E0-91D0-6C95E4CA2D45	DBD2621E-9F39-45C6-B9AE-67873AECA03D	TCGA-FE-A3PA-01A-12D-A221-26	HG19_Broad_variant	TCGA-FE-A3PA	TCGA-THCA	NA	s12760	MD Anderson - Institute for Applied Cancer Science	Ohio State University	United States	NO	T4	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6cef7	58cfa832e4b0c9d6adf6cef7	TCGA-IG-A5B8-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IG-A5B8-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_3_rg.sorted	TCGA-IG-A5B8-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_3_rg.sorted.bam	23.16	NA	0.14	58cfa832e4b0c9d6adf6cef7	TCGA-IG-A5B8-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A5B8-01A	A4D36E09-5D8E-4006-855C-E466682B6813	Primary Tumor	Illumina HiSeq	948983f4-15f3-4b59-983e-18a248b1f4d9	Esophagus	72	C7E7425E-1F33-42B3-A2A2-ADDAAE6365E9	09D7FAFF-2E10-4C45-BB7E-E58B50911EFE	TCGA-IG-A5B8-01A-11D-A28P-26	HG19_Broad_variant	TCGA-IG-A5B8	TCGA-ESCA	24	s1817	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO	T3	N0	Not available	Stage IB	A28P-26	TRUE
13722.58cfa832e4b0c9d6adf6ce5a	58cfa832e4b0c9d6adf6ce5a	TCGA-GV-A3QG-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_3_rg.sorted.filtered.	WGS	TCGA-GV-A3QG-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_3_rg.sorted	TCGA-GV-A3QG-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_3_rg.sorted.bam	32.14	NA	0.15	58cfa832e4b0c9d6adf6ce5a	TCGA-GV-A3QG-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3QG-01A	79F23A0E-5AAE-4618-8191-7DD7C0552408	Primary Tumor	Illumina HiSeq	2102b9a0-6afe-47a9-89ae-9778452a6dcd	Bladder	65	FB9B1639-242F-4019-937F-DD13C40D9C2B	27EDCB5C-D1E4-4683-A967-A436E22D1958	TCGA-GV-A3QG-01A-11D-A221-26	HG19_Broad_variant	TCGA-GV-A3QG	TCGA-BLCA	NA	s3309	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T3a	N3	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6cefe	58cfa832e4b0c9d6adf6cefe	TCGA-H2-A3RI-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_2_rg.sorted.filtered.	WGS	TCGA-H2-A3RI-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_2_rg.sorted	TCGA-H2-A3RI-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_2_rg.sorted.bam	58.31	NA	0.15	58cfa832e4b0c9d6adf6cefe	TCGA-H2-A3RI-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-H2-A3RI-01A	BF193C4F-FBAC-41BC-B1AF-19B6CE856F0F	Primary Tumor	Illumina HiSeq	24a690e4-62f0-4e09-bbb1-ec78dafcf3cd	Thyroid	29	EAAE1A05-7D7E-406A-A02B-282A8B66F95C	5E15CB1B-B0D3-4FB9-9B30-3AEBE4DFC96B	TCGA-H2-A3RI-01A-11D-A221-26	HG19_Broad_variant	TCGA-H2-A3RI	TCGA-THCA	NA	s12259	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6cf94	58cfa832e4b0c9d6adf6cf94	TCGA-FU-A3NI-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FU-A3NI-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_8_rg.sorted	TCGA-FU-A3NI-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_8_rg.sorted.bam	36.82	NA	0.16	58cfa832e4b0c9d6adf6cf94	TCGA-FU-A3NI-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3NI-01A	DAC27C24-CDBF-4527-9214-178FDE3D098A	Primary Tumor	Illumina HiSeq	e3d152ec-0ab5-4fb6-b2ca-ecdb79e43095	Cervix	45	C75C6FD3-79EF-48B8-B3BD-D097EF2A73AD	90DC57B8-74B7-4FB0-9EE7-52A4264D395F	TCGA-FU-A3NI-01A-11D-A245-26	HG19_Broad_variant	TCGA-FU-A3NI	TCGA-CESC	NA	s1204	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T1b1	N1	Cervical Squamous Cell Carcinoma	Not available	A245-26	TRUE
13722.58cfa832e4b0c9d6adf6cfa8	58cfa832e4b0c9d6adf6cfa8	TCGA-GV-A3JV-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-GV-A3JV-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_1_rg.sorted	TCGA-GV-A3JV-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_1_rg.sorted.bam	63.27	NA	0.14	58cfa832e4b0c9d6adf6cfa8	TCGA-GV-A3JV-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3JV-01A	01EE41EF-1894-4408-9E96-A22A1F068190	Primary Tumor	Illumina HiSeq	8f626567-33e0-4b6a-974f-6b41b341c60e	Bladder	66	55072935-CD20-4355-897B-F60F77A18847	E5863D29-E61D-4EE2-B04E-FE61C9B9CA5E	TCGA-GV-A3JV-01A-11D-A221-26	HG19_Broad_variant	TCGA-GV-A3JV	TCGA-BLCA	NA	s3308	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T3b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6d020	58cfa832e4b0c9d6adf6d020	TCGA-GV-A3JZ-01A-11D-A21C_120830_SN590_0178_AD143RACXX_s_7_rg.sorted.filtered.	WGS	TCGA-GV-A3JZ-01A-11D-A21C_120830_SN590_0178_AD143RACXX_s_7_rg.sorted	TCGA-GV-A3JZ-01A-11D-A21C_120830_SN590_0178_AD143RACXX_s_7_rg.sorted.bam	63.92	NA	0.14	58cfa832e4b0c9d6adf6d020	TCGA-GV-A3JZ-01A-11D-A21C_120830_SN590_0178_AD143RACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3JZ-01A	9CC92795-7A24-4875-87F0-3EFCCBFCC970	Primary Tumor	Illumina HiSeq	d4d5d34c-9665-4291-a3d6-14bc9b48f2fa	Bladder	55	449E18FB-CBC0-4365-AEEC-EDC6A6B276BD	5A651606-6D92-445B-AA0B-B73CC9329402	TCGA-GV-A3JZ-01A-11D-A21C-26	HG19_Broad_variant	TCGA-GV-A3JZ	TCGA-BLCA	NA	s2738	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T4a	N3	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A21C-26	TRUE
13722.58cfa832e4b0c9d6adf6d186	58cfa832e4b0c9d6adf6d186	TCGA-IR-A3L7-01A-21D-A20X_140117_SN590_0245_AC371LACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IR-A3L7-01A-21D-A20X_140117_SN590_0245_AC371LACXX_s_3_rg.sorted	TCGA-IR-A3L7-01A-21D-A20X_140117_SN590_0245_AC371LACXX_s_3_rg.sorted.bam	59.39	NA	0.15	58cfa832e4b0c9d6adf6d186	TCGA-IR-A3L7-01A-21D-A20X_140117_SN590_0245_AC371LACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3L7-01A	66229DD6-C771-4455-A90C-C66FB40CF7FE	Primary Tumor	Illumina HiSeq	c50ab1fa-015d-4420-a67f-b023a5377b16	Cervix	37	F571523C-758C-4F34-A44B-F8E6A3EEBE0F	27168C7B-D67E-4B11-B5BA-A79FB523400B	TCGA-IR-A3L7-01A-21D-A20X-26	HG19_Broad_variant	TCGA-IR-A3L7	TCGA-CESC	NA	s1211	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa832e4b0c9d6adf6d44e	58cfa832e4b0c9d6adf6d44e	TCGA-VD-A8KG-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-VD-A8KG-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_4_rg.sorted	TCGA-VD-A8KG-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_4_rg.sorted.bam	43.78	NA	0.17	58cfa832e4b0c9d6adf6d44e	TCGA-VD-A8KG-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-A8KG-01A	9F57834A-4DC4-45ED-97DE-ED4DA9D0598D	Primary Tumor	Illumina HiSeq	4a7b8d85-7b0f-4e37-b941-e61363166648	Eye	47	75A06E1E-CF06-418C-BFB7-3B9147D19078	376A6943-6FCC-406B-B543-4C0C385D2E22	TCGA-VD-A8KG-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KG	TCGA-UVM	NA	s272	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T2a	NX	Not available	Stage IIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d40e	58cfa832e4b0c9d6adf6d40e	TCGA-VD-A8KF-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-VD-A8KF-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_3_rg.sorted	TCGA-VD-A8KF-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_3_rg.sorted.bam	45.75	NA	0.16	58cfa832e4b0c9d6adf6d40e	TCGA-VD-A8KF-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_3_rg.sorted.bam	Dead	MALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-A8KF-01A	78039723-94A9-4903-8BB4-C00852E8E889	Primary Tumor	Illumina HiSeq	29607312-d3fc-46a7-97ec-8515bd642e3a	Eye	68	B48C5179-16E6-47F1-87C7-EE8B71989BF9	8EB5960A-3FDC-4641-AF72-C80755429C8D	TCGA-VD-A8KF-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KF	TCGA-UVM	40	s266	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T4b	NX	Not available	Stage IIIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d478	58cfa832e4b0c9d6adf6d478	TCGA-VD-A8KD-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-VD-A8KD-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_1_rg.sorted	TCGA-VD-A8KD-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_1_rg.sorted.bam	49.59	NA	0.17	58cfa832e4b0c9d6adf6d478	TCGA-VD-A8KD-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_1_rg.sorted.bam	Dead	MALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-A8KD-01A	73B3E4DD-C53D-4FE3-8607-EE462C9CBBD1	Primary Tumor	Illumina HiSeq	32e66b83-1d91-4ed8-b672-cc125bbe3b57	Eye	72	4F0319B2-722C-48E1-A5E1-798463E9EA02	347DBA4E-7CA8-4432-A0F7-90F9009F8AA3	TCGA-VD-A8KD-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KD	TCGA-UVM	114	s270	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T4a	NX	Not available	Stage IV	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d40a	58cfa832e4b0c9d6adf6d40a	TCGA-V4-A9F3-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V4-A9F3-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_3_rg.sorted	TCGA-V4-A9F3-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_3_rg.sorted.bam	49.28	NA	0.16	58cfa832e4b0c9d6adf6d40a	TCGA-V4-A9F3-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F3-01A	E21D8018-8FE9-4C92-8B36-28D7D3F7DF2B	Primary Tumor	Illumina HiSeq	cae118e4-484b-45f4-b225-3d7297583648	Eye	49	6805D6DB-775C-4817-9F1B-5BE44AE2DA45	395ECE1C-9831-48BF-A933-A4A94566CD9D	TCGA-V4-A9F3-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F3	TCGA-UVM	NA	s229	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4da	58cfa832e4b0c9d6adf6d4da	TCGA-VD-A8KE-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-VD-A8KE-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_2_rg.sorted	TCGA-VD-A8KE-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_2_rg.sorted.bam	35.8	NA	0.15	58cfa832e4b0c9d6adf6d4da	TCGA-VD-A8KE-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-A8KE-01A	C9BFC2A7-0914-4080-A0A3-1C6A4E58E1AB	Primary Tumor	Illumina HiSeq	54db22ce-0562-4448-825c-d4e883f4aca6	Eye	74	35DFEB9D-1F64-4D51-B27A-24AD8AA3327B	119B486A-77DF-49A2-80A0-19555DEB7573	TCGA-VD-A8KE-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KE	TCGA-UVM	NA	s279	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T2a	NX	Not available	Stage IIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d576	58cfa832e4b0c9d6adf6d576	TCGA-V4-A9EZ-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V4-A9EZ-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_3_rg.sorted	TCGA-V4-A9EZ-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_3_rg.sorted.bam	34.26	NA	0.16	58cfa832e4b0c9d6adf6d576	TCGA-V4-A9EZ-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EZ-01A	39E494BC-7710-4F9F-98B0-0F509F7AEF1A	Primary Tumor	Illumina HiSeq	5c8725d3-7d4e-4fa4-9626-127c91f5ea5c	Eye	78	9FEE606B-30E8-4BD6-B4C3-E21EFE64870C	6C22A928-CD61-4D62-B401-A4BE19418177	TCGA-V4-A9EZ-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EZ	TCGA-UVM	NA	s225	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa831e4b0c9d6adf6cd16	58cfa831e4b0c9d6adf6cd16	TCGA-FD-A3SL-01A-21D-A233_120830_SN208_0423_AC190AACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FD-A3SL-01A-21D-A233_120830_SN208_0423_AC190AACXX_s_3_rg.sorted	TCGA-FD-A3SL-01A-21D-A233_120830_SN208_0423_AC190AACXX_s_3_rg.sorted.bam	18.6	NA	0.16	58cfa831e4b0c9d6adf6cd16	TCGA-FD-A3SL-01A-21D-A233_120830_SN208_0423_AC190AACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SL-01A	4570B6E2-D430-41CA-AAB1-CE4D14C36463	Primary Tumor	Illumina HiSeq	764ae567-a7b6-4d13-bef1-8cc55afb4524	Bladder	60	0A1E88E0-3593-40BA-86E5-751074885578	2BF89FED-C215-4893-BA35-2FE0C7DD5DD0	TCGA-FD-A3SL-01A-21D-A233-26	HG19_Broad_variant	TCGA-FD-A3SL	TCGA-BLCA	NA	s2720	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T4a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	TRUE
13722.58cfa831e4b0c9d6adf6c4d6	58cfa831e4b0c9d6adf6c4d6	TCGA-CF-A3MF-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CF-A3MF-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_1_rg.sorted	TCGA-CF-A3MF-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_1_rg.sorted.bam	55.07	NA	0.16	58cfa831e4b0c9d6adf6c4d6	TCGA-CF-A3MF-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A3MF-01A	1E308B12-0590-4DAE-94D0-A539FCF25DF7	Primary Tumor	Illumina HiSeq	57be2848-15e4-489c-b122-a660f03c68dd	Bladder	34	E9889071-4C6E-4761-9D65-06C6B5989FB7	6646401F-5235-4847-A4E6-006F98CAFE85	TCGA-CF-A3MF-01A-12D-A21C-26	HG19_Broad_variant	TCGA-CF-A3MF	TCGA-BLCA	NA	s3092	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A21C-26	TRUE
13722.58cfa831e4b0c9d6adf6c5f0	58cfa831e4b0c9d6adf6c5f0	TCGA-CG-4440-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-4440-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_5_rg.sorted	TCGA-CG-4440-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_5_rg.sorted.bam	126.2	1.9	0.14	58cfa831e4b0c9d6adf6c5f0	TCGA-CG-4440-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_5_rg.sorted.bam	Dead	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4440-01A	8CA597DB-AC21-43D1-9329-586B2EAF6982	Primary Tumor	Illumina HiSeq	d72343ff-91f0-4705-a398-914c5d2344d9	Stomach	68	C7B05D36-0386-4B2C-9E8B-2C7502CC4F21	8743D838-FD82-47D4-9BD0-0BAC137FE644	TCGA-CG-4440-01A-01D-A326-26	HG19_Broad_variant	TCGA-CG-4440	TCGA-STAD	122	s15397	MD Anderson - Institute for Applied Cancer Science	Indivumed	Germany	NO	T3	N3	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	A326-26	TRUE
13722.58cfa831e4b0c9d6adf6c655	58cfa831e4b0c9d6adf6c655	TCGA-CG-4444-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4444-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_7_rg.sorted	TCGA-CG-4444-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_7_rg.sorted.bam	51.2	1.9	0.14	58cfa831e4b0c9d6adf6c655	TCGA-CG-4444-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_7_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4444-01A	5C087D33-0BD3-407D-8350-FABBA6AEC597	Primary Tumor	Illumina HiSeq	37421315-54a7-4a59-9939-4706dcd66019	Stomach	76	8563E95B-8E50-4E23-95D1-25AE8437B1DB	37738374-DDCD-4710-A1CC-BF86868C252A	TCGA-CG-4444-01A-01D-A326-26	HG19_Broad_variant	TCGA-CG-4444	TCGA-STAD	NA	s15192	MD Anderson - Institute for Applied Cancer Science	Indivumed	Germany	NO	T2b	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	A326-26	TRUE
13722.58cfa831e4b0c9d6adf6c654	58cfa831e4b0c9d6adf6c654	TCGA-CG-4449-01A-01D-A326_131015_SN1440_0171_AC2DLBACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4449-01A-01D-A326_131015_SN1440_0171_AC2DLBACXX_s_7_rg.sorted	TCGA-CG-4449-01A-01D-A326_131015_SN1440_0171_AC2DLBACXX_s_7_rg.sorted.bam	127.2	1.9	0.14	58cfa831e4b0c9d6adf6c654	TCGA-CG-4449-01A-01D-A326_131015_SN1440_0171_AC2DLBACXX_s_7_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4449-01A	10B5774D-7079-4B4B-B824-F4745F5598C7	Primary Tumor	Illumina HiSeq	c8b033d1-998b-4fee-88e7-33c14e8c3ffc	Stomach	81	E98BD336-1B0D-4655-A537-2A5DAE99114D	9D1B5FD6-77DA-4EB5-B849-BDD7AA698D70	TCGA-CG-4449-01A-01D-A326-26	HG19_Broad_variant	TCGA-CG-4449	TCGA-STAD	NA	s15123	MD Anderson - Institute for Applied Cancer Science	Indivumed	Germany	NO	T2	N1	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	A326-26	TRUE
13722.58cfa832e4b0c9d6adf6cf6a	58cfa832e4b0c9d6adf6cf6a	TCGA-GC-A3OO-01A-11D-A233_120905_SN1120_0187_AD1E4NACXX_s_5_rg.sorted.filtered.	WGS	TCGA-GC-A3OO-01A-11D-A233_120905_SN1120_0187_AD1E4NACXX_s_5_rg.sorted	TCGA-GC-A3OO-01A-11D-A233_120905_SN1120_0187_AD1E4NACXX_s_5_rg.sorted.bam	11.56	NA	0.16	58cfa832e4b0c9d6adf6cf6a	TCGA-GC-A3OO-01A-11D-A233_120905_SN1120_0187_AD1E4NACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3OO-01A	1FF60FD9-3CA3-43BE-92A8-8DBA2CD4D4DF	Primary Tumor	Illumina HiSeq	8c665767-edb1-4860-b26a-4171237962fa	Bladder	79	91E7F41C-17B3-4724-96EF-D3C207B964E1	67B2932F-8C9D-4D38-8791-D4D8AAB7F3B2	TCGA-GC-A3OO-01A-11D-A233-26	HG19_Broad_variant	TCGA-GC-A3OO	TCGA-BLCA	NA	s3306	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A233-26	TRUE
13722.58cfa832e4b0c9d6adf6d160	58cfa832e4b0c9d6adf6d160	TCGA-IG-A4P3-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IG-A4P3-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_3_rg.sorted	TCGA-IG-A4P3-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_3_rg.sorted.bam	40.74	NA	0.15	58cfa832e4b0c9d6adf6d160	TCGA-IG-A4P3-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A4P3-01A	6594ACD5-4D2A-4CC5-8CF8-4064E252C5F6	Primary Tumor	Illumina HiSeq	a5b7767c-9dba-49bf-8711-9a76a0ab0e4f	Esophagus	48	784021B2-5F94-48F9-9DF7-854B4FBDF802	84882FB6-6ED6-42E8-9179-90CE089C4664	TCGA-IG-A4P3-01A-11D-A267-26	HG19_Broad_variant	TCGA-IG-A4P3	TCGA-ESCA	NA	s1826	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO	T2	N1	Not available	Stage IIB	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d374	58cfa832e4b0c9d6adf6d374	TCGA-LN-A49M-01A-21D-A267_131001_SN1222_0222_BC2CN2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-LN-A49M-01A-21D-A267_131001_SN1222_0222_BC2CN2ACXX_s_1_rg.sorted	TCGA-LN-A49M-01A-21D-A267_131001_SN1222_0222_BC2CN2ACXX_s_1_rg.sorted.bam	23.64	NA	0.16	58cfa832e4b0c9d6adf6d374	TCGA-LN-A49M-01A-21D-A267_131001_SN1222_0222_BC2CN2ACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49M-01A	B3E248B5-5D40-495C-BD10-90ECF0ED6A95	Primary Tumor	Illumina HiSeq	821eaabe-92ee-4e30-9254-77b2ce89ea42	Esophagus	62	E6BEF2C0-1C6A-4137-A099-920F1F811489	9C284314-4356-44EA-8087-E64F5A614179	TCGA-LN-A49M-01A-21D-A267-26	HG19_Broad_variant	TCGA-LN-A49M	TCGA-ESCA	NA	s1862	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0	Not available	Stage IIA	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d3ee	58cfa832e4b0c9d6adf6d3ee	TCGA-V4-A9ES-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9ES-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_4_rg.sorted	TCGA-V4-A9ES-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_4_rg.sorted.bam	57.9	NA	0.15	58cfa832e4b0c9d6adf6d3ee	TCGA-V4-A9ES-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9ES-01A	C510A423-6AB1-431E-9248-D2AC91FDEDBA	Primary Tumor	Illumina HiSeq	0edc5349-7b58-4f3e-ae40-3c517bcc8d47	Eye	54	1BC52C96-A28E-4E9C-AD3F-0797234C5A12	B16AE1A2-403B-4573-A6B0-9CBB05CEA149	TCGA-V4-A9ES-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9ES	TCGA-UVM	NA	s201	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3b	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d3bc	58cfa832e4b0c9d6adf6d3bc	TCGA-L5-A43M-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-L5-A43M-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_7_rg.sorted	TCGA-L5-A43M-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_7_rg.sorted.bam	22.55	NA	0.16	58cfa832e4b0c9d6adf6d3bc	TCGA-L5-A43M-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_7_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A43M-01A	29DA08F4-C9E2-4E7A-9733-B4EC5B9C5F13	Primary Tumor	Illumina HiSeq	4e3268fa-d698-4529-abb8-7a235754a070	Esophagus	84	AEEC137A-E929-439C-B7E7-33943CFFB642	97721561-B3CE-4B56-B0D2-B7C70E978526	TCGA-L5-A43M-01A-11D-A248-26	HG19_Broad_variant	TCGA-L5-A43M	TCGA-ESCA	NA	s1745	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T3	N2	Not available	Not available	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d42e	58cfa832e4b0c9d6adf6d42e	TCGA-VD-A8K8-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_1_rg.sorted.filtered.	WGS	TCGA-VD-A8K8-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_1_rg.sorted	TCGA-VD-A8K8-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_1_rg.sorted.bam	51.97	NA	0.15	58cfa832e4b0c9d6adf6d42e	TCGA-VD-A8K8-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-A8K8-01A	9B1ECFB2-9DFB-4E71-B51A-D2A0C5A7940E	Primary Tumor	Illumina HiSeq	874e4766-c478-4406-91cf-977d43d9ed07	Eye	56	F23780FD-DFEB-472B-B747-84ECE2A6226D	E0DBB55F-2753-4B23-B621-F8003B05D814	TCGA-VD-A8K8-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8K8	TCGA-UVM	NA	s283	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T3a	NX	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4b4	58cfa832e4b0c9d6adf6d4b4	TCGA-V4-A9EV-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_7_rg.sorted.filtered.	WGS	TCGA-V4-A9EV-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_7_rg.sorted	TCGA-V4-A9EV-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_7_rg.sorted.bam	56.76	NA	0.15	58cfa832e4b0c9d6adf6d4b4	TCGA-V4-A9EV-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EV-01A	DA6F0ED2-A6D5-4D87-823E-122EBD59AABA	Primary Tumor	Illumina HiSeq	463c617e-a31f-4ebe-9bb0-bdf35b3823f8	Eye	59	42BBB13B-DA94-44FF-A01C-4776A74AEA6F	A08A9A90-323B-48AB-89C8-4805FE59BC70	TCGA-V4-A9EV-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EV	TCGA-UVM	NA	s204	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d514	58cfa832e4b0c9d6adf6d514	TCGA-V4-A9EU-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_6_rg.sorted.filtered.	WGS	TCGA-V4-A9EU-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_6_rg.sorted	TCGA-V4-A9EU-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_6_rg.sorted.bam	49	NA	0.14	58cfa832e4b0c9d6adf6d514	TCGA-V4-A9EU-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EU-01A	DF685F8C-645A-47AE-A471-63BF1973A0AE	Primary Tumor	Illumina HiSeq	929aff65-5561-439c-9850-a5ce595efc28	Eye	83	2DAC7136-D3A0-4FFD-B22D-7F1F9B8B8E4C	4C43B0FD-D2D3-456F-AFDD-EC90DBBD5FBA	TCGA-V4-A9EU-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EU	TCGA-UVM	NA	s213	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4d	N0	Not available	Stage IIIC	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4fe	58cfa832e4b0c9d6adf6d4fe	TCGA-L5-A4OG-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_7_rg.sorted.filtered.	WGS	TCGA-L5-A4OG-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_7_rg.sorted	TCGA-L5-A4OG-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_7_rg.sorted.bam	40.59	NA	0.16	58cfa832e4b0c9d6adf6d4fe	TCGA-L5-A4OG-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OG-01A	EB4AD376-4CC1-4D2C-9B93-AD2B082C77C4	Primary Tumor	Illumina HiSeq	cef87877-7e34-43b9-9599-f98660d7b833	Esophagus	79	E8E44C65-B4E4-4688-A217-206905E68A7F	04C91C91-E55A-4075-B08A-F80568BB4A7B	TCGA-L5-A4OG-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OG	TCGA-ESCA	NA	s1926	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0	Not available	Stage I	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d52e	58cfa832e4b0c9d6adf6d52e	TCGA-LN-A4A8-01A-32D-A267_131018_SN590_0241_BC30HBACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A4A8-01A-32D-A267_131018_SN590_0241_BC30HBACXX_s_5_rg.sorted	TCGA-LN-A4A8-01A-32D-A267_131018_SN590_0241_BC30HBACXX_s_5_rg.sorted.bam	34.22	NA	0.15	58cfa832e4b0c9d6adf6d52e	TCGA-LN-A4A8-01A-32D-A267_131018_SN590_0241_BC30HBACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4A8-01A	AA364B98-0097-43A4-976D-742FAA0276DF	Primary Tumor	Illumina HiSeq	fd30434f-5a9a-4128-99f1-85d8d06ead73	Esophagus	52	0C0582CA-A181-4EFB-8486-C4312B250BA9	E42ECB6E-825E-407C-9CC7-C153C8F40DDC	TCGA-LN-A4A8-01A-32D-A267-26	HG19_Broad_variant	TCGA-LN-A4A8	TCGA-ESCA	NA	s1935	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0	Not available	Stage IIA	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d5bc	58cfa832e4b0c9d6adf6d5bc	TCGA-LN-A4A4-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-LN-A4A4-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_3_rg.sorted	TCGA-LN-A4A4-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_3_rg.sorted.bam	24.3	NA	0.16	58cfa832e4b0c9d6adf6d5bc	TCGA-LN-A4A4-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4A4-01A	E89D7900-915D-4936-B1B2-CAC3670EA2F4	Primary Tumor	Illumina HiSeq	8f2d7e64-e129-494b-9068-ad15dcb9457e	Esophagus	36	C7A31A25-A496-4D26-A9D2-C42ADB22BB45	655BFF55-E213-442B-8C1F-A1A959E89CDB	TCGA-LN-A4A4-01A-11D-A267-26	HG19_Broad_variant	TCGA-LN-A4A4	TCGA-ESCA	NA	s1778	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1	Not available	Stage III	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d5d7	58cfa832e4b0c9d6adf6d5d7	TCGA-LN-A49L-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-LN-A49L-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_3_rg.sorted	TCGA-LN-A49L-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_3_rg.sorted.bam	15.51	NA	0.16	58cfa832e4b0c9d6adf6d5d7	TCGA-LN-A49L-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49L-01A	AD29744C-A09D-463A-84B5-63CFEB7FF786	Primary Tumor	Illumina HiSeq	a9a8bab1-537c-4252-8ec0-8e76946ff9c5	Esophagus	44	D2B00CB1-19A7-4A41-97E1-F2D60108590B	BB9C6E8A-5D74-40DC-A5FF-779E4511B584	TCGA-LN-A49L-01A-11D-A248-26	HG19_Broad_variant	TCGA-LN-A49L	TCGA-ESCA	NA	s1855	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0	Not available	Stage IIA	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d5cc	58cfa832e4b0c9d6adf6d5cc	TCGA-LN-A49V-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-LN-A49V-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_7_rg.sorted	TCGA-LN-A49V-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_7_rg.sorted.bam	39.36	NA	0.17	58cfa832e4b0c9d6adf6d5cc	TCGA-LN-A49V-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49V-01A	0AB29DE2-EB9E-4A25-99DE-5F543CFBDB53	Primary Tumor	Illumina HiSeq	331651f5-689d-41cf-b0d4-379dc314bf42	Esophagus	49	BF039639-98CF-496D-9A11-44DFAFBD7DD7	CF32B517-90B2-400E-B3CE-FD19CC09B10F	TCGA-LN-A49V-01A-11D-A248-26	HG19_Broad_variant	TCGA-LN-A49V	TCGA-ESCA	NA	s1877	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0	Not available	Stage IIA	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d5d0	58cfa832e4b0c9d6adf6d5d0	TCGA-L7-A56G-01A-21D-A267_131001_SN1120_0280_BD2FDEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-L7-A56G-01A-21D-A267_131001_SN1120_0280_BD2FDEACXX_s_3_rg.sorted	TCGA-L7-A56G-01A-21D-A267_131001_SN1120_0280_BD2FDEACXX_s_3_rg.sorted.bam	26.05	NA	0.15	58cfa832e4b0c9d6adf6d5d0	TCGA-L7-A56G-01A-21D-A267_131001_SN1120_0280_BD2FDEACXX_s_3_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-L7-A56G-01A	70C5CE85-4022-46C0-8BD0-F5E9009DDF41	Primary Tumor	Illumina HiSeq	8e835c63-a680-469e-82b7-850d8f01da57	Esophagus	65	3DD6751A-6FA6-4365-8E5E-FCB3D17910F6	6AD8F7F3-2EEC-47F7-9176-B10EBEB78F7E	TCGA-L7-A56G-01A-21D-A267-26	HG19_Broad_variant	TCGA-L7-A56G	TCGA-ESCA	NA	s1851	MD Anderson - Institute for Applied Cancer Science	Christiana Care	United States	NO	Not available	Not available	Not available	Not available	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d604	58cfa832e4b0c9d6adf6d604	TCGA-LN-A49W-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A49W-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_5_rg.sorted	TCGA-LN-A49W-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_5_rg.sorted.bam	22.73	NA	0.15	58cfa832e4b0c9d6adf6d604	TCGA-LN-A49W-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	Not available	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49W-01A	DAF211F2-941E-4244-8CF5-D31492269443	Primary Tumor	Illumina HiSeq	30b9eb80-84d4-4582-aa2d-a826faadd2f2	Esophagus	73	25E6A27B-B015-4936-B57E-CF39DD5AF9BA	38678D1B-A9D9-4231-95B8-95D5AB4D64F2	TCGA-LN-A49W-01A-11D-A267-26	HG19_Broad_variant	TCGA-LN-A49W	TCGA-ESCA	NA	s1772	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1	Not available	Stage III	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d608	58cfa832e4b0c9d6adf6d608	TCGA-LN-A5U5-01A-21D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-LN-A5U5-01A-21D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_4_rg.sorted	TCGA-LN-A5U5-01A-21D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_4_rg.sorted.bam	66.44	NA	0.15	58cfa832e4b0c9d6adf6d608	TCGA-LN-A5U5-01A-21D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_4_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A5U5-01A	656E3C14-1FC6-473A-813E-719753E7B408	Primary Tumor	Illumina HiSeq	d3861f7c-bb4e-48be-b15b-0c082a3b6ff5	Esophagus	57	945DA36D-32AD-4996-9D77-BE6D09B858F9	E9CE892D-BF42-4445-B566-A8D7AC73AED0	TCGA-LN-A5U5-01A-21D-A28P-26	HG19_Broad_variant	TCGA-LN-A5U5	TCGA-ESCA	NA	s1682	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1	Not available	Stage IV	A28P-26	TRUE
13722.58cfa832e4b0c9d6adf6d84d	58cfa832e4b0c9d6adf6d84d	TCGA-LN-A4A6-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-LN-A4A6-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_7_rg.sorted	TCGA-LN-A4A6-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_7_rg.sorted.bam	24.13	NA	0.16	58cfa832e4b0c9d6adf6d84d	TCGA-LN-A4A6-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4A6-01A	FFCFA005-A04F-458E-9D1D-86143DD823E5	Primary Tumor	Illumina HiSeq	113e1f46-b529-435b-bb5a-879746bc79bb	Esophagus	65	14A1D0B5-CA52-4E95-B965-66A9E6BEAE43	B0BB8A76-3BF2-44E3-884A-F94A2D687F53	TCGA-LN-A4A6-01A-11D-A267-26	HG19_Broad_variant	TCGA-LN-A4A6	TCGA-ESCA	NA	s1775	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0	Not available	Stage II	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d5e3	58cfa832e4b0c9d6adf6d5e3	TCGA-LN-A49U-01A-31D-A267_131001_SN1222_0222_BC2CN2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-LN-A49U-01A-31D-A267_131001_SN1222_0222_BC2CN2ACXX_s_7_rg.sorted	TCGA-LN-A49U-01A-31D-A267_131001_SN1222_0222_BC2CN2ACXX_s_7_rg.sorted.bam	24.19	NA	0.15	58cfa832e4b0c9d6adf6d5e3	TCGA-LN-A49U-01A-31D-A267_131001_SN1222_0222_BC2CN2ACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49U-01A	931A50FF-3149-4C4A-9456-45ED3A9DD457	Primary Tumor	Illumina HiSeq	c075129e-527d-4603-9336-8b26a5ce10d2	Esophagus	62	9B3E9E79-52EB-40F7-87EC-E1CB360004E6	FF6F10D6-874C-4281-AB3B-79FF2440A901	TCGA-LN-A49U-01A-31D-A267-26	HG19_Broad_variant	TCGA-LN-A49U	TCGA-ESCA	NA	s1777	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0	Not available	Stage IIA	A267-26	TRUE
13722.58cfa831e4b0c9d6adf6c3d4	58cfa831e4b0c9d6adf6c3d4	TCGA-C5-A3HF-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-C5-A3HF-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_1_rg.sorted	TCGA-C5-A3HF-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_1_rg.sorted.bam	62.13	NA	0.16	58cfa831e4b0c9d6adf6c3d4	TCGA-C5-A3HF-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HF-01A	085DF27C-9BC2-425A-9A49-547D692EA028	Primary Tumor	Illumina HiSeq	4b4bea19-4db4-4996-8037-4129a4494419	Cervix	24	79C43439-BC01-4033-85FA-3191A79277C6	0C08A31F-1414-42E3-986A-00BAF9C926F8	TCGA-C5-A3HF-01A-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A3HF	TCGA-CESC	543	s1358	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	Not available	Not available	Mucinous Adenocarcinoma of Endocervical Type	Not available	A20X-26	TRUE
13722.58cfa831e4b0c9d6adf6c4d2	58cfa831e4b0c9d6adf6c4d2	TCGA-CF-A3MG-01A-11D-A210_120914_SN590_0180_BC19KDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CF-A3MG-01A-11D-A210_120914_SN590_0180_BC19KDACXX_s_7_rg.sorted	TCGA-CF-A3MG-01A-11D-A210_120914_SN590_0180_BC19KDACXX_s_7_rg.sorted.bam	66.73	NA	0.14	58cfa831e4b0c9d6adf6c4d2	TCGA-CF-A3MG-01A-11D-A210_120914_SN590_0180_BC19KDACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A3MG-01A	39EFA06A-FFE5-40B3-8F8A-A2D7071BC9E3	Primary Tumor	Illumina HiSeq	695ed631-423c-4381-ae8f-4a70fd6266b9	Bladder	48	1ACF91C8-4971-4893-AC27-64EA4A4C3023	99993BCD-8555-407A-A918-3F51D57BA720	TCGA-CF-A3MG-01A-11D-A210-26	HG19_Broad_variant	TCGA-CF-A3MG	TCGA-BLCA	NA	s3095	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	TRUE
13722.58cfa831e4b0c9d6adf6c62c	58cfa831e4b0c9d6adf6c62c	TCGA-CG-4301-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4301-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_1_rg.sorted	TCGA-CG-4301-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_1_rg.sorted.bam	84.9	1.9	0.15	58cfa831e4b0c9d6adf6c62c	TCGA-CG-4301-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_1_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4301-01A	7E13FE2A-3D6E-487F-900D-F5891D986AA2	Primary Tumor	Illumina HiSeq	7d1cd13f-5ac5-457f-8e7b-89cabb2463c6	Stomach	75	F8CCC777-65A2-41FA-95AC-AB33C3E9AD9A	55F814EC-D386-4277-8CF1-245313CF373D	TCGA-CG-4301-01A-01D-A326-26	HG19_Broad_variant	TCGA-CG-4301	TCGA-STAD	NA	s15456	MD Anderson - Institute for Applied Cancer Science	Indivumed	Germany	NO	T4	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	A326-26	TRUE
13722.58cfa831e4b0c9d6adf6c6c3	58cfa831e4b0c9d6adf6c6c3	TCGA-CU-A3QU-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CU-A3QU-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_1_rg.sorted	TCGA-CU-A3QU-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_1_rg.sorted.bam	73.31	NA	0.15	58cfa831e4b0c9d6adf6c6c3	TCGA-CU-A3QU-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A3QU-01A	AE6D853B-A7F0-4465-B7BF-5A45006AB3B3	Primary Tumor	Illumina HiSeq	c4c9ea17-be51-4e92-8cdc-0d5880def11c	Bladder	58	75448068-DED8-42F0-BB99-6D1C4B3FFA4E	98A4CFCF-34FE-433A-A598-4191742DC977	TCGA-CU-A3QU-01A-11D-A233-26	HG19_Broad_variant	TCGA-CU-A3QU	TCGA-BLCA	NA	s3278	MD Anderson - Institute for Applied Cancer Science	UNC	United States	NO	T2b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	TRUE
13722.58cfa831e4b0c9d6adf6c7ce	58cfa831e4b0c9d6adf6c7ce	TCGA-CV-7434-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-7434-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_3_rg.sorted	TCGA-CV-7434-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_3_rg.sorted.bam	274.73	NA	0.14	58cfa831e4b0c9d6adf6c7ce	TCGA-CV-7434-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7434-01A	63B50E1C-7948-464F-BFF1-8E0E5DAAFCC5	Primary Tumor	Illumina HiSeq	c645c62d-79d3-478c-a9c4-16294daad71c	Head and Neck	64	2CB75C6E-CA4F-4A88-9679-812A51C7B832	4A4BF5E3-272F-492C-9755-BBFE14D3BEE1	TCGA-CV-7434-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7434	TCGA-HNSC	218	s15528	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T4a	N1	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c8e0	58cfa831e4b0c9d6adf6c8e0	TCGA-DK-A3IV-01A-22D-A21C_120830_SN590_0177_BD141PACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A3IV-01A-22D-A21C_120830_SN590_0177_BD141PACXX_s_7_rg.sorted	TCGA-DK-A3IV-01A-22D-A21C_120830_SN590_0177_BD141PACXX_s_7_rg.sorted.bam	71.23	NA	0.16	58cfa831e4b0c9d6adf6c8e0	TCGA-DK-A3IV-01A-22D-A21C_120830_SN590_0177_BD141PACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IV-01A	F953DC5D-58BF-4936-B9FE-74B45E8C00E5	Primary Tumor	Illumina HiSeq	5bf5cb9d-7592-4967-8440-fe80dfe9c2a6	Bladder	60	BC065247-1179-4FC2-B45C-8EFB13AADE65	62148C98-8E6F-4CA0-9EC6-C7FD7F96495D	TCGA-DK-A3IV-01A-22D-A21C-26	HG19_Broad_variant	TCGA-DK-A3IV	TCGA-BLCA	294	s3108	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	Not available	NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A21C-26	TRUE
13722.58cfa831e4b0c9d6adf6c958	58cfa831e4b0c9d6adf6c958	TCGA-DK-A3IK-01A-32D-A21C_120914_SN590_0179_AD13PPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A3IK-01A-32D-A21C_120914_SN590_0179_AD13PPACXX_s_3_rg.sorted	TCGA-DK-A3IK-01A-32D-A21C_120914_SN590_0179_AD13PPACXX_s_3_rg.sorted.bam	35.88	NA	0.16	58cfa831e4b0c9d6adf6c958	TCGA-DK-A3IK-01A-32D-A21C_120914_SN590_0179_AD13PPACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IK-01A	3F0A0748-9ACC-4D0B-BA18-7C08BD183F86	Primary Tumor	Illumina HiSeq	6c286798-955c-487f-b541-72f253866ada	Bladder	87	4FF20C48-29EE-4101-B409-C4573E38CF92	B13B80DE-1722-44D3-888D-EEE8677F205C	TCGA-DK-A3IK-01A-32D-A21C-26	HG19_Broad_variant	TCGA-DK-A3IK	TCGA-BLCA	NA	s2887	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A21C-26	TRUE
13722.58cfa831e4b0c9d6adf6c99c	58cfa831e4b0c9d6adf6c99c	TCGA-DK-A3WX-01A-22D-A233_120829_SN1120_0183_AC18U8ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DK-A3WX-01A-22D-A233_120829_SN1120_0183_AC18U8ACXX_s_5_rg.sorted	TCGA-DK-A3WX-01A-22D-A233_120829_SN1120_0183_AC18U8ACXX_s_5_rg.sorted.bam	36.57	NA	0.16	58cfa831e4b0c9d6adf6c99c	TCGA-DK-A3WX-01A-22D-A233_120829_SN1120_0183_AC18U8ACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3WX-01A	D63C186D-ADD6-492E-8250-E83F46D39D00	Primary Tumor	Illumina HiSeq	12365344-0a7a-4ef2-a651-2f1f3a15f6a1	Bladder	67	FED73C89-75F1-45C9-B14B-7840C52C305F	A6D2A8FB-6A01-4625-AEB9-FFA9476B658E	TCGA-DK-A3WX-01A-22D-A233-26	HG19_Broad_variant	TCGA-DK-A3WX	TCGA-BLCA	321	s2899	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	TRUE
13722.58cfa831e4b0c9d6adf6c9ce	58cfa831e4b0c9d6adf6c9ce	TCGA-DK-A3WY-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A3WY-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_7_rg.sorted	TCGA-DK-A3WY-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_7_rg.sorted.bam	13.9	NA	0.15	58cfa831e4b0c9d6adf6c9ce	TCGA-DK-A3WY-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3WY-01A	9BB5D187-033E-4E86-A76E-E1A6D20488F7	Primary Tumor	Illumina HiSeq	ae1b3911-b342-4886-b75a-3e9be21dae41	Bladder	67	33D579B3-198D-46CA-B2CF-574A0673E26F	ABA3AF01-2CBD-4450-9CCB-698DF8982E91	TCGA-DK-A3WY-01A-11D-A233-26	HG19_Broad_variant	TCGA-DK-A3WY	TCGA-BLCA	NA	s2895	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	TRUE
13722.58cfa831e4b0c9d6adf6cb30	58cfa831e4b0c9d6adf6cb30	TCGA-EA-A3HQ-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EA-A3HQ-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_3_rg.sorted	TCGA-EA-A3HQ-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_3_rg.sorted.bam	14.36	NA	0.15	58cfa831e4b0c9d6adf6cb30	TCGA-EA-A3HQ-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HQ-01A	6BF00B63-89F8-420C-8D36-F680FB0908B1	Primary Tumor	Illumina HiSeq	33c80031-f923-4aa0-adfa-9e229f413f83	Cervix	60	E4B391D9-2F3E-474C-AFA0-FDF4FD11FDF9	0032959A-5D7B-4D74-927E-25F79EF25D49	TCGA-EA-A3HQ-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EA-A3HQ	TCGA-CESC	NA	s1180	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T2a	N0	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa832e4b0c9d6adf6ce0e	58cfa832e4b0c9d6adf6ce0e	TCGA-FD-A3N5-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FD-A3N5-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_5_rg.sorted	TCGA-FD-A3N5-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_5_rg.sorted.bam	30.45	NA	0.15	58cfa832e4b0c9d6adf6ce0e	TCGA-FD-A3N5-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_5_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3N5-01A	A658BECF-3934-49F2-9E74-291DCA61D4BB	Primary Tumor	Illumina HiSeq	b9214ac8-956d-471d-8cad-a44ddc8825e8	Bladder	69	66559B5F-AB2F-406B-9EDB-0F5085EEC7C5	BA548041-624F-4357-A9F9-3BE29A3FF4FD	TCGA-FD-A3N5-01A-11D-A21C-26	HG19_Broad_variant	TCGA-FD-A3N5	TCGA-BLCA	NA	s2907	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A21C-26	TRUE
13722.58cfa832e4b0c9d6adf6cfc9	58cfa832e4b0c9d6adf6cfc9	TCGA-FU-A3HZ-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FU-A3HZ-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_4_rg.sorted	TCGA-FU-A3HZ-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_4_rg.sorted.bam	19.8	NA	0.16	58cfa832e4b0c9d6adf6cfc9	TCGA-FU-A3HZ-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3HZ-01A	6FF12A54-10DA-4941-BFEA-7B66E19B4BE9	Primary Tumor	Illumina HiSeq	40af9367-bd77-4c64-98d6-d2e2c6e5c11a	Cervix	64	6408A1F5-F5F7-40C8-A2EE-CB8038C15C95	230B8BFA-EBC7-4058-AA0C-78CA7DD01386	TCGA-FU-A3HZ-01A-11D-A20X-26	HG19_Broad_variant	TCGA-FU-A3HZ	TCGA-CESC	NA	s1202	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2a2	N0	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa832e4b0c9d6adf6d0c9	58cfa832e4b0c9d6adf6d0c9	TCGA-IG-A3YB-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IG-A3YB-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_3_rg.sorted	TCGA-IG-A3YB-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_3_rg.sorted.bam	34.41	NA	0.15	58cfa832e4b0c9d6adf6d0c9	TCGA-IG-A3YB-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3YB-01A	A1A233EA-5DDA-4EEB-BD92-6667E8B3EF57	Primary Tumor	Illumina HiSeq	6b51ea9f-5ca3-4973-bc0f-8df5ae95abbd	Esophagus	61	F936DE42-1441-4C4C-882A-DC67D332C125	335AAD40-B278-4EEC-BEE6-FC4F77C63370	TCGA-IG-A3YB-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3YB	TCGA-ESCA	NA	s1911	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T3	N1	Not available	Stage IIIA	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6cfe8	58cfa832e4b0c9d6adf6cfe8	TCGA-GV-A3JX-01A-11D-A210_120912_SN1222_0148_AC188PACXX_s_1_rg.sorted.filtered.	WGS	TCGA-GV-A3JX-01A-11D-A210_120912_SN1222_0148_AC188PACXX_s_1_rg.sorted	TCGA-GV-A3JX-01A-11D-A210_120912_SN1222_0148_AC188PACXX_s_1_rg.sorted.bam	67.04	NA	0.15	58cfa832e4b0c9d6adf6cfe8	TCGA-GV-A3JX-01A-11D-A210_120912_SN1222_0148_AC188PACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3JX-01A	D9DCBB57-F6C2-4465-8A60-AFE876E113CA	Primary Tumor	Illumina HiSeq	317cc3f0-7a98-402b-bb1f-81a0437fbaf8	Bladder	59	CE32612D-F504-4164-AE50-04C4AC2999FB	A8636E11-C752-46F4-A6A8-42D5B7DCBD02	TCGA-GV-A3JX-01A-11D-A210-26	HG19_Broad_variant	TCGA-GV-A3JX	TCGA-BLCA	NA	s2736	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	TRUE
13722.58cfa832e4b0c9d6adf6d0e2	58cfa832e4b0c9d6adf6d0e2	TCGA-IG-A3YC-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-IG-A3YC-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_5_rg.sorted	TCGA-IG-A3YC-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_5_rg.sorted.bam	24.61	NA	0.15	58cfa832e4b0c9d6adf6d0e2	TCGA-IG-A3YC-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3YC-01A	6A05288E-D051-40A5-9F4E-864AB806A5DC	Primary Tumor	Illumina HiSeq	a1261941-39f5-47ec-a6a4-ab07b298fb93	Esophagus	62	C754C363-924A-404A-9D60-4CA2A3930D2A	44EE541C-5657-43A9-9D56-6D88319E4617	TCGA-IG-A3YC-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3YC	TCGA-ESCA	NA	s1622	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T3	N1	Not available	Stage IIIA	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d126	58cfa832e4b0c9d6adf6d126	TCGA-FY-A3ON-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FY-A3ON-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_1_rg.sorted	TCGA-FY-A3ON-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_1_rg.sorted.bam	44.16	NA	0.14	58cfa832e4b0c9d6adf6d126	TCGA-FY-A3ON-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3ON-01A	4D1AEC67-C345-4721-8EE8-356B0DFF009B	Primary Tumor	Illumina HiSeq	276539e6-e471-4dc2-96e7-0c80fb486af1	Thyroid	20	1392A49C-87BC-45E7-B7D2-ACD53E921467	68FEC551-495D-47E6-BF85-FBD422FC68D6	TCGA-FY-A3ON-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3ON	TCGA-THCA	NA	s12121	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6d196	58cfa832e4b0c9d6adf6d196	TCGA-K4-A3WV-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_6_rg.sorted.filtered.	WGS	TCGA-K4-A3WV-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_6_rg.sorted	TCGA-K4-A3WV-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_6_rg.sorted.bam	33.77	NA	0.15	58cfa832e4b0c9d6adf6d196	TCGA-K4-A3WV-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-K4-A3WV-01A	D53EADE8-A845-4252-AECE-92F3573486A7	Primary Tumor	Illumina HiSeq	ca7a6b06-a6fa-4314-80ef-725b81781598	Bladder	77	3ADFA409-A9F8-4EDB-AAF7-C5285AE5F895	9A7CA3A1-631F-41BA-A490-04D470C4AF8E	TCGA-K4-A3WV-01A-11D-A23Q-26	HG19_Broad_variant	TCGA-K4-A3WV	TCGA-BLCA	NA	s2937	MD Anderson - Institute for Applied Cancer Science	ABS - Lahey Clinic	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A23Q-26	TRUE
13722.58cfa832e4b0c9d6adf6d2a6	58cfa832e4b0c9d6adf6d2a6	TCGA-IR-A3LL-01A-11D-A20X_140117_SN590_0245_AC371LACXX_s_4_rg.sorted.filtered.	WGS	TCGA-IR-A3LL-01A-11D-A20X_140117_SN590_0245_AC371LACXX_s_4_rg.sorted	TCGA-IR-A3LL-01A-11D-A20X_140117_SN590_0245_AC371LACXX_s_4_rg.sorted.bam	66.26	NA	0.15	58cfa832e4b0c9d6adf6d2a6	TCGA-IR-A3LL-01A-11D-A20X_140117_SN590_0245_AC371LACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LL-01A	7C4AB1CA-4BDD-4EF7-9A42-F6C0C7136D26	Primary Tumor	Illumina HiSeq	817ccf3b-ceaa-45cf-a938-67e531a9f57a	Cervix	60	A0FB972A-CE8F-441F-8707-C3CC1081DEE0	5457562E-E184-4D13-B11C-49728B689275	TCGA-IR-A3LL-01A-11D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LL	TCGA-CESC	NA	s1378	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa832e4b0c9d6adf6d362	58cfa832e4b0c9d6adf6d362	TCGA-L5-A4OH-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-L5-A4OH-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_5_rg.sorted	TCGA-L5-A4OH-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_5_rg.sorted.bam	43.66	NA	0.17	58cfa832e4b0c9d6adf6d362	TCGA-L5-A4OH-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OH-01A	3FA7FC16-49DA-4BF6-90C4-74DF5CF68B65	Primary Tumor	Illumina HiSeq	ba83865e-0ba3-48ab-841f-de07856ee9bc	Esophagus	71	4029F7BA-1D2D-49B8-A37B-4D4A5D0ACB79	C886B6DD-1595-49DD-B4DA-B69AA9C813E4	TCGA-L5-A4OH-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OH	TCGA-ESCA	NA	s1747	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0	Not available	Stage I	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d388	58cfa832e4b0c9d6adf6d388	TCGA-L5-A4OP-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OP-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_1_rg.sorted	TCGA-L5-A4OP-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_1_rg.sorted.bam	41.04	NA	0.17	58cfa832e4b0c9d6adf6d388	TCGA-L5-A4OP-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OP-01A	97031483-1185-41D6-9722-0A03B63CAA19	Primary Tumor	Illumina HiSeq	940f64ee-414a-4190-9fc9-c697ad112dfe	Esophagus	67	BA02D5B4-9CA9-4455-81D4-E5F2C8C0DF74	5D8E8DA5-04FF-4548-96EC-AE1E80C57CD1	TCGA-L5-A4OP-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OP	TCGA-ESCA	NA	s1923	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0	Not available	Stage IA	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d386	58cfa832e4b0c9d6adf6d386	TCGA-LN-A4A3-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A4A3-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_5_rg.sorted	TCGA-LN-A4A3-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_5_rg.sorted.bam	20.45	NA	0.16	58cfa832e4b0c9d6adf6d386	TCGA-LN-A4A3-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4A3-01A	3C0BB5E2-AD33-4D91-A31E-2A18F1C94D2D	Primary Tumor	Illumina HiSeq	e04a9b3d-9bc4-4857-9030-288efed94e80	Esophagus	61	3C85B0AB-C83E-4371-9F53-6A71D3763F3F	5402975D-7AE7-46FC-847A-4EE7DEBCD553	TCGA-LN-A4A3-01A-11D-A267-26	HG19_Broad_variant	TCGA-LN-A4A3	TCGA-ESCA	NA	s1770	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1	Not available	Stage III	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d418	58cfa832e4b0c9d6adf6d418	TCGA-V4-A9F2-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9F2-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_2_rg.sorted	TCGA-V4-A9F2-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_2_rg.sorted.bam	38.01	NA	0.16	58cfa832e4b0c9d6adf6d418	TCGA-V4-A9F2-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F2-01A	411DDF79-FE92-44AD-8D10-EEB703F11BE7	Primary Tumor	Illumina HiSeq	c4fcd1a4-5246-4a6b-b5b0-45b8b838edf2	Eye	78	2F2FF6C7-9568-47E4-AB09-6050F84BBF5C	87781EA6-C3E9-476A-B5D2-E58FC557FC7A	TCGA-V4-A9F2-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F2	TCGA-UVM	NA	s207	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3b	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d474	58cfa832e4b0c9d6adf6d474	TCGA-V4-A9EI-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-V4-A9EI-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_6_rg.sorted	TCGA-V4-A9EI-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_6_rg.sorted.bam	32.62	NA	0.17	58cfa832e4b0c9d6adf6d474	TCGA-V4-A9EI-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EI-01A	B533E555-90CF-4657-80C6-15B67DA8AD26	Primary Tumor	Illumina HiSeq	ffc1ec43-7da7-4a9b-ab87-1ad3a3ba5c42	Eye	78	0077CCB8-615D-4725-95E7-72708732E963	B0CCF5D2-B334-4B7C-858E-53005B6FD0D7	TCGA-V4-A9EI-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EI	TCGA-UVM	389	s203	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4c	N0	Not available	Stage IIIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d416	58cfa832e4b0c9d6adf6d416	TCGA-VD-A8K9-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_2_rg.sorted.filtered.	WGS	TCGA-VD-A8K9-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_2_rg.sorted	TCGA-VD-A8K9-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_2_rg.sorted.bam	33.22	NA	0.15	58cfa832e4b0c9d6adf6d416	TCGA-VD-A8K9-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-A8K9-01A	FA9089FA-9AF9-4932-8AB7-0E7F2FD6B121	Primary Tumor	Illumina HiSeq	bd825a81-851e-4e11-a617-ff32ec721c33	Eye	71	25BDDCB7-2759-42F7-A8EB-D67F0D973802	03211DE4-51EB-4AB9-84CB-30D7A6F12025	TCGA-VD-A8K9-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8K9	TCGA-UVM	NA	s277	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T2a	NX	Not available	Stage IIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4aa	58cfa832e4b0c9d6adf6d4aa	TCGA-V4-A9ET-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_5_rg.sorted.filtered.	WGS	TCGA-V4-A9ET-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_5_rg.sorted	TCGA-V4-A9ET-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_5_rg.sorted.bam	57.02	NA	0.17	58cfa832e4b0c9d6adf6d4aa	TCGA-V4-A9ET-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9ET-01A	5383FB57-69C2-4B34-AF7F-C67208EFB2B5	Primary Tumor	Illumina HiSeq	98f43560-a2c1-4edb-a936-9c84114cf0c2	Eye	57	C16B2576-AB56-4BEB-B621-22EA9FC4E898	D544884F-7E0D-4029-B778-55E14B5C2C38	TCGA-V4-A9ET-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9ET	TCGA-UVM	NA	s244	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4b	N0	Not available	Stage IIIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d426	58cfa832e4b0c9d6adf6d426	TCGA-V4-A9F0-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9F0-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_4_rg.sorted	TCGA-V4-A9F0-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_4_rg.sorted.bam	54.63	NA	0.15	58cfa832e4b0c9d6adf6d426	TCGA-V4-A9F0-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F0-01A	92FCA97D-6123-46A7-9C34-7A6F877FE612	Primary Tumor	Illumina HiSeq	96f55937-5d74-4e04-8ab5-f928a9a23da4	Eye	59	62859C7E-4B8D-4122-9365-B1595E944C42	C752F975-1E44-4EDF-87BA-4823698AC3F5	TCGA-V4-A9F0-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F0	TCGA-UVM	NA	s227	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4b	N0	Not available	Stage IIIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4a6	58cfa832e4b0c9d6adf6d4a6	TCGA-V4-A9EW-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_8_rg.sorted.filtered.	WGS	TCGA-V4-A9EW-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_8_rg.sorted	TCGA-V4-A9EW-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_8_rg.sorted.bam	43.67	NA	0.16	58cfa832e4b0c9d6adf6d4a6	TCGA-V4-A9EW-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EW-01A	6BE5176C-4980-4663-ADFF-D04F05737DA0	Primary Tumor	Illumina HiSeq	3dd4d560-67ce-426b-9eeb-63fec58eaf05	Eye	44	685D5387-B35F-40EE-8F14-491CE212F0DE	6B52C651-649F-41C5-B0DD-197F77F2AA10	TCGA-V4-A9EW-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EW	TCGA-UVM	NA	s216	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4c6	58cfa832e4b0c9d6adf6d4c6	TCGA-VD-A8KA-01B-11D-A40D_140716_SN208_0518_AC59RNACXX_s_3_rg.sorted.filtered.	WGS	TCGA-VD-A8KA-01B-11D-A40D_140716_SN208_0518_AC59RNACXX_s_3_rg.sorted	TCGA-VD-A8KA-01B-11D-A40D_140716_SN208_0518_AC59RNACXX_s_3_rg.sorted.bam	26.17	NA	0.16	58cfa832e4b0c9d6adf6d4c6	TCGA-VD-A8KA-01B-11D-A40D_140716_SN208_0518_AC59RNACXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-A8KA-01B	AF04CA52-8B71-497E-8135-6DDFCA9AB221	Primary Tumor	Illumina HiSeq	c48413ae-339d-4a00-8615-5fbb50dad7b2	Eye	22	F028A8C2-1AD9-4CCD-9EF4-076F90D73806	CE40220B-D109-4A14-9C17-3C7DFD0A737A	TCGA-VD-A8KA-01B-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KA	TCGA-UVM	NA	s262	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T3a	NX	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4ca	58cfa832e4b0c9d6adf6d4ca	TCGA-V4-A9F5-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-V4-A9F5-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_1_rg.sorted	TCGA-V4-A9F5-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_1_rg.sorted.bam	57.62	NA	0.17	58cfa832e4b0c9d6adf6d4ca	TCGA-V4-A9F5-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F5-01A	BBF07E1F-8C17-4C2E-89ED-38332D82E455	Primary Tumor	Illumina HiSeq	11ec05e6-4b9a-4abf-8b47-45f259c5eaf3	Eye	85	16FCA21C-963E-4D77-8B5A-3C178DAC6168	38812469-1716-4B6F-8DBE-822654AC13F6	TCGA-V4-A9F5-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F5	TCGA-UVM	NA	s245	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4e	N0	Not available	Stage IV	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d54e	58cfa832e4b0c9d6adf6d54e	TCGA-L5-A4OS-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-L5-A4OS-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_3_rg.sorted	TCGA-L5-A4OS-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_3_rg.sorted.bam	26.15	NA	0.16	58cfa832e4b0c9d6adf6d54e	TCGA-L5-A4OS-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OS-01A	D5AC647F-0C6D-40D7-87A8-FAA1CC968C82	Primary Tumor	Illumina HiSeq	5c0f7af4-2359-4784-8db9-a4acac6fbb09	Esophagus	86	8734680B-CA7B-49F4-A539-0182B45454F3	C3CAE2EF-E23F-4D72-8B4F-E9F9AF08340D	TCGA-L5-A4OS-01A-11D-A28P-26	HG19_Broad_variant	TCGA-L5-A4OS	TCGA-ESCA	NA	s1849	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T2	N1	Not available	Stage IIB	A28P-26	TRUE
13722.58cfa832e4b0c9d6adf6d528	58cfa832e4b0c9d6adf6d528	TCGA-L5-A4OJ-01A-11D-A267_131018_SN590_0241_BC30HBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OJ-01A-11D-A267_131018_SN590_0241_BC30HBACXX_s_1_rg.sorted	TCGA-L5-A4OJ-01A-11D-A267_131018_SN590_0241_BC30HBACXX_s_1_rg.sorted.bam	44.72	NA	0.17	58cfa832e4b0c9d6adf6d528	TCGA-L5-A4OJ-01A-11D-A267_131018_SN590_0241_BC30HBACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OJ-01A	CB419344-6148-43D4-B549-570BD09B3E05	Primary Tumor	Illumina HiSeq	b8117191-ea00-451f-85ca-53357a42b44f	Esophagus	70	4F03824A-79D6-40E8-A9E0-4079B1209F38	74221A72-4B40-4943-877D-7979EB4BD268	TCGA-L5-A4OJ-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OJ	TCGA-ESCA	NA	s1651	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0	Not available	Stage I	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d4f8	58cfa832e4b0c9d6adf6d4f8	TCGA-L5-A4OT-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-L5-A4OT-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_7_rg.sorted	TCGA-L5-A4OT-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_7_rg.sorted.bam	28.48	NA	0.14	58cfa832e4b0c9d6adf6d4f8	TCGA-L5-A4OT-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OT-01A	9559F579-5D9A-4C96-9836-8A039D394795	Primary Tumor	Illumina HiSeq	7d4e10aa-fe0f-4c18-800f-98fde94f819b	Esophagus	77	6671C9B7-5445-40F1-ADB6-FCC8BAD25301	79E420D7-8852-45A0-BBEB-CAEEC5BE685F	TCGA-L5-A4OT-01A-11D-A28P-26	HG19_Broad_variant	TCGA-L5-A4OT	TCGA-ESCA	149	s1927	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T3	N1	Not available	Stage IV	A28P-26	TRUE
13722.58cfa832e4b0c9d6adf6d5a8	58cfa832e4b0c9d6adf6d5a8	TCGA-LN-A49S-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A49S-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_5_rg.sorted	TCGA-LN-A49S-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_5_rg.sorted.bam	29.69	NA	0.17	58cfa832e4b0c9d6adf6d5a8	TCGA-LN-A49S-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49S-01A	E9F82800-647A-4D61-BD1F-2C17C4CCAFBA	Primary Tumor	Illumina HiSeq	f173addf-1b74-441d-b167-5eb17cdfe1c3	Esophagus	59	A83FF623-8AF0-44A9-8468-95457A017E5A	151B9A13-9D3D-4AF2-A779-24F62A13975B	TCGA-LN-A49S-01A-11D-A248-26	HG19_Broad_variant	TCGA-LN-A49S	TCGA-ESCA	NA	s1680	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0	Not available	Stage IIA	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d4fa	58cfa832e4b0c9d6adf6d4fa	TCGA-L5-A4OE-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OE-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_1_rg.sorted	TCGA-L5-A4OE-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_1_rg.sorted.bam	43.86	NA	0.16	58cfa832e4b0c9d6adf6d4fa	TCGA-L5-A4OE-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OE-01A	0A466142-C513-4257-85D4-4BD7CFD0EF29	Primary Tumor	Illumina HiSeq	49822c02-a9e7-4e7e-bd12-f1756b639beb	Esophagus	81	BD8CADB2-1382-4BF5-A68F-C5A71837FE95	C5F599A9-1398-4E49-9CC7-77129658E143	TCGA-L5-A4OE-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OE	TCGA-ESCA	NA	s1838	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T3	N2	Not available	Stage IIIB	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d5f8	58cfa832e4b0c9d6adf6d5f8	TCGA-LN-A49K-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-LN-A49K-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_1_rg.sorted	TCGA-LN-A49K-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_1_rg.sorted.bam	28.24	NA	0.15	58cfa832e4b0c9d6adf6d5f8	TCGA-LN-A49K-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49K-01A	0F06153A-0F28-4A7E-9E81-1E0B3F4412AB	Primary Tumor	Illumina HiSeq	acf1b0d3-d28b-4f31-acbc-52f1f4e5dca1	Esophagus	66	F60AAA21-7D4E-4988-94BD-69F0929560A5	E09E9D66-13C9-481C-BAE1-C5DF26292666	TCGA-LN-A49K-01A-11D-A248-26	HG19_Broad_variant	TCGA-LN-A49K	TCGA-ESCA	NA	s1666	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0	Not available	Stage IIA	A248-26	TRUE
13722.58cfa830e4b0c9d6adf6c260	58cfa830e4b0c9d6adf6c260	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted.bam	48.29	NA	0.14	58cfa830e4b0c9d6adf6c260	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HL-01A	09329A53-D58D-4480-95D8-32043E40DE6E	Primary Tumor	Illumina HiSeq	84c6e022-f737-4fae-a2c7-812ef4f00adf	Cervix	76	2A3CC87B-B120-49EC-93E6-8BDDBAE5C97C	04FC6219-3EAC-4BB8-82CA-CD0AA6B0ACE3	TCGA-C5-A3HL-01A-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A3HL	TCGA-CESC	NA	s1516	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa831e4b0c9d6adf6c4e4	58cfa831e4b0c9d6adf6c4e4	TCGA-C5-A2LZ-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_2_rg.sorted.filtered.	WGS	TCGA-C5-A2LZ-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_2_rg.sorted	TCGA-C5-A2LZ-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_2_rg.sorted.bam	58.89	NA	0.17	58cfa831e4b0c9d6adf6c4e4	TCGA-C5-A2LZ-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2LZ-01A	BE8FA67D-C2D3-4FFF-82FE-A46BA1FA8DF0	Primary Tumor	Illumina HiSeq	19f84215-7f5d-4cf8-a6f5-e135327ccd50	Cervix	65	6B9F4254-DBD3-4D82-BAE8-D43A4915A7CD	837B293C-0843-4002-A8AB-3A945E040C75	TCGA-C5-A2LZ-01A-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A2LZ	TCGA-CESC	3046	s1173	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	Not available	Not available	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa831e4b0c9d6adf6c63a	58cfa831e4b0c9d6adf6c63a	TCGA-CG-4304-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-4304-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_3_rg.sorted	TCGA-CG-4304-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_3_rg.sorted.bam	286.2	1.9	0.16	58cfa831e4b0c9d6adf6c63a	TCGA-CG-4304-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4304-01A	8E005891-D6FE-4FEE-A699-971FEE4E70F1	Primary Tumor	Illumina HiSeq	4fbdbad3-32cb-45de-990a-1337f32a25fa	Stomach	84	CC852701-8996-4C8B-828D-5C4AC1F4CFD4	46FB2601-D210-4528-B7D9-BE054DD54BFD	TCGA-CG-4304-01A-01D-A326-26	HG19_Broad_variant	TCGA-CG-4304	TCGA-STAD	NA	s14549	MD Anderson - Institute for Applied Cancer Science	Indivumed	Germany	NO	T2a	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	A326-26	TRUE
13722.58cfa831e4b0c9d6adf6c68f	58cfa831e4b0c9d6adf6c68f	TCGA-CU-A3YL-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CU-A3YL-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_3_rg.sorted	TCGA-CU-A3YL-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_3_rg.sorted.bam	42.41	NA	0.15	58cfa831e4b0c9d6adf6c68f	TCGA-CU-A3YL-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A3YL-01A	087A7F70-2FA8-4A16-B130-4DF10A70C662	Primary Tumor	Illumina HiSeq	8753d7f5-4d92-4781-8d19-d44710fa4f45	Bladder	67	F66AD788-E2D8-4688-820F-49A609701533	CAD008C4-3B53-4E9D-8730-9807E4753DDD	TCGA-CU-A3YL-01A-11D-A233-26	HG19_Broad_variant	TCGA-CU-A3YL	TCGA-BLCA	NA	s3274	MD Anderson - Institute for Applied Cancer Science	UNC	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	TRUE
13722.58cfa831e4b0c9d6adf6c741	58cfa831e4b0c9d6adf6c741	TCGA-CV-7247-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CV-7247-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_7_rg.sorted	TCGA-CV-7247-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_7_rg.sorted.bam	52.73	NA	0.13	58cfa831e4b0c9d6adf6c741	TCGA-CV-7247-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7247-01A	5E25AB76-A8AB-4779-AA03-8DE658F18DA1	Primary Tumor	Illumina HiSeq	0b4ae8f3-7acd-4d37-a39f-cb4fc2b537b4	Head and Neck	55	F84AE44B-4BB7-4841-AEE0-139CD79B9680	A5BA905A-C959-4118-B1C9-F6466CB5541A	TCGA-CV-7247-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7247	TCGA-HNSC	577	s15904	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c830	58cfa831e4b0c9d6adf6c830	TCGA-CV-7407-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-7407-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_8_rg.sorted	TCGA-CV-7407-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_8_rg.sorted.bam	131.73	NA	0.16	58cfa831e4b0c9d6adf6c830	TCGA-CV-7407-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7407-01A	8B63BE59-9CE6-45A0-80D9-4D20F4918CB9	Primary Tumor	Illumina HiSeq	e5709830-4141-4354-94f0-94f576fe84c9	Head and Neck	67	6ABAF81A-B228-4AFE-B931-BC1FC39CD265	4CC9AD85-2F84-4657-8F3E-6C5DD69F1B30	TCGA-CV-7407-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7407	TCGA-HNSC	1081	s15909	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c8ba	58cfa831e4b0c9d6adf6c8ba	TCGA-DK-A3IM-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A3IM-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_7_rg.sorted	TCGA-DK-A3IM-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_7_rg.sorted.bam	26.41	NA	0.15	58cfa831e4b0c9d6adf6c8ba	TCGA-DK-A3IM-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IM-01A	41B59716-116F-4942-8B63-409870A87E26	Primary Tumor	Illumina HiSeq	27ca0d22-3ef8-4c3c-814a-94dfb76c3289	Bladder	76	7A37AE7C-6B46-410D-AE2B-12FD868C25B3	CDAC6FE7-FB06-4F9A-86D0-DF0DF26FD558	TCGA-DK-A3IM-01A-11D-A210-26	HG19_Broad_variant	TCGA-DK-A3IM	TCGA-BLCA	NA	s2882	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	TRUE
13722.58cfa831e4b0c9d6adf6c9e6	58cfa831e4b0c9d6adf6c9e6	TCGA-DK-A3X1-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A3X1-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_1_rg.sorted	TCGA-DK-A3X1-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_1_rg.sorted.bam	47.57	NA	0.16	58cfa831e4b0c9d6adf6c9e6	TCGA-DK-A3X1-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3X1-01A	6BDDAFDE-7004-49B6-80CF-8081CD4B7D44	Primary Tumor	Illumina HiSeq	4c8de054-fd6d-4ebd-8a6e-b5061ef5913b	Bladder	78	3D440A83-214E-432F-89D2-B523BFE7C6EF	4A8B5117-AF70-40AB-9698-B736EF20F3DE	TCGA-DK-A3X1-01A-12D-A233-26	HG19_Broad_variant	TCGA-DK-A3X1	TCGA-BLCA	NA	s3286	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	TRUE
13722.58cfa831e4b0c9d6adf6ca0f	58cfa831e4b0c9d6adf6ca0f	TCGA-DK-A3X2-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A3X2-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_3_rg.sorted	TCGA-DK-A3X2-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_3_rg.sorted.bam	51.32	NA	0.15	58cfa831e4b0c9d6adf6ca0f	TCGA-DK-A3X2-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3X2-01A	40551D53-388B-4067-9341-76E94D023703	Primary Tumor	Illumina HiSeq	a8b7a158-32d0-421e-82bd-edb6a44d69e0	Bladder	85	3B816277-91CB-413E-BC7C-BA33CD72B67D	5D13DEBC-82D6-45EA-A9EA-A85B85CF659F	TCGA-DK-A3X2-01A-11D-A233-26	HG19_Broad_variant	TCGA-DK-A3X2	TCGA-BLCA	547	s2716	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	TRUE
13722.58cfa831e4b0c9d6adf6caf8	58cfa831e4b0c9d6adf6caf8	TCGA-EA-A3HR-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EA-A3HR-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_1_rg.sorted	TCGA-EA-A3HR-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_1_rg.sorted.bam	47.83	NA	0.16	58cfa831e4b0c9d6adf6caf8	TCGA-EA-A3HR-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HR-01A	638035F6-2909-4A44-980F-468AC5D74E18	Primary Tumor	Illumina HiSeq	a2c5a51a-5933-4597-b207-2c761c54f7c2	Cervix	57	1FBFA952-F272-4531-9F9D-1B8BD1DD0845	2B1D8BBD-0F37-40D4-AF38-C78C4BB556BB	TCGA-EA-A3HR-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EA-A3HR	TCGA-CESC	NA	s1179	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T2a	N0	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa831e4b0c9d6adf6cb28	58cfa831e4b0c9d6adf6cb28	TCGA-E7-A3Y1-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-E7-A3Y1-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_7_rg.sorted	TCGA-E7-A3Y1-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_7_rg.sorted.bam	43.56	NA	0.17	58cfa831e4b0c9d6adf6cb28	TCGA-E7-A3Y1-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-E7-A3Y1-01A	F7C891EB-3B09-4E01-BB8A-53D570518CBE	Primary Tumor	Illumina HiSeq	aaeb4857-84bb-4a72-9e0d-81280de1ca61	Bladder	57	FABE5B98-4586-445D-9513-598BB7FD1909	46542747-5AF3-4F7E-AE97-7E0689976D0A	TCGA-E7-A3Y1-01A-11D-A233-26	HG19_Broad_variant	TCGA-E7-A3Y1	TCGA-BLCA	NA	s3109	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO	Not available	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A233-26	TRUE
13722.58cfa831e4b0c9d6adf6cc1e	58cfa831e4b0c9d6adf6cc1e	TCGA-EM-A3OB-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EM-A3OB-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_7_rg.sorted	TCGA-EM-A3OB-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_7_rg.sorted.bam	51.44	NA	0.15	58cfa831e4b0c9d6adf6cc1e	TCGA-EM-A3OB-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_7_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A3OB-01A	8CFC2589-B0AD-4FE6-8420-8F6FE0178BCC	Primary Tumor	Illumina HiSeq	2d07ef47-3523-49c8-9f8e-64e984c3ceda	Thyroid	33	8133FCFE-ECC4-4503-B81E-00FDF6F87426	F90A631C-4556-43E2-8AA2-1114326B6984	TCGA-EM-A3OB-01A-11D-A221-26	HG19_Broad_variant	TCGA-EM-A3OB	TCGA-THCA	NA	s12384	MD Anderson - Institute for Applied Cancer Science	University Health Network	Canada	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A221-26	TRUE
13722.58cfa831e4b0c9d6adf6cc63	58cfa831e4b0c9d6adf6cc63	TCGA-EA-A3HU-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EA-A3HU-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_3_rg.sorted	TCGA-EA-A3HU-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_3_rg.sorted.bam	40.2	NA	0.16	58cfa831e4b0c9d6adf6cc63	TCGA-EA-A3HU-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HU-01A	9912432E-74BC-4846-93B4-FA2BF8070BD1	Primary Tumor	Illumina HiSeq	4f5312e3-89a9-41d7-a296-8b90e22cb408	Cervix	43	05409DA8-60DC-4073-91F0-F91832F3A607	B66F8B97-9149-4C12-A66E-4BC7D1352269	TCGA-EA-A3HU-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EA-A3HU	TCGA-CESC	NA	s1520	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T2a2	N0	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa831e4b0c9d6adf6cc3e	58cfa831e4b0c9d6adf6cc3e	TCGA-EM-A3FR-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EM-A3FR-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_6_rg.sorted	TCGA-EM-A3FR-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_6_rg.sorted.bam	45.93	NA	0.15	58cfa831e4b0c9d6adf6cc3e	TCGA-EM-A3FR-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_6_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A3FR-01A	2B84CFBC-7CF6-4CB1-A1E3-BA85DAFB89F4	Primary Tumor	Illumina HiSeq	0430ed44-5b5d-4b22-b78a-9b9ecd259736	Thyroid	55	319E3498-D5FB-4142-A09F-ABA779DBC094	FEA6D565-EDBC-4FB7-ADB8-090914F4259E	TCGA-EM-A3FR-01A-11D-A221-26	HG19_Broad_variant	TCGA-EM-A3FR	TCGA-THCA	NA	s12247	MD Anderson - Institute for Applied Cancer Science	University Health Network	Canada	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	TRUE
13722.58cfa831e4b0c9d6adf6cc9c	58cfa831e4b0c9d6adf6cc9c	TCGA-FD-A3SM-01A-11D-A233_120830_SN208_0423_AC190AACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FD-A3SM-01A-11D-A233_120830_SN208_0423_AC190AACXX_s_5_rg.sorted	TCGA-FD-A3SM-01A-11D-A233_120830_SN208_0423_AC190AACXX_s_5_rg.sorted.bam	22.6	NA	0.16	58cfa831e4b0c9d6adf6cc9c	TCGA-FD-A3SM-01A-11D-A233_120830_SN208_0423_AC190AACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SM-01A	474582F2-8DEC-4FBC-803F-4FD9BA2E0957	Primary Tumor	Illumina HiSeq	bacf3136-6605-4a66-a869-8d91e4003a0d	Bladder	70	5F7DE481-C011-43A8-844B-F47569499F0D	AF7DFCCA-999E-4EA2-A14B-1E923C2ECE38	TCGA-FD-A3SM-01A-11D-A233-26	HG19_Broad_variant	TCGA-FD-A3SM	TCGA-BLCA	NA	s3299	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	TRUE
13722.58cfa831e4b0c9d6adf6ccd2	58cfa831e4b0c9d6adf6ccd2	TCGA-EM-A3OA-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EM-A3OA-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_6_rg.sorted	TCGA-EM-A3OA-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_6_rg.sorted.bam	47.85	NA	0.16	58cfa831e4b0c9d6adf6ccd2	TCGA-EM-A3OA-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_6_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A3OA-01A	24CF6397-60EF-4635-81F0-78A67157AAC0	Primary Tumor	Illumina HiSeq	ddf917ff-6b4d-45ca-a503-8d6449f76e72	Thyroid	55	8B048263-6C2F-4BF6-8F37-C69DA9F3839F	2604E6C9-A117-49DC-A06E-082E63859DCA	TCGA-EM-A3OA-01A-11D-A221-26	HG19_Broad_variant	TCGA-EM-A3OA	TCGA-THCA	NA	s12249	MD Anderson - Institute for Applied Cancer Science	University Health Network	Canada	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6d11f	58cfa832e4b0c9d6adf6d11f	TCGA-IR-A3LK-01A-12D-A20X_140417_SN590_0248_AC3EUFACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IR-A3LK-01A-12D-A20X_140417_SN590_0248_AC3EUFACXX_s_3_rg.sorted	TCGA-IR-A3LK-01A-12D-A20X_140417_SN590_0248_AC3EUFACXX_s_3_rg.sorted.bam	71.39	NA	0.16	58cfa832e4b0c9d6adf6d11f	TCGA-IR-A3LK-01A-12D-A20X_140417_SN590_0248_AC3EUFACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LK-01A	B79558C5-1DB2-4B1E-A7B8-EFBD19AA855E	Primary Tumor	Illumina HiSeq	1c6981be-5fe3-4898-ba63-e0cd0eecc5e5	Cervix	69	DCA9FF1F-DD32-43DD-8FD4-446D014F5DB8	9E7C0BE8-042F-4B5F-BFE9-E993081589AD	TCGA-IR-A3LK-01A-12D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LK	TCGA-CESC	NA	s1376	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa832e4b0c9d6adf6d190	58cfa832e4b0c9d6adf6d190	TCGA-IR-A3LH-01A-21D-A20X_140117_SN590_0246_BC37BDACXX_s_8_rg.sorted.filtered.	WGS	TCGA-IR-A3LH-01A-21D-A20X_140117_SN590_0246_BC37BDACXX_s_8_rg.sorted	TCGA-IR-A3LH-01A-21D-A20X_140117_SN590_0246_BC37BDACXX_s_8_rg.sorted.bam	62.48	NA	0.15	58cfa832e4b0c9d6adf6d190	TCGA-IR-A3LH-01A-21D-A20X_140117_SN590_0246_BC37BDACXX_s_8_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LH-01A	F24ED9C0-92BB-4003-86D2-42AB26617A05	Primary Tumor	Illumina HiSeq	159f94e1-d4e4-45d7-9220-90578144802f	Cervix	49	D95E5389-DD55-4D55-AB01-6A770C66502F	7BDB76AA-01BA-48A8-A58A-29B118B8118A	TCGA-IR-A3LH-01A-21D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LH	TCGA-CESC	NA	s1535	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T2a1	N0	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa832e4b0c9d6adf6d19c	58cfa832e4b0c9d6adf6d19c	TCGA-HG-A2PA-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HG-A2PA-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_4_rg.sorted	TCGA-HG-A2PA-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_4_rg.sorted.bam	61.98	NA	0.15	58cfa832e4b0c9d6adf6d19c	TCGA-HG-A2PA-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-HG-A2PA-01A	E2FF7CFD-A101-45B9-895F-26F403E7BDFB	Primary Tumor	Illumina HiSeq	2c605f98-0c77-45ff-bcea-2fcf6094ca2d	Cervix	38	235DBD13-5052-4E19-9C1C-A72A1A9A79CE	ECE06317-01F9-4EF2-ACE0-E9B18C7F4DE1	TCGA-HG-A2PA-01A-11D-A20X-26	HG19_Broad_variant	TCGA-HG-A2PA	TCGA-CESC	NA	s1534	MD Anderson - Institute for Applied Cancer Science	Roswell Park	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa832e4b0c9d6adf6d19a	58cfa832e4b0c9d6adf6d19a	TCGA-IR-A3LC-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IR-A3LC-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_3_rg.sorted	TCGA-IR-A3LC-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_3_rg.sorted.bam	81.15	NA	0.15	58cfa832e4b0c9d6adf6d19a	TCGA-IR-A3LC-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LC-01A	58BDCACE-0047-456E-A225-68953EDAFE5E	Primary Tumor	Illumina HiSeq	8b84ea0a-0512-427e-8456-2facdcd978b9	Cervix	40	AC6D15A0-67CF-42AA-97DC-BA50D0E9F409	47A900B4-52E8-448E-B092-EEE4E394A309	TCGA-IR-A3LC-01A-11D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LC	TCGA-CESC	NA	s1375	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa832e4b0c9d6adf6d1f4	58cfa832e4b0c9d6adf6d1f4	TCGA-IG-A51D-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IG-A51D-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_3_rg.sorted	TCGA-IG-A51D-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_3_rg.sorted.bam	23.75	NA	0.16	58cfa832e4b0c9d6adf6d1f4	TCGA-IG-A51D-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A51D-01A	F8DBAB24-B9F4-4B8A-BFEA-57856CCF6364	Primary Tumor	Illumina HiSeq	c422f0b8-8f83-4d33-b800-bab29faa7b7b	Esophagus	63	3889C9FE-3777-4B3D-9CF1-12135D4D7F7D	02AA44BC-DD51-4A76-B94E-FF273011E904	TCGA-IG-A51D-01A-11D-A267-26	HG19_Broad_variant	TCGA-IG-A51D	TCGA-ESCA	NA	s1825	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1	N1	Not available	Stage IIB	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d222	58cfa832e4b0c9d6adf6d222	TCGA-IR-A3LI-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_5_rg.sorted.filtered.	WGS	TCGA-IR-A3LI-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_5_rg.sorted	TCGA-IR-A3LI-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_5_rg.sorted.bam	19.9	NA	0.16	58cfa832e4b0c9d6adf6d222	TCGA-IR-A3LI-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LI-01A	75BC22D8-738D-45F8-B6C0-C664F5FEF47C	Primary Tumor	Illumina HiSeq	3a9d3f81-919f-44e3-a9cc-813b4dcaf027	Cervix	48	EBFA4682-49C9-4AC1-8147-E3860D852D28	689630AD-8262-403B-9983-B4BAE99B8A45	TCGA-IR-A3LI-01A-11D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LI	TCGA-CESC	NA	s1210	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T2b	N1	Endocervical Type of Adenocarcinoma	Not available	A20X-26	TRUE
13722.58cfa832e4b0c9d6adf6d322	58cfa832e4b0c9d6adf6d322	TCGA-L5-A43C-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A43C-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_1_rg.sorted	TCGA-L5-A43C-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_1_rg.sorted.bam	21.33	NA	0.16	58cfa832e4b0c9d6adf6d322	TCGA-L5-A43C-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A43C-01A	A935DAEB-1EFD-4113-A614-A5E4D446C72B	Primary Tumor	Illumina HiSeq	f5b917a1-f719-4ee6-b994-c4bc7dbbc159	Esophagus	81	2DD3A5ED-42EF-4CA1-AC40-B2F486F0395A	74016C2E-EEC8-4FE9-A297-A4E64D797DEE	TCGA-L5-A43C-01A-11D-A248-26	HG19_Broad_variant	TCGA-L5-A43C	TCGA-ESCA	NA	s1646	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	Not available	Not available	Not available	Not available	A248-26	TRUE
13722.58cfa832e4b0c9d6adf6d37a	58cfa832e4b0c9d6adf6d37a	TCGA-LN-A4A2-01A-31D-A267_131001_SN1120_0279_AC2DKPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A4A2-01A-31D-A267_131001_SN1120_0279_AC2DKPACXX_s_5_rg.sorted	TCGA-LN-A4A2-01A-31D-A267_131001_SN1120_0279_AC2DKPACXX_s_5_rg.sorted.bam	18.85	NA	0.15	58cfa832e4b0c9d6adf6d37a	TCGA-LN-A4A2-01A-31D-A267_131001_SN1120_0279_AC2DKPACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4A2-01A	A91C3F09-5F48-4B54-B669-C768F9FE9682	Primary Tumor	Illumina HiSeq	2f75f56a-b508-4f23-97ee-ccf05449e360	Esophagus	57	9FA38DD4-123F-4A89-9124-372E03184A9C	F64DF8A5-1964-46A4-829C-6B0B8CD97516	TCGA-LN-A4A2-01A-31D-A267-26	HG19_Broad_variant	TCGA-LN-A4A2	TCGA-ESCA	NA	s1684	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0	Not available	Stage IIA	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d3ea	58cfa832e4b0c9d6adf6d3ea	TCGA-V4-A9EO-01A-12D-A40D_140808_SN590_0253_AC499NACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V4-A9EO-01A-12D-A40D_140808_SN590_0253_AC499NACXX_s_3_rg.sorted	TCGA-V4-A9EO-01A-12D-A40D_140808_SN590_0253_AC499NACXX_s_3_rg.sorted.bam	16.22	NA	0.17	58cfa832e4b0c9d6adf6d3ea	TCGA-V4-A9EO-01A-12D-A40D_140808_SN590_0253_AC499NACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EO-01A	BCB87378-9F43-45E4-BDF2-F6DFA6AC5B8C	Primary Tumor	Illumina HiSeq	e433357d-cafe-49f8-b481-e9b804bd4a06	Eye	74	C46DB8A8-DAF3-4E99-9307-E6C6CD8F79D5	B0A67E95-2ED2-43EB-9490-5F94BB8E21F4	TCGA-V4-A9EO-01A-12D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EO	TCGA-UVM	NA	s240	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d1fa	58cfa832e4b0c9d6adf6d1fa	TCGA-GV-A3JW-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-GV-A3JW-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_7_rg.sorted	TCGA-GV-A3JW-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_7_rg.sorted.bam	45.77	NA	0.15	58cfa832e4b0c9d6adf6d1fa	TCGA-GV-A3JW-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3JW-01A	3D644EAF-82FC-4BC7-93B7-3E600E8C6511	Primary Tumor	Illumina HiSeq	586abfdd-f50a-4834-8143-3bda5638ea60	Bladder	74	B02C03B6-24AA-42D3-9310-741DE1EF0D30	D7EFF32B-E9EB-4891-93D7-4C3D10BE21EA	TCGA-GV-A3JW-01A-11D-A210-26	HG19_Broad_variant	TCGA-GV-A3JW	TCGA-BLCA	NA	s2737	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T2	NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	TRUE
13722.58cfa832e4b0c9d6adf6d414	58cfa832e4b0c9d6adf6d414	TCGA-VD-A8KB-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_4_rg.sorted.filtered.	WGS	TCGA-VD-A8KB-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_4_rg.sorted	TCGA-VD-A8KB-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_4_rg.sorted.bam	41.19	NA	0.15	58cfa832e4b0c9d6adf6d414	TCGA-VD-A8KB-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_4_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-A8KB-01A	31771082-C094-4749-A9C7-80B67762F4D1	Primary Tumor	Illumina HiSeq	55fb2927-8427-4ec7-a0cd-d9250ff855be	Eye	66	3106274B-1330-4C1D-9D6F-EE36138BC929	DEE2EF23-9722-4006-AC98-0F262EB9ECF7	TCGA-VD-A8KB-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KB	TCGA-UVM	NA	s273	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T3a	NX	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4be	58cfa832e4b0c9d6adf6d4be	TCGA-V4-A9F7-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9F7-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_2_rg.sorted	TCGA-V4-A9F7-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_2_rg.sorted.bam	49.86	NA	0.16	58cfa832e4b0c9d6adf6d4be	TCGA-V4-A9F7-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F7-01A	64422CC5-5E5B-4EF9-A9E2-214CEBF8DFBC	Primary Tumor	Illumina HiSeq	8388df36-e4c1-4450-bc87-acc118ce705e	Eye	78	44AD0268-6B48-4264-A1DD-58C2302224D7	07397855-A0D5-4287-A21B-5AB83A4E0DE0	TCGA-V4-A9F7-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F7	TCGA-UVM	NA	s257	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d498	58cfa832e4b0c9d6adf6d498	TCGA-V4-A9EF-01A-21D-A40D_140725_SN590_0251_AC41YJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9EF-01A-21D-A40D_140725_SN590_0251_AC41YJACXX_s_4_rg.sorted	TCGA-V4-A9EF-01A-21D-A40D_140725_SN590_0251_AC41YJACXX_s_4_rg.sorted.bam	37.33	NA	0.17	58cfa832e4b0c9d6adf6d498	TCGA-V4-A9EF-01A-21D-A40D_140725_SN590_0251_AC41YJACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EF-01A	A18D3BA3-E2F4-4144-9C25-2019CAD193F4	Primary Tumor	Illumina HiSeq	bf602ec4-fef9-41b6-9f28-a773493f4507	Eye	56	0966DF5C-5838-4E92-ADA6-304241CCAEF1	0CE78DDD-32D4-43DB-B7A4-FE7C3AD9563D	TCGA-V4-A9EF-01A-21D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EF	TCGA-UVM	NA	s215	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4b	N0	Not available	Stage IIIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4a7	58cfa832e4b0c9d6adf6d4a7	TCGA-VD-A8KH-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-VD-A8KH-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_5_rg.sorted	TCGA-VD-A8KH-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_5_rg.sorted.bam	39.6	NA	0.17	58cfa832e4b0c9d6adf6d4a7	TCGA-VD-A8KH-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_5_rg.sorted.bam	Alive	MALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-A8KH-01A	39AF6E0F-908C-4B2B-97B8-A4D1966E47E1	Primary Tumor	Illumina HiSeq	c1aaf5dd-316d-42b5-9471-88f8c886efd8	Eye	69	98A73F7B-83C7-4160-944E-7A19B07AD696	4A25E140-632B-481F-8D50-49433ECEF545	TCGA-VD-A8KH-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KH	TCGA-UVM	NA	s251	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T4b	NX	Not available	Stage IIIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d56c	58cfa832e4b0c9d6adf6d56c	TCGA-V4-A9EY-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9EY-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_2_rg.sorted	TCGA-V4-A9EY-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_2_rg.sorted.bam	24.77	NA	0.16	58cfa832e4b0c9d6adf6d56c	TCGA-V4-A9EY-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EY-01A	15D19CCC-52B8-41F6-B1C1-2CC55691AED5	Primary Tumor	Illumina HiSeq	27c8b2d4-9133-49cb-a86b-84553dcf1c8e	Eye	66	E8C4DEFB-7781-4B3D-B209-7D444A1A1BB5	FDFEA8DC-451B-4493-B7ED-DBF97D7C1D78	TCGA-V4-A9EY-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EY	TCGA-UVM	NA	s218	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d55a	58cfa832e4b0c9d6adf6d55a	TCGA-L5-A4OF-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-L5-A4OF-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_7_rg.sorted	TCGA-L5-A4OF-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_7_rg.sorted.bam	26.16	NA	0.16	58cfa832e4b0c9d6adf6d55a	TCGA-L5-A4OF-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OF-01A	0C78B1B5-F480-45AD-A253-19297BC886B4	Primary Tumor	Illumina HiSeq	0b3ce949-4295-46f8-8809-392587ea21dc	Esophagus	63	B11F1BF7-3546-4F3C-872F-A4A910D910E7	921BE625-9769-4D00-B2FC-ACAE3ADFCAE7	TCGA-L5-A4OF-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OF	TCGA-ESCA	NA	s1741	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N1	Not available	Stage IIB	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d42a	58cfa832e4b0c9d6adf6d42a	TCGA-VD-AA8O-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_3_rg.sorted.filtered.	WGS	TCGA-VD-AA8O-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_3_rg.sorted	TCGA-VD-AA8O-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_3_rg.sorted.bam	48.76	NA	0.16	58cfa832e4b0c9d6adf6d42a	TCGA-VD-AA8O-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_3_rg.sorted.bam	Alive	MALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-AA8O-01A	99D1BFCC-1989-4DD2-A5E9-78E08F6CE7CF	Primary Tumor	Illumina HiSeq	cfc969dd-923b-4187-808c-584f86e0c276	Eye	77	9C21476F-E62A-4259-BD84-52E539EB5806	9E3B6CA4-5102-4C1E-99FD-3E149D0E4B6D	TCGA-VD-AA8O-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-AA8O	TCGA-UVM	NA	s269	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T3a	N0	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4a2	58cfa832e4b0c9d6adf6d4a2	TCGA-V4-A9F8-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V4-A9F8-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_3_rg.sorted	TCGA-V4-A9F8-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_3_rg.sorted.bam	54.24	NA	0.17	58cfa832e4b0c9d6adf6d4a2	TCGA-V4-A9F8-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F8-01A	64BD88BD-1D5A-4569-9F46-F668D448C336	Primary Tumor	Illumina HiSeq	05bff1f2-adb9-4252-892d-c86207753ca1	Eye	68	6B903079-A499-4AE3-B399-59276DCB9C70	5FABEAFA-9ADE-43AA-B4EB-979826FAE9BF	TCGA-V4-A9F8-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F8	TCGA-UVM	NA	s252	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4dc	58cfa832e4b0c9d6adf6d4dc	TCGA-VD-A8KN-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-VD-A8KN-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_8_rg.sorted	TCGA-VD-A8KN-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_8_rg.sorted.bam	23.55	NA	0.15	58cfa832e4b0c9d6adf6d4dc	TCGA-VD-A8KN-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_8_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-A8KN-01A	B26CB5F2-4FF0-4476-8D02-7256ACE7D8A3	Primary Tumor	Illumina HiSeq	48635af7-70bf-40ad-8bc3-2acb2a60ab81	Eye	60	3DD23C74-0B1D-40F4-8E8E-A5032CC7C87D	CBCBD0D3-2964-4D54-9872-0442D37D9D04	TCGA-VD-A8KN-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KN	TCGA-UVM	NA	s258	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T2a	NX	Not available	Stage IIA	A40D-26	TRUE
13722.58cfa831e4b0c9d6adf6c42c	58cfa831e4b0c9d6adf6c42c	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted.bam	16.84	NA	0.18	58cfa831e4b0c9d6adf6c42c	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A2LD-01A	9DD97821-7AFD-4982-8B1D-F14F845B79F7	Primary Tumor	Illumina HiSeq	205bfe9f-2bc9-4236-930c-a862874ad8e0	Bladder	78	AEB379D5-B157-4BCE-82C5-0CD0077DB01F	BF6A16B2-9DC9-4E9A-A810-2EBA7E9B56A1	TCGA-BT-A2LD-01A-12D-A210-26	HG19_Broad_variant	TCGA-BT-A2LD	TCGA-BLCA	NA	s3089	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3a	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A210-26	TRUE
13722.58cfa832e4b0c9d6adf6ce19	58cfa832e4b0c9d6adf6ce19	TCGA-FD-A3N6-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FD-A3N6-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_3_rg.sorted	TCGA-FD-A3N6-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_3_rg.sorted.bam	47.84	NA	0.16	58cfa832e4b0c9d6adf6ce19	TCGA-FD-A3N6-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_3_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3N6-01A	8C1DD7F7-B74A-4FA2-B6A7-86F0348D2567	Primary Tumor	Illumina HiSeq	2beb0463-75e7-4244-b88e-022e447445f2	Bladder	43	6CD6D1F4-D8E4-47F9-812F-EB7FEC925F8D	C218A6A8-78F5-472B-A1CA-886E2331A688	TCGA-FD-A3N6-01A-11D-A21C-26	HG19_Broad_variant	TCGA-FD-A3N6	TCGA-BLCA	NA	s3292	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A21C-26	TRUE
13722.58cfa832e4b0c9d6adf6d234	58cfa832e4b0c9d6adf6d234	TCGA-JX-A3Q8-01A-11D-A245_140206_SN1222_0239_BC2RAKACXX_s_3_rg.sorted.filtered.	WGS	TCGA-JX-A3Q8-01A-11D-A245_140206_SN1222_0239_BC2RAKACXX_s_3_rg.sorted	TCGA-JX-A3Q8-01A-11D-A245_140206_SN1222_0239_BC2RAKACXX_s_3_rg.sorted.bam	63.47	NA	0.14	58cfa832e4b0c9d6adf6d234	TCGA-JX-A3Q8-01A-11D-A245_140206_SN1222_0239_BC2RAKACXX_s_3_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-JX-A3Q8-01A	34629EB8-0C5E-4910-8E13-BF7D6A1E337F	Primary Tumor	Illumina HiSeq	e8f02d77-0077-4817-a34b-ab4ddd64bbd5	Cervix	40	28954012-3732-40B0-8EA7-F48CBEEF4105	52CB86FE-6EFF-4FF4-BC53-FD82E04854FB	TCGA-JX-A3Q8-01A-11D-A245-26	HG19_Broad_variant	TCGA-JX-A3Q8	TCGA-CESC	NA	s1380	MD Anderson - Institute for Applied Cancer Science	Washington University	United States	NO	T1b1	N0	Endocervical Type of Adenocarcinoma	Not available	A245-26	TRUE
13722.58cfa832e4b0c9d6adf6d3f0	58cfa832e4b0c9d6adf6d3f0	TCGA-V4-A9ED-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9ED-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_2_rg.sorted	TCGA-V4-A9ED-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_2_rg.sorted.bam	53.75	NA	0.17	58cfa832e4b0c9d6adf6d3f0	TCGA-V4-A9ED-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9ED-01A	367869F9-BBE7-4E57-A16F-F2B63F2DE697	Primary Tumor	Illumina HiSeq	db951476-e1a5-4731-8c40-dbe710922b60	Eye	45	F1A146CE-B2C6-4CD5-9153-F640D38ABAF1	8CDB01C8-C2D9-40DB-84EE-00B50B9EC314	TCGA-V4-A9ED-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9ED	TCGA-UVM	NA	s220	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3b	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d3d7	58cfa832e4b0c9d6adf6d3d7	TCGA-V4-A9EJ-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_7_rg.sorted.filtered.	WGS	TCGA-V4-A9EJ-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_7_rg.sorted	TCGA-V4-A9EJ-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_7_rg.sorted.bam	36.7	NA	0.17	58cfa832e4b0c9d6adf6d3d7	TCGA-V4-A9EJ-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EJ-01A	D9CCBA9B-6BF0-44D9-8097-A97AB747F0BD	Primary Tumor	Illumina HiSeq	9a75e8fd-7cbd-4d0f-a91b-22e52e02c00d	Eye	38	6D2FBFD2-E1BF-483E-B0A0-A308F93871D4	42B46C86-61F4-4C2E-9EC3-0ED0113F3EC3	TCGA-V4-A9EJ-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EJ	TCGA-UVM	NA	s206	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d400	58cfa832e4b0c9d6adf6d400	TCGA-V4-A9EK-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_8_rg.sorted.filtered.	WGS	TCGA-V4-A9EK-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_8_rg.sorted	TCGA-V4-A9EK-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_8_rg.sorted.bam	48.23	NA	0.16	58cfa832e4b0c9d6adf6d400	TCGA-V4-A9EK-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EK-01A	4464418C-EC35-4826-B3D5-152AC2A27A04	Primary Tumor	Illumina HiSeq	9f84d9e1-572c-43b9-8fa8-695decf3b44e	Eye	37	9F324851-EAAE-41B8-BB0E-5D5CEB9E5B23	01AA5AFA-5877-45CA-98DB-9547B99B30C5	TCGA-V4-A9EK-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EK	TCGA-UVM	NA	s234	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4e4	58cfa832e4b0c9d6adf6d4e4	TCGA-V4-A9EE-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V4-A9EE-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_3_rg.sorted	TCGA-V4-A9EE-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_3_rg.sorted.bam	37.61	NA	0.17	58cfa832e4b0c9d6adf6d4e4	TCGA-V4-A9EE-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EE-01A	EDBF6720-467E-4928-B1CB-0E7336358D18	Primary Tumor	Illumina HiSeq	88edb951-b2e0-476d-bc63-3f5883671a8f	Eye	86	1C5AB1BD-67EF-43AB-B46B-17E126DF2B82	0E1D56AE-4213-4443-BDD3-A652CFC60104	TCGA-V4-A9EE-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EE	TCGA-UVM	398	s223	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d47f	58cfa832e4b0c9d6adf6d47f	TCGA-V4-A9EC-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-V4-A9EC-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_1_rg.sorted	TCGA-V4-A9EC-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_1_rg.sorted.bam	44.61	NA	0.16	58cfa832e4b0c9d6adf6d47f	TCGA-V4-A9EC-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EC-01A	EEAB0529-31E6-4EDB-BD2C-A21F2A169381	Primary Tumor	Illumina HiSeq	b19262ce-546a-4f20-b2c6-542d12745c33	Eye	75	3234E814-AD34-48F0-AEBD-19E1A694ED8E	3ED594C4-5AF5-4461-838D-367758D3BA55	TCGA-V4-A9EC-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EC	TCGA-UVM	NA	s232	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4f4	58cfa832e4b0c9d6adf6d4f4	TCGA-V3-A9ZX-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V3-A9ZX-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_2_rg.sorted	TCGA-V3-A9ZX-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_2_rg.sorted.bam	47.71	NA	0.15	58cfa832e4b0c9d6adf6d4f4	TCGA-V3-A9ZX-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V3-A9ZX-01A	5019E7F1-DB46-4A07-9E7B-B6E5D1481B84	Primary Tumor	Illumina HiSeq	ad32c24c-f4fa-4356-95a8-15d394368122	Eye	56	A2DFEBBB-9A38-4CC2-A3F3-857C2A70DCF4	314EE286-7E1A-4CF8-A39D-D12E23C6DAAB	TCGA-V3-A9ZX-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V3-A9ZX	TCGA-UVM	NA	s195	MD Anderson - Institute for Applied Cancer Science	Cleveland Clinic Foundation	United States	NO	T2b	NX	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4f6	58cfa832e4b0c9d6adf6d4f6	TCGA-L5-A4OI-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OI-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_1_rg.sorted	TCGA-L5-A4OI-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_1_rg.sorted.bam	40.07	NA	0.16	58cfa832e4b0c9d6adf6d4f6	TCGA-L5-A4OI-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	Not available	Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OI-01A	CB2AF13B-CBED-4657-8FD4-FED8DB375CBA	Primary Tumor	Illumina HiSeq	61f0c88a-c61d-400f-b8cf-b9cacd5fcada	Esophagus	79	1B1CBB34-DA71-4441-B1A1-C936E8F04C73	8D5A0D62-D9C1-46D1-9B81-685293B45E6B	TCGA-L5-A4OI-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OI	TCGA-ESCA	NA	s1924	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T3	N3	Not available	Stage IIIC	A267-26	TRUE
13722.58cfa832e4b0c9d6adf6d4d7	58cfa832e4b0c9d6adf6d4d7	TCGA-RZ-AB0B-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_1_rg.sorted.filtered.	WGS	TCGA-RZ-AB0B-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_1_rg.sorted	TCGA-RZ-AB0B-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_1_rg.sorted.bam	44.7	NA	0.14	58cfa832e4b0c9d6adf6d4d7	TCGA-RZ-AB0B-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	Not available	Uveal Melanoma	Aligned reads	TCGA-RZ-AB0B-01A	2BF47A88-DF0A-4102-AF2E-998C3D252B9C	Primary Tumor	Illumina HiSeq	e284c77f-87fb-456b-8707-5f7b1219d267	Eye	47	78DA02B6-41D6-4911-8762-A71657F26F3C	B2D03978-B98B-4FB4-BA5C-50CE935C0056	TCGA-RZ-AB0B-01A-11D-A40D-26	HG19_Broad_variant	TCGA-RZ-AB0B	TCGA-UVM	149	s187	MD Anderson - Institute for Applied Cancer Science	Wills Eye Institute	United States	NO	T4b	Not available	Not available	Stage IV	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d401	58cfa832e4b0c9d6adf6d401	TCGA-V4-A9EH-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-V4-A9EH-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_5_rg.sorted	TCGA-V4-A9EH-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_5_rg.sorted.bam	32.48	NA	0.17	58cfa832e4b0c9d6adf6d401	TCGA-V4-A9EH-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EH-01A	5E54122F-1C4D-45CC-8842-CD1C1DF0EED8	Primary Tumor	Illumina HiSeq	f23ae536-eb5e-4d13-baf2-94a4eb03d083	Eye	53	A320EAC2-C0FB-44D0-9849-DD541C2428E1	AC2BA0CC-C007-44BF-8C99-4C88D55C022E	TCGA-V4-A9EH-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EH	TCGA-UVM	NA	s222	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4c	N0	Not available	Stage IIIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d582	58cfa832e4b0c9d6adf6d582	TCGA-V4-A9EA-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_8_rg.sorted.filtered.	WGS	TCGA-V4-A9EA-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_8_rg.sorted	TCGA-V4-A9EA-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_8_rg.sorted.bam	33.08	NA	0.17	58cfa832e4b0c9d6adf6d582	TCGA-V4-A9EA-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EA-01A	A9FE64A9-6D22-4E9F-96F3-F16AF7D298F8	Primary Tumor	Illumina HiSeq	35b1a08b-2b90-4f04-887c-7e95542f287e	Eye	66	1A18A8C2-C00F-42B2-B5C6-3AAB27BCE06D	10EEDA0C-C4C3-4F47-A3AF-599FDFCD62DF	TCGA-V4-A9EA-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EA	TCGA-UVM	NA	s188	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d58a	58cfa832e4b0c9d6adf6d58a	TCGA-V4-A9E9-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_7_rg.sorted.filtered.	WGS	TCGA-V4-A9E9-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_7_rg.sorted	TCGA-V4-A9E9-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_7_rg.sorted.bam	31.06	NA	0.16	58cfa832e4b0c9d6adf6d58a	TCGA-V4-A9E9-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9E9-01A	418152BD-7D33-4F0A-B890-2356B30D6F44	Primary Tumor	Illumina HiSeq	d8293c54-78cb-49a0-a69f-f36723632ddd	Eye	50	5CB8105A-6D8B-441B-A8F7-89308DD4FC92	3782E96A-456F-4747-B75B-A48597EDFD90	TCGA-V4-A9E9-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9E9	TCGA-UVM	NA	s189	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d586	58cfa832e4b0c9d6adf6d586	TCGA-V4-A9E8-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_6_rg.sorted.filtered.	WGS	TCGA-V4-A9E8-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_6_rg.sorted	TCGA-V4-A9E8-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_6_rg.sorted.bam	31.12	NA	0.16	58cfa832e4b0c9d6adf6d586	TCGA-V4-A9E8-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9E8-01A	DF941BC1-6356-4F2E-A3F5-AE190266B441	Primary Tumor	Illumina HiSeq	20fb461e-733f-4247-b4ad-e78418cd1866	Eye	49	7C95738B-C7F2-470F-AB95-88CDABBEEF21	F5FF03D8-69DA-49EC-8BF3-8132071649AC	TCGA-V4-A9E8-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9E8	TCGA-UVM	808	s183	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d590	58cfa832e4b0c9d6adf6d590	TCGA-V3-A9ZY-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V3-A9ZY-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_3_rg.sorted	TCGA-V3-A9ZY-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_3_rg.sorted.bam	50.6	NA	0.15	58cfa832e4b0c9d6adf6d590	TCGA-V3-A9ZY-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V3-A9ZY-01A	2112A42A-9B85-475A-A31B-4CE7751CDEB9	Primary Tumor	Illumina HiSeq	00a09c4d-5a88-4562-b9f3-e397798bdc18	Eye	54	E835BB77-E3EE-41B0-B8E0-D39E966F91A7	CD97490D-738A-48A2-B014-F9DB48DE45FA	TCGA-V3-A9ZY-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V3-A9ZY	TCGA-UVM	NA	s192	MD Anderson - Institute for Applied Cancer Science	Cleveland Clinic Foundation	United States	NO	T3a	NX	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d58c	58cfa832e4b0c9d6adf6d58c	TCGA-V4-A9E7-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_5_rg.sorted.filtered.	WGS	TCGA-V4-A9E7-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_5_rg.sorted	TCGA-V4-A9E7-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_5_rg.sorted.bam	32.61	NA	0.16	58cfa832e4b0c9d6adf6d58c	TCGA-V4-A9E7-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	Not available	Uveal Melanoma	Aligned reads	TCGA-V4-A9E7-01A	B5C516BA-4785-41DC-BD07-B129D47808DD	Primary Tumor	Illumina HiSeq	18accc0b-97a3-4386-b4c6-9213eeb4da3e	Eye	76	76AF65DC-CCCD-4257-8D05-38334D3110DA	3D700A8D-7760-4095-B537-1171444D1A5D	TCGA-V4-A9E7-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9E7	TCGA-UVM	415	s193	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d6a6	58cfa832e4b0c9d6adf6d6a6	TCGA-V4-A9E5-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9E5-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_4_rg.sorted	TCGA-V4-A9E5-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_4_rg.sorted.bam	30.36	NA	0.16	58cfa832e4b0c9d6adf6d6a6	TCGA-V4-A9E5-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9E5-01A	029CC59C-60DF-4411-A044-3A2EEEE7B110	Primary Tumor	Illumina HiSeq	6d4c51c2-0829-4ab2-9c4e-0a4653d8b744	Eye	51	9FD9F385-A009-44AE-836F-F18BAD96628F	CE4927D1-2A65-4BEF-98E5-EDD02A341820	TCGA-V4-A9E5-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9E5	TCGA-UVM	NA	s190	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4b	N0	Not available	Stage IIIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d61a	58cfa832e4b0c9d6adf6d61a	TCGA-LN-A49X-01A-31D-A267_131018_SN590_0241_BC30HBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-LN-A49X-01A-31D-A267_131018_SN590_0241_BC30HBACXX_s_3_rg.sorted	TCGA-LN-A49X-01A-31D-A267_131018_SN590_0241_BC30HBACXX_s_3_rg.sorted.bam	16.61	NA	0.16	58cfa832e4b0c9d6adf6d61a	TCGA-LN-A49X-01A-31D-A267_131018_SN590_0241_BC30HBACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49X-01A	B05AEFC4-2D61-44B6-9451-E660D10D8A79	Primary Tumor	Illumina HiSeq	e3d2b395-b1fa-4edd-86a9-72ca75792159	Esophagus	44	F67F4ACC-E1DC-41F5-AF25-F4C03856B1AC	92F976C9-1D13-4347-ADDB-6C8F4C2E078F	TCGA-LN-A49X-01A-31D-A267-26	HG19_Broad_variant	TCGA-LN-A49X	TCGA-ESCA	NA	s1683	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0	Not available	Stage IIA	A267-26	TRUE
13722.58cfa830e4b0c9d6adf6c224	58cfa830e4b0c9d6adf6c224	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted.bam	49.75	NA	0.15	58cfa830e4b0c9d6adf6c224	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2LS-01A	185E1520-92EE-4AF5-AF15-FBEEFB352C99	Primary Tumor	Illumina HiSeq	3c012d75-0d17-4b4d-834f-cd4767f6b023	Cervix	37	79248694-77E1-4FBE-8C94-64A308FC982D	DE7180EF-3E7E-43D5-8ACE-C7ED57992345	TCGA-C5-A2LS-01A-22D-A232-26	HG19_Broad_variant	TCGA-C5-A2LS	TCGA-CESC	NA	s1356	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	T1b2	N0	Endocervical Adenocarcinoma of the Usual Type	Not available	A232-26	TRUE
13722.58cfa831e4b0c9d6adf6c4ac	58cfa831e4b0c9d6adf6c4ac	TCGA-CF-A3MH-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CF-A3MH-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_1_rg.sorted	TCGA-CF-A3MH-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_1_rg.sorted.bam	63.16	NA	0.15	58cfa831e4b0c9d6adf6c4ac	TCGA-CF-A3MH-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A3MH-01A	B8A8D2FC-421B-4393-8D5A-946CF72CB496	Primary Tumor	Illumina HiSeq	f82c1606-fe81-428d-9889-58cafa1f29e4	Bladder	75	8CF68BB1-5966-40CD-A038-E9E91E608766	463978F0-D37A-4035-9D1C-8C0E7B0F721C	TCGA-CF-A3MH-01A-11D-A210-26	HG19_Broad_variant	TCGA-CF-A3MH	TCGA-BLCA	NA	s2874	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	TRUE
13722.58cfa831e4b0c9d6adf6c6b6	58cfa831e4b0c9d6adf6c6b6	TCGA-CQ-7065-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CQ-7065-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_1_rg.sorted	TCGA-CQ-7065-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_1_rg.sorted.bam	15.93	NA	0.13	58cfa831e4b0c9d6adf6c6b6	TCGA-CQ-7065-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-7065-01A	20ECE2CA-8601-4CCA-AEC5-0A5C0B92594D	Primary Tumor	Illumina HiSeq	a7ab0507-8b7a-45aa-9e07-21bfc50fddd0	Head and Neck	40	65B44EBF-F817-4B29-8FB6-01B07BC2E7D1	DFB72780-B485-403B-997C-6F6FD0EF0E75	TCGA-CQ-7065-01A-11D-2317-26	HG19_Broad_variant	TCGA-CQ-7065	TCGA-HNSC	NA	s16040	MD Anderson - Institute for Applied Cancer Science	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c7da	58cfa831e4b0c9d6adf6c7da	TCGA-CV-7091-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-7091-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_8_rg.sorted	TCGA-CV-7091-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_8_rg.sorted.bam	289.73	NA	0.15	58cfa831e4b0c9d6adf6c7da	TCGA-CV-7091-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7091-01A	2A192049-6435-49AB-8444-DDEB2B9EE774	Primary Tumor	Illumina HiSeq	8a0170b3-9cda-4426-be4b-9e488f6244c2	Head and Neck	54	3AB78DC4-682E-4B5A-ADDA-223ACF0FBB6A	78998DCE-A468-416B-9F81-D64E43B52883	TCGA-CV-7091-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7091	TCGA-HNSC	NA	s16342	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c828	58cfa831e4b0c9d6adf6c828	TCGA-CV-7238-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-7238-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_4_rg.sorted	TCGA-CV-7238-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_4_rg.sorted.bam	143.73	NA	0.14	58cfa831e4b0c9d6adf6c828	TCGA-CV-7238-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7238-01A	78FCC813-D0A8-44AA-B004-62810DCA9D12	Primary Tumor	Illumina HiSeq	3eb627a6-bbcf-4699-ad23-e52a26cd4453	Head and Neck	69	831808D5-1883-4F6F-B252-1BB397FBD62A	D051D2CB-F8DE-4E42-B9CF-E7CBE43861A0	TCGA-CV-7238-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7238	TCGA-HNSC	NA	s15520	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c837	58cfa831e4b0c9d6adf6c837	TCGA-CV-7095-01A-21D-2317_120730_SN1222_0140_AC11GKACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CV-7095-01A-21D-2317_120730_SN1222_0140_AC11GKACXX_s_2_rg.sorted	TCGA-CV-7095-01A-21D-2317_120730_SN1222_0140_AC11GKACXX_s_2_rg.sorted.bam	90.73	NA	0.14	58cfa831e4b0c9d6adf6c837	TCGA-CV-7095-01A-21D-2317_120730_SN1222_0140_AC11GKACXX_s_2_rg.sorted.bam	Dead	FEMALE	Not available	HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7095-01A	D7D49895-032F-4385-8B68-AE16F8675CA7	Primary Tumor	Illumina HiSeq	d944910b-a3cf-45e9-84be-5ea0e6cd6f03	Head and Neck	87	E7D35C82-8992-4CC0-AA65-DF5CAB5727EB	F85FA02B-0695-4F2E-957B-FF11F1E6FCE6	TCGA-CV-7095-01A-21D-2317-26	HG19_Broad_variant	TCGA-CV-7095	TCGA-HNSC	572	s16052	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6cae0	58cfa831e4b0c9d6adf6cae0	TCGA-DJ-A13L-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DJ-A13L-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_5_rg.sorted	TCGA-DJ-A13L-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_5_rg.sorted.bam	32.87	NA	0.15	58cfa831e4b0c9d6adf6cae0	TCGA-DJ-A13L-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13L-01A	C7A2F394-3E3F-4C90-9F1E-F2BE3E5B0D6B	Primary Tumor	Illumina HiSeq	9424534d-10ae-4669-9a13-75ab8e7a7432	Thyroid	85	AB13FB1A-8B7F-4D84-84A9-C4F7EE59CAF8	417BD826-C151-459E-AAEA-DFA2CB4182DF	TCGA-DJ-A13L-01A-11D-A221-26	HG19_Broad_variant	TCGA-DJ-A13L	TCGA-THCA	NA	s12105	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage I	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6ce0c	58cfa832e4b0c9d6adf6ce0c	TCGA-FD-A3B6-01A-21D-A210_120912_SN1120_0192_AC18ALACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FD-A3B6-01A-21D-A210_120912_SN1120_0192_AC18ALACXX_s_3_rg.sorted	TCGA-FD-A3B6-01A-21D-A210_120912_SN1120_0192_AC18ALACXX_s_3_rg.sorted.bam	61.5	NA	0.16	58cfa832e4b0c9d6adf6ce0c	TCGA-FD-A3B6-01A-21D-A210_120912_SN1120_0192_AC18ALACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B6-01A	36054200-3FA4-4541-A25C-47282E4EF88D	Primary Tumor	Illumina HiSeq	15aeae5e-1ef3-4574-a7af-025ac4d4be89	Bladder	75	D6818C85-5857-44B0-AD64-1EEB53B80606	D8D4A23A-F993-4A8F-9414-AD25149B4CB3	TCGA-FD-A3B6-01A-21D-A210-26	HG19_Broad_variant	TCGA-FD-A3B6	TCGA-BLCA	NA	s3298	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	TRUE
13722.58cfa832e4b0c9d6adf6ce9c	58cfa832e4b0c9d6adf6ce9c	TCGA-FD-A3B7-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FD-A3B7-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_5_rg.sorted	TCGA-FD-A3B7-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_5_rg.sorted.bam	28.25	NA	0.16	58cfa832e4b0c9d6adf6ce9c	TCGA-FD-A3B7-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_5_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B7-01A	EF5DD4B3-B77A-444A-B5B0-C999A5A3D129	Primary Tumor	Illumina HiSeq	4a37fdf6-816c-46ca-b703-cf3d58b32149	Bladder	66	A307CA46-3A09-4F0C-84AB-9A9E8954DE38	6014D6A8-5495-4D71-AB6E-622E3E6C4DC6	TCGA-FD-A3B7-01A-31D-A210-26	HG19_Broad_variant	TCGA-FD-A3B7	TCGA-BLCA	122	s2901	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	TRUE
13722.58cfa832e4b0c9d6adf6cfe0	58cfa832e4b0c9d6adf6cfe0	TCGA-GC-A3WC-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-GC-A3WC-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_1_rg.sorted	TCGA-GC-A3WC-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_1_rg.sorted.bam	23.27	NA	0.17	58cfa832e4b0c9d6adf6cfe0	TCGA-GC-A3WC-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3WC-01A	DB52C68A-ED44-4EC4-9381-D75F9BCBC29A	Primary Tumor	Illumina HiSeq	5d982317-5753-41de-85ef-30ee85c56ba9	Bladder	80	24F9D01B-1210-4716-9466-8FE9F3612B8B	50E62704-6262-4426-BDAE-0490DC108B61	TCGA-GC-A3WC-01A-31D-A233-26	HG19_Broad_variant	TCGA-GC-A3WC	TCGA-BLCA	NA	s3307	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	TRUE
13722.58cfa832e4b0c9d6adf6d134	58cfa832e4b0c9d6adf6d134	TCGA-G2-A3VY-01A-11D-A233_120913_SN208_0428_BC188KACXX_s_6_rg.sorted.filtered.	WGS	TCGA-G2-A3VY-01A-11D-A233_120913_SN208_0428_BC188KACXX_s_6_rg.sorted	TCGA-G2-A3VY-01A-11D-A233_120913_SN208_0428_BC188KACXX_s_6_rg.sorted.bam	27.44	NA	0.15	58cfa832e4b0c9d6adf6d134	TCGA-G2-A3VY-01A-11D-A233_120913_SN208_0428_BC188KACXX_s_6_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A3VY-01A	CD50C69F-0F45-4C57-B61A-8C6B41AB4F7E	Primary Tumor	Illumina HiSeq	fc9767fe-ddfb-4540-b151-0a80300c0a1d	Bladder	66	5A66149F-8FB0-41BC-880C-56D5541E3D94	8263C8A3-7CE5-4487-B8A1-29CE9417D1E3	TCGA-G2-A3VY-01A-11D-A233-26	HG19_Broad_variant	TCGA-G2-A3VY	TCGA-BLCA	NA	s2914	MD Anderson - Institute for Applied Cancer Science	MD Anderson	United States	NO	Not available	Not available	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A233-26	TRUE
13722.58cfa832e4b0c9d6adf6d254	58cfa832e4b0c9d6adf6d254	TCGA-IR-A3LA-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-IR-A3LA-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_7_rg.sorted	TCGA-IR-A3LA-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_7_rg.sorted.bam	56.17	NA	0.15	58cfa832e4b0c9d6adf6d254	TCGA-IR-A3LA-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LA-01A	7B8C04D7-824D-493D-8F2C-9ED87A907192	Primary Tumor	Illumina HiSeq	96c944ec-9e55-4b27-aa91-b936b4d7cff5	Cervix	60	7925EA80-8AAE-4D99-AFE2-74AD1AAE6D9D	B541AE4A-279F-49A1-9877-1F2226A51737	TCGA-IR-A3LA-01A-11D-A232-26	HG19_Broad_variant	TCGA-IR-A3LA	TCGA-CESC	NA	s1377	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Endometrioid Adenocarcinoma of Endocervix	Not available	A232-26	TRUE
13722.58cfa832e4b0c9d6adf6d269	58cfa832e4b0c9d6adf6d269	TCGA-K4-A3WS-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_1_rg.sorted.filtered.	WGS	TCGA-K4-A3WS-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_1_rg.sorted	TCGA-K4-A3WS-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_1_rg.sorted.bam	18.56	NA	0.16	58cfa832e4b0c9d6adf6d269	TCGA-K4-A3WS-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-K4-A3WS-01A	68ADACD1-A16E-4489-9E68-792A6BD8811C	Primary Tumor	Illumina HiSeq	891c215b-20ad-4eb3-9e53-87910b1d06f4	Bladder	66	54070AE0-0C10-4C10-B8BB-A7313B80A45F	F1840542-AEBE-4B4C-BA50-1686740847D4	TCGA-K4-A3WS-01A-11D-A23Q-26	HG19_Broad_variant	TCGA-K4-A3WS	TCGA-BLCA	NA	s3131	MD Anderson - Institute for Applied Cancer Science	ABS - Lahey Clinic	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A23Q-26	TRUE
13722.58cfa832e4b0c9d6adf6d490	58cfa832e4b0c9d6adf6d490	TCGA-VD-AA8M-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-VD-AA8M-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_1_rg.sorted	TCGA-VD-AA8M-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_1_rg.sorted.bam	57.94	NA	0.15	58cfa832e4b0c9d6adf6d490	TCGA-VD-AA8M-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_1_rg.sorted.bam	Alive	MALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-AA8M-01A	9DC5CC23-C903-4FE2-8354-64F8316FF0D4	Primary Tumor	Illumina HiSeq	4a38e73e-520a-4721-a89a-7a2b3b334ee6	Eye	64	DDC9047A-FD34-4874-87B0-72DAB50311E6	ABFED748-0BF8-4E64-8AB1-2A4DA1BB5A62	TCGA-VD-AA8M-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-AA8M	TCGA-UVM	NA	s271	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T2a	N0	Not available	Stage IIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4d4	58cfa832e4b0c9d6adf6d4d4	TCGA-VD-AA8P-01A-11D-A40D_140829_SN208_0523_BC5FKTACXX_s_7_rg.sorted.filtered.	WGS	TCGA-VD-AA8P-01A-11D-A40D_140829_SN208_0523_BC5FKTACXX_s_7_rg.sorted	TCGA-VD-AA8P-01A-11D-A40D_140829_SN208_0523_BC5FKTACXX_s_7_rg.sorted.bam	65.26	NA	0.16	58cfa832e4b0c9d6adf6d4d4	TCGA-VD-AA8P-01A-11D-A40D_140829_SN208_0523_BC5FKTACXX_s_7_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-AA8P-01A	B224E42D-8B6D-4578-963C-BF528B954900	Primary Tumor	Illumina HiSeq	c3957866-f525-4f68-b483-cf444a24bb38	Eye	64	6029915F-6337-4816-998A-9754C770ED93	6331804A-DC4D-4244-9C0D-A5CEC20E593C	TCGA-VD-AA8P-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-AA8P	TCGA-UVM	NA	s261	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T3a	N0	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa830e4b0c9d6adf6bf87	58cfa830e4b0c9d6adf6bf87	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted.bam	45.84	NA	0.15	58cfa830e4b0c9d6adf6bf87	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A3PR-01A	FD036EC5-3FFB-40B1-8002-943BE0E2532E	Primary Tumor	Illumina HiSeq	c8c8646f-54e4-4440-bf91-d2cd90083c44	Thyroid	69	E058A8E1-ED00-48A5-A46B-77538D7B73F1	57FD6BDA-C7B4-4B74-B21A-B7FF5D1C87EE	TCGA-BJ-A3PR-01A-11D-A221-26	HG19_Broad_variant	TCGA-BJ-A3PR	TCGA-THCA	NA	s12358	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T1a	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	TRUE
13722.58cfa830e4b0c9d6adf6c266	58cfa830e4b0c9d6adf6c266	TCGA-C5-A1BQ-01C-11D-A20X_140106_SN590_0243_AC371BACXX_s_2_rg.sorted.filtered.	WGS	TCGA-C5-A1BQ-01C-11D-A20X_140106_SN590_0243_AC371BACXX_s_2_rg.sorted	TCGA-C5-A1BQ-01C-11D-A20X_140106_SN590_0243_AC371BACXX_s_2_rg.sorted.bam	43.3	NA	0.15	58cfa830e4b0c9d6adf6c266	TCGA-C5-A1BQ-01C-11D-A20X_140106_SN590_0243_AC371BACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A1BQ-01C	E77C3F70-08D1-40D3-B038-F09A519423CC	Primary Tumor	Illumina HiSeq	58d97d84-99da-4b08-ae63-7e49f4b861b7	Cervix	65	6EF38E19-07AC-4032-8FB4-59129A126D3F	359691B6-9EB5-40F2-8F9E-16AA5A1D32F4	TCGA-C5-A1BQ-01C-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A1BQ	TCGA-CESC	604	s1170	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	Not available	Not available	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa831e4b0c9d6adf6c47a	58cfa831e4b0c9d6adf6c47a	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted.bam	57.66	NA	0.17	58cfa831e4b0c9d6adf6c47a	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A3PK-01A	73041FCF-F3B6-4851-B34D-1D62A1FCF6FE	Primary Tumor	Illumina HiSeq	637e8bd5-61ee-4d45-8cc5-e3b89950d020	Bladder	80	F09E1EEB-BCD5-4DBA-92F0-7D4B34B81CE7	EE975BE9-76BF-4B5A-BF4C-155750C168CD	TCGA-BT-A3PK-01A-21D-A221-26	HG19_Broad_variant	TCGA-BT-A3PK	TCGA-BLCA	NA	s2858	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A221-26	TRUE
13722.58cfa831e4b0c9d6adf6c6c8	58cfa831e4b0c9d6adf6c6c8	TCGA-CU-A3KJ-01A-11D-A21C_120914_SN590_0179_AD13PPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CU-A3KJ-01A-11D-A21C_120914_SN590_0179_AD13PPACXX_s_7_rg.sorted	TCGA-CU-A3KJ-01A-11D-A21C_120914_SN590_0179_AD13PPACXX_s_7_rg.sorted.bam	49.18	NA	0.15	58cfa831e4b0c9d6adf6c6c8	TCGA-CU-A3KJ-01A-11D-A21C_120914_SN590_0179_AD13PPACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A3KJ-01A	A75584BC-BEF7-48F6-B4B3-C1472A3AF768	Primary Tumor	Illumina HiSeq	6b7a9ee7-ee89-4473-9170-7372313595f7	Bladder	75	3D92F5A6-949A-4176-9309-4294CCA6FC25	25847D62-9932-4A04-9B00-378794D2CE72	TCGA-CU-A3KJ-01A-11D-A21C-26	HG19_Broad_variant	TCGA-CU-A3KJ	TCGA-BLCA	NA	s3098	MD Anderson - Institute for Applied Cancer Science	UNC	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A21C-26	TRUE
13722.58cfa831e4b0c9d6adf6c772	58cfa831e4b0c9d6adf6c772	TCGA-CQ-7068-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CQ-7068-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_6_rg.sorted	TCGA-CQ-7068-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_6_rg.sorted.bam	637.73	NA	0.15	58cfa831e4b0c9d6adf6c772	TCGA-CQ-7068-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-7068-01A	8EBE8C25-5EF9-42D4-9414-8313227B673F	Primary Tumor	Illumina HiSeq	77b40e7d-41a7-4e5d-a3e9-ce1e2d077c98	Head and Neck	80	1C86E4AF-03CE-477C-BE08-0CFA565861B7	F0B87929-92F5-4AB9-849F-00F970E56577	TCGA-CQ-7068-01A-11D-2317-26	HG19_Broad_variant	TCGA-CQ-7068	TCGA-HNSC	NA	s15506	MD Anderson - Institute for Applied Cancer Science	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c8e6	58cfa831e4b0c9d6adf6c8e6	TCGA-CV-6960-01A-41D-2317_120623_SN1222_0118_AD13T1ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CV-6960-01A-41D-2317_120623_SN1222_0118_AD13T1ACXX_s_6_rg.sorted	TCGA-CV-6960-01A-41D-2317_120623_SN1222_0118_AD13T1ACXX_s_6_rg.sorted.bam	52.73	NA	0.13	58cfa831e4b0c9d6adf6c8e6	TCGA-CV-6960-01A-41D-2317_120623_SN1222_0118_AD13T1ACXX_s_6_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	Not available	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6960-01A	2C985B30-0F8F-4C8F-A924-CC6AAD7EBF0D	Primary Tumor	Illumina HiSeq	5fdfb781-64fd-48dd-9d26-3de7bfdf5908	Head and Neck	49	967F6CC9-95D2-4666-A20A-717D768613A4	F41864FE-49FA-4037-AF02-E3F8E2515614	TCGA-CV-6960-01A-41D-2317-26	HG19_Broad_variant	TCGA-CV-6960	TCGA-HNSC	862	s15902	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6c8de	58cfa831e4b0c9d6adf6c8de	TCGA-CV-7429-01A-11D-2317_120710_SN590_0165_BC0VU7ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-7429-01A-11D-2317_120710_SN590_0165_BC0VU7ACXX_s_4_rg.sorted	TCGA-CV-7429-01A-11D-2317_120710_SN590_0165_BC0VU7ACXX_s_4_rg.sorted.bam	262.73	NA	0.15	58cfa831e4b0c9d6adf6c8de	TCGA-CV-7429-01A-11D-2317_120710_SN590_0165_BC0VU7ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7429-01A	44D99F11-EF5B-45D7-B7DF-B5C5893D878F	Primary Tumor	Illumina HiSeq	4860e1b8-251e-4894-91f2-c9416a9b7f28	Head and Neck	55	A8A03639-FAD0-4B1B-9802-E3882BBFC7B8	18E1FCE0-D678-48D9-AD23-432E23C9077D	TCGA-CV-7429-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7429	TCGA-HNSC	107	s15908	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	TRUE
13722.58cfa831e4b0c9d6adf6cb12	58cfa831e4b0c9d6adf6cb12	TCGA-EA-A3HS-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EA-A3HS-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_3_rg.sorted	TCGA-EA-A3HS-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_3_rg.sorted.bam	76.91	NA	0.16	58cfa831e4b0c9d6adf6cb12	TCGA-EA-A3HS-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HS-01A	753EE373-FBCF-4349-B9B2-5A41936E27E9	Primary Tumor	Illumina HiSeq	684e83c6-0894-4bfd-a2ee-6b1877c74f82	Cervix	35	0835FA38-9870-472E-B9A0-2A2652807BC5	E87CC37B-FD44-4DD9-9D14-455B89C6D4C2	TCGA-EA-A3HS-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EA-A3HS	TCGA-CESC	NA	s1522	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1b	N0	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa831e4b0c9d6adf6cbaf	58cfa831e4b0c9d6adf6cbaf	TCGA-EK-A3GN-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EK-A3GN-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_2_rg.sorted	TCGA-EK-A3GN-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_2_rg.sorted.bam	50.85	NA	0.14	58cfa831e4b0c9d6adf6cbaf	TCGA-EK-A3GN-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A3GN-01A	F727FCB9-E457-4643-9468-F739133B7E9C	Primary Tumor	Illumina HiSeq	b9e845ee-3e61-4ccf-b14e-f8a6b8481bd3	Cervix	47	EB5034E2-D4A7-48E0-9524-31DDD63C9D94	49F2E671-D283-4B5C-B8A3-490C0A383FC1	TCGA-EK-A3GN-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EK-A3GN	TCGA-CESC	NA	s1364	MD Anderson - Institute for Applied Cancer Science	Gynecologic Oncology Group	United States	NO	TX	NX	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa831e4b0c9d6adf6cbbe	58cfa831e4b0c9d6adf6cbbe	TCGA-EK-A3GM-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EK-A3GM-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_4_rg.sorted	TCGA-EK-A3GM-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_4_rg.sorted.bam	59.88	NA	0.15	58cfa831e4b0c9d6adf6cbbe	TCGA-EK-A3GM-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A3GM-01A	CB780C10-8810-4384-B829-954AAB1C16C8	Primary Tumor	Illumina HiSeq	2ec77e09-5fb7-4247-9027-1db441eab2b8	Cervix	65	A4B92B76-FF87-475E-924B-840F652FC019	4981CFD4-2A8C-4CF8-8AC2-31BDF9DC02CD	TCGA-EK-A3GM-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EK-A3GM	TCGA-CESC	NA	s1186	MD Anderson - Institute for Applied Cancer Science	Gynecologic Oncology Group	United States	NO	Not available	Not available	Endocervical Type of Adenocarcinoma	Not available	A20X-26	TRUE
13722.58cfa831e4b0c9d6adf6cbb4	58cfa831e4b0c9d6adf6cbb4	TCGA-EK-A2RN-01A-12D-A20X_140117_SN590_0246_BC37BDACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EK-A2RN-01A-12D-A20X_140117_SN590_0246_BC37BDACXX_s_2_rg.sorted	TCGA-EK-A2RN-01A-12D-A20X_140117_SN590_0246_BC37BDACXX_s_2_rg.sorted.bam	17.97	NA	0.17	58cfa831e4b0c9d6adf6cbb4	TCGA-EK-A2RN-01A-12D-A20X_140117_SN590_0246_BC37BDACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2RN-01A	B610D391-0C9D-4114-94D6-5E4AA4270122	Primary Tumor	Illumina HiSeq	def278f8-93eb-4373-a525-98b2cf12af7a	Cervix	45	24BACABF-8C6F-416A-B1F3-B0BAAA2F0AD9	3B5905A9-4B73-4946-A10B-D3E7ECAFFC7C	TCGA-EK-A2RN-01A-12D-A20X-26	HG19_Broad_variant	TCGA-EK-A2RN	TCGA-CESC	NA	s1368	MD Anderson - Institute for Applied Cancer Science	Gynecologic Oncology Group	United States	NO	T2b	N1	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa831e4b0c9d6adf6cbf1	58cfa831e4b0c9d6adf6cbf1	TCGA-EM-A3O3-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EM-A3O3-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_5_rg.sorted	TCGA-EM-A3O3-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_5_rg.sorted.bam	48.3	NA	0.16	58cfa831e4b0c9d6adf6cbf1	TCGA-EM-A3O3-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_5_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A3O3-01A	2A398AF1-AEA5-4AAE-AB00-A2DC152F965A	Primary Tumor	Illumina HiSeq	52b6fd69-3b74-441b-a40b-77c172dd0979	Thyroid	83	60C1BA59-C04E-4237-A8B9-FA0D894BBAFA	EEBDC565-A071-4356-8CBF-1560A8BB034D	TCGA-EM-A3O3-01A-11D-A221-26	HG19_Broad_variant	TCGA-EM-A3O3	TCGA-THCA	NA	s12111	MD Anderson - Institute for Applied Cancer Science	University Health Network	Canada	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	TRUE
13722.58cfa831e4b0c9d6adf6cc80	58cfa831e4b0c9d6adf6cc80	TCGA-EL-A3T6-01A-11D-A221_120523_SN1222_0108_AC0VL4ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EL-A3T6-01A-11D-A221_120523_SN1222_0108_AC0VL4ACXX_s_7_rg.sorted	TCGA-EL-A3T6-01A-11D-A221_120523_SN1222_0108_AC0VL4ACXX_s_7_rg.sorted.bam	40.31	NA	0.15	58cfa831e4b0c9d6adf6cc80	TCGA-EL-A3T6-01A-11D-A221_120523_SN1222_0108_AC0VL4ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-EL-A3T6-01A	90507BAA-B716-4BCF-A18E-9D8AE97D809A	Primary Tumor	Illumina HiSeq	fb31d05f-8a2e-416d-92b9-fd333e80561f	Thyroid	34	61367375-8317-4CAE-86CF-2FD65AB8ABC8	C1FE07E8-83AC-47A7-B8E5-FA62DE03BB17	TCGA-EL-A3T6-01A-11D-A221-26	HG19_Broad_variant	TCGA-EL-A3T6	TCGA-THCA	NA	s12518	MD Anderson - Institute for Applied Cancer Science	MD Anderson	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	TRUE
13722.58cfa831e4b0c9d6adf6cce7	58cfa831e4b0c9d6adf6cce7	TCGA-EK-A3GJ-01A-21D-A20X_140106_SN590_0243_AC371BACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EK-A3GJ-01A-21D-A20X_140106_SN590_0243_AC371BACXX_s_1_rg.sorted	TCGA-EK-A3GJ-01A-21D-A20X_140106_SN590_0243_AC371BACXX_s_1_rg.sorted.bam	68.37	NA	0.16	58cfa831e4b0c9d6adf6cce7	TCGA-EK-A3GJ-01A-21D-A20X_140106_SN590_0243_AC371BACXX_s_1_rg.sorted.bam	Alive	FEMALE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	Not available	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A3GJ-01A	DEDA68DD-E9AD-45CC-9DBB-1C5836EF6519	Primary Tumor	Illumina HiSeq	dde88a3f-8602-42a1-9b43-037c49cb3d34	Cervix	51	93AB0265-4851-4A8E-BEE3-496EA8DE56F7	1DE48F6B-49E4-4FE8-9D1B-0C7773DD7671	TCGA-EK-A3GJ-01A-21D-A20X-26	HG19_Broad_variant	TCGA-EK-A3GJ	TCGA-CESC	NA	s1192	MD Anderson - Institute for Applied Cancer Science	Gynecologic Oncology Group	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma	Not available	A20X-26	TRUE
13722.58cfa832e4b0c9d6adf6cdfc	58cfa832e4b0c9d6adf6cdfc	TCGA-FD-A3SN-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FD-A3SN-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_7_rg.sorted	TCGA-FD-A3SN-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_7_rg.sorted.bam	33.16	NA	0.15	58cfa832e4b0c9d6adf6cdfc	TCGA-FD-A3SN-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SN-01A	0FB043D3-D86B-4CD8-8C01-9E2B3E965BB0	Primary Tumor	Illumina HiSeq	2281a267-dad6-42d6-9df2-8d37a696c507	Bladder	79	127892ED-8A7A-41CB-8ABE-353E09E6D327	B0AD1373-0C51-41A3-9F8B-BDE28C67CFB8	TCGA-FD-A3SN-01A-12D-A233-26	HG19_Broad_variant	TCGA-FD-A3SN	TCGA-BLCA	NA	s2719	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	TRUE
13722.58cfa832e4b0c9d6adf6ce63	58cfa832e4b0c9d6adf6ce63	TCGA-GV-A3QH-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_5_rg.sorted.filtered.	WGS	TCGA-GV-A3QH-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_5_rg.sorted	TCGA-GV-A3QH-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_5_rg.sorted.bam	38.38	NA	0.14	58cfa832e4b0c9d6adf6ce63	TCGA-GV-A3QH-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3QH-01A	33BC6A7C-9844-41E3-96B3-1E34BB3FEDD5	Primary Tumor	Illumina HiSeq	5672aee8-638c-45c6-af4f-0ccc5e2a1b45	Bladder	67	DEB7311F-E747-44EC-92C3-1E56CD5CACF2	B14D2F40-53F3-4A3A-8FA8-1BE7F102CA25	TCGA-GV-A3QH-01A-11D-A221-26	HG19_Broad_variant	TCGA-GV-A3QH	TCGA-BLCA	NA	s3129	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	Not available	NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6ce8b	58cfa832e4b0c9d6adf6ce8b	TCGA-FY-A3RA-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FY-A3RA-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_6_rg.sorted	TCGA-FY-A3RA-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_6_rg.sorted.bam	38.77	NA	0.17	58cfa832e4b0c9d6adf6ce8b	TCGA-FY-A3RA-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3RA-01A	58FF4366-20A3-40A2-A87A-551E17CDB5D3	Primary Tumor	Illumina HiSeq	a7a005ec-f27f-4c17-8bb6-879c800bb0ae	Thyroid	21	E67E2BBE-8C3F-41B1-BE3C-C89555A10AEE	40CA310C-DB41-44D5-A76C-72938CF4AED0	TCGA-FY-A3RA-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3RA	TCGA-THCA	NA	s12651	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6ce99	58cfa832e4b0c9d6adf6ce99	TCGA-FY-A3R8-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FY-A3R8-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_3_rg.sorted	TCGA-FY-A3R8-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_3_rg.sorted.bam	51.96	NA	0.15	58cfa832e4b0c9d6adf6ce99	TCGA-FY-A3R8-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3R8-01A	C77976B6-35EA-4623-A92A-6D9440A978E6	Primary Tumor	Illumina HiSeq	7d0e9d6d-fb33-481e-93f7-84ae9641ce75	Thyroid	62	BAA64E5A-237E-44AC-8B22-2D86E710F7DB	3D9D0EC4-8C81-40D9-886F-8813570E732D	TCGA-FY-A3R8-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3R8	TCGA-THCA	NA	s12392	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6cee4	58cfa832e4b0c9d6adf6cee4	TCGA-EM-A3O8-01A-11D-A221_120530_SN1222_0111_BD12L1ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EM-A3O8-01A-11D-A221_120530_SN1222_0111_BD12L1ACXX_s_2_rg.sorted	TCGA-EM-A3O8-01A-11D-A221_120530_SN1222_0111_BD12L1ACXX_s_2_rg.sorted.bam	55.95	NA	0.15	58cfa832e4b0c9d6adf6cee4	TCGA-EM-A3O8-01A-11D-A221_120530_SN1222_0111_BD12L1ACXX_s_2_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Thyroid Carcinoma	Aligned reads	TCGA-EM-A3O8-01A	97B5017C-2066-4472-AB3F-31CFE64A6762	Primary Tumor	Illumina HiSeq	63701f3e-e258-497f-a7b6-1dddce3369f2	Thyroid	33	7F540311-430C-46B2-98C8-F314B27ECB0E	F125CCA1-271D-4716-9746-9AB9DD2A1C43	TCGA-EM-A3O8-01A-11D-A221-26	HG19_Broad_variant	TCGA-EM-A3O8	TCGA-THCA	NA	s12252	MD Anderson - Institute for Applied Cancer Science	University Health Network	Canada	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6cf9f	58cfa832e4b0c9d6adf6cf9f	TCGA-H2-A3RH-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-H2-A3RH-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_2_rg.sorted	TCGA-H2-A3RH-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_2_rg.sorted.bam	62.17	NA	0.15	58cfa832e4b0c9d6adf6cf9f	TCGA-H2-A3RH-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-H2-A3RH-01A	0314B145-2F3A-4A90-A580-375B5F0A63A4	Primary Tumor	Illumina HiSeq	dddfb702-cb09-4a5f-b023-b31d89ec07a8	Thyroid	41	1A9E811D-1C60-409C-A7D2-1D58AFA473E9	8358E269-BD6E-4189-86AB-520C84405DAA	TCGA-H2-A3RH-01A-11D-A221-26	HG19_Broad_variant	TCGA-H2-A3RH	TCGA-THCA	NA	s12532	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6d024	58cfa832e4b0c9d6adf6d024	TCGA-GC-A3BM-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_3_rg.sorted.filtered.	WGS	TCGA-GC-A3BM-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_3_rg.sorted	TCGA-GC-A3BM-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_3_rg.sorted.bam	51.48	NA	0.15	58cfa832e4b0c9d6adf6d024	TCGA-GC-A3BM-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3BM-01A	7840AEA9-40C4-473E-BE33-8FA0B9F332C9	Primary Tumor	Illumina HiSeq	1901f2a9-837a-482c-8073-472f3c4d9ba1	Bladder	70	5C631CE8-F96A-4C35-A459-556FC4AB21E1	5FE3FF9D-CCF4-4C76-820D-26FD5D1FCD15	TCGA-GC-A3BM-01A-11D-A23Q-26	HG19_Broad_variant	TCGA-GC-A3BM	TCGA-BLCA	NA	s2924	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A23Q-26	TRUE
13722.58cfa832e4b0c9d6adf6d042	58cfa832e4b0c9d6adf6d042	TCGA-FU-A3EO-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FU-A3EO-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_1_rg.sorted	TCGA-FU-A3EO-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_1_rg.sorted.bam	43.71	NA	0.16	58cfa832e4b0c9d6adf6d042	TCGA-FU-A3EO-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3EO-01A	B7F2958F-256E-4C30-9C61-11E76DDB36BA	Primary Tumor	Illumina HiSeq	31874bb0-fa47-43d4-8135-1be05e8163eb	Cervix	55	59F1684E-5631-4E1E-A1DC-91739F7C159C	50DBFC58-57DC-4878-8506-7B6B21899DF5	TCGA-FU-A3EO-01A-11D-A20X-26	HG19_Broad_variant	TCGA-FU-A3EO	TCGA-CESC	NA	s1201	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2b	N0	Endocervical Type of Adenocarcinoma	Not available	A20X-26	TRUE
13722.58cfa832e4b0c9d6adf6d026	58cfa832e4b0c9d6adf6d026	TCGA-GD-A3OQ-01A-32D-A221_120902_SN1222_0147_AC195DACXX_s_4_rg.sorted.filtered.	WGS	TCGA-GD-A3OQ-01A-32D-A221_120902_SN1222_0147_AC195DACXX_s_4_rg.sorted	TCGA-GD-A3OQ-01A-32D-A221_120902_SN1222_0147_AC195DACXX_s_4_rg.sorted.bam	40.42	NA	0.15	58cfa832e4b0c9d6adf6d026	TCGA-GD-A3OQ-01A-32D-A221_120902_SN1222_0147_AC195DACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GD-A3OQ-01A	2E85C30C-C4C4-4096-9EEF-4EB2C7D991A3	Primary Tumor	Illumina HiSeq	a07d0456-032d-409c-af8d-c4d6349ef4db	Bladder	48	E3D22638-C0AE-48AA-A523-8C9A6CFBF063	F77305E9-430E-4E7D-97A6-C97FFDDC3B65	TCGA-GD-A3OQ-01A-32D-A221-26	HG19_Broad_variant	TCGA-GD-A3OQ	TCGA-BLCA	NA	s2923	MD Anderson - Institute for Applied Cancer Science	ABS - IUPUI	United States	NO	T4a	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6d132	58cfa832e4b0c9d6adf6d132	TCGA-FY-A3R6-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FY-A3R6-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_1_rg.sorted	TCGA-FY-A3R6-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_1_rg.sorted.bam	10.85	NA	0.16	58cfa832e4b0c9d6adf6d132	TCGA-FY-A3R6-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3R6-01A	905469D2-4C97-4293-A20C-1B1F0462A25D	Primary Tumor	Illumina HiSeq	bd320251-720a-4498-a699-419a2544fe75	Thyroid	57	65414BA0-8800-4626-9488-10D79274CF32	EFF7FEA8-DF07-4DAD-BD26-7384906844E9	TCGA-FY-A3R6-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3R6	TCGA-THCA	NA	s12258	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6d191	58cfa832e4b0c9d6adf6d191	TCGA-FE-A3PC-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FE-A3PC-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_2_rg.sorted	TCGA-FE-A3PC-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_2_rg.sorted.bam	48.5	NA	0.15	58cfa832e4b0c9d6adf6d191	TCGA-FE-A3PC-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A3PC-01A	A86AC3B5-B5E9-4420-8DE0-A358FCAD85B6	Primary Tumor	Illumina HiSeq	7072b927-397f-4821-a834-0b1e21ec3434	Thyroid	37	7A5628FF-C5C2-4F25-809B-640415323477	8B0BF4B5-9846-473B-A2DB-8390B0DB90A7	TCGA-FE-A3PC-01A-11D-A221-26	HG19_Broad_variant	TCGA-FE-A3PC	TCGA-THCA	NA	s12647	MD Anderson - Institute for Applied Cancer Science	Ohio State University	United States	NO	T3	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	TRUE
13722.58cfa832e4b0c9d6adf6d3e3	58cfa832e4b0c9d6adf6d3e3	TCGA-V4-A9EL-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_1_rg.sorted.filtered.	WGS	TCGA-V4-A9EL-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_1_rg.sorted	TCGA-V4-A9EL-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_1_rg.sorted.bam	36.66	NA	0.17	58cfa832e4b0c9d6adf6d3e3	TCGA-V4-A9EL-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EL-01A	8DE236F1-C029-44DF-A2A9-319145488BAA	Primary Tumor	Illumina HiSeq	37f105ff-ac0b-4651-9c5f-008d937dc883	Eye	60	DB91E719-82B1-4E9A-AB28-AC67B726340B	50022AEA-CB52-4402-9FC2-C8A4EC1600FF	TCGA-V4-A9EL-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EL	TCGA-UVM	NA	s199	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d49c	58cfa832e4b0c9d6adf6d49c	TCGA-V4-A9F4-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9F4-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_4_rg.sorted	TCGA-V4-A9F4-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_4_rg.sorted.bam	55.04	NA	0.16	58cfa832e4b0c9d6adf6d49c	TCGA-V4-A9F4-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F4-01A	4B9FD822-17AA-4A22-8E17-175A72931D5D	Primary Tumor	Illumina HiSeq	1f82d81a-7827-4bb8-89b2-fc4bd009cdde	Eye	41	AD550F5E-1469-4A09-9CDA-3F069B1AE258	1837571E-8D54-4BA2-A9FB-B7160BFD38BB	TCGA-V4-A9F4-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F4	TCGA-UVM	NA	s236	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d412	58cfa832e4b0c9d6adf6d412	TCGA-V4-A9EX-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_1_rg.sorted.filtered.	WGS	TCGA-V4-A9EX-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_1_rg.sorted	TCGA-V4-A9EX-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_1_rg.sorted.bam	48.32	NA	0.15	58cfa832e4b0c9d6adf6d412	TCGA-V4-A9EX-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EX-01A	892E7630-B11E-47BD-987C-327D33258E11	Primary Tumor	Illumina HiSeq	9f56ee51-fd1c-43d8-9e64-faacd67069e0	Eye	55	69F3ECE7-394D-4FA7-93E7-B6DCD538831A	9A4969D9-222E-4BA3-B0F4-34F42C0D1A19	TCGA-V4-A9EX-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EX	TCGA-UVM	730	s210	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4e5	58cfa832e4b0c9d6adf6d4e5	TCGA-V4-A9F1-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-V4-A9F1-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_1_rg.sorted	TCGA-V4-A9F1-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_1_rg.sorted.bam	51.84	NA	0.17	58cfa832e4b0c9d6adf6d4e5	TCGA-V4-A9F1-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F1-01A	94F3D9B0-0EE4-4F6A-A8FF-CE7A4D8FAB76	Primary Tumor	Illumina HiSeq	83f97de6-ac60-4cc0-bcff-bdecfe40f951	Eye	46	6C6A3062-B453-434B-9168-7837CAABC4EF	706721D2-3759-4664-BFB7-8FF7273C2786	TCGA-V4-A9F1-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F1	TCGA-UVM	NA	s226	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4cc	58cfa832e4b0c9d6adf6d4cc	TCGA-VD-A8KL-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-VD-A8KL-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_7_rg.sorted	TCGA-VD-A8KL-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_7_rg.sorted.bam	30.16	NA	0.15	58cfa832e4b0c9d6adf6d4cc	TCGA-VD-A8KL-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_7_rg.sorted.bam	Alive	FEMALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-A8KL-01A	A9F956A0-660F-4185-A843-D9911D2484DE	Primary Tumor	Illumina HiSeq	e7c1dbaa-f0ee-479a-b2ad-cbbb8555e36e	Eye	77	86E0C8DD-546C-4B53-A56B-2C985E58CE68	4D1068DC-E769-4374-B895-4430A9B03322	TCGA-VD-A8KL-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KL	TCGA-UVM	NA	s263	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T3a	NX	Not available	Stage IIB	A40D-26	TRUE
13722.58cfa832e4b0c9d6adf6d4ba	58cfa832e4b0c9d6adf6d4ba	TCGA-VD-A8K7-01B-11D-A40D_140716_SN208_0519_BC5946ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-VD-A8K7-01B-11D-A40D_140716_SN208_0519_BC5946ACXX_s_4_rg.sorted	TCGA-VD-A8K7-01B-11D-A40D_140716_SN208_0519_BC5946ACXX_s_4_rg.sorted.bam	27.7	NA	0.16	58cfa832e4b0c9d6adf6d4ba	TCGA-VD-A8K7-01B-11D-A40D_140716_SN208_0519_BC5946ACXX_s_4_rg.sorted.bam	Alive	MALE	Not available	Not available	Uveal Melanoma	Aligned reads	TCGA-VD-A8K7-01B	6103E640-8B62-4E39-908B-B62A0DEBEB0E	Primary Tumor	Illumina HiSeq	649c4e6f-5b69-4d14-b5cc-99938c78d650	Eye	39	1B626599-EC44-409D-8123-ED69D8442C19	4208E47B-01BB-4C91-9411-F214F46F656C	TCGA-VD-A8K7-01B-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8K7	TCGA-UVM	NA	s260	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T4a	NX	Not available	Stage IIIA	A40D-26	TRUE
13722.58cfa831e4b0c9d6adf6ca5a	58cfa831e4b0c9d6adf6ca5a	TCGA-DK-A3IN-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A3IN-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_1_rg.sorted	TCGA-DK-A3IN-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_1_rg.sorted.bam	36.12	NA	0.15	58cfa831e4b0c9d6adf6ca5a	TCGA-DK-A3IN-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IN-01A	FC0032DB-B6D8-4DA3-BD1B-BEEC4196ABF0	Primary Tumor	Illumina HiSeq	ff3d1235-2aed-4091-a8a2-72340b403e05	Bladder	72	F8C14183-3982-44E5-967E-03967EAA8123	11901B8B-BE4C-4914-8D50-06EA0128EB39	TCGA-DK-A3IN-01A-11D-A210-26	HG19_Broad_variant	TCGA-DK-A3IN	TCGA-BLCA	250	s2890	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	TRUE
13722.58cfa832e4b0c9d6adf6d0cc	58cfa832e4b0c9d6adf6d0cc	TCGA-IG-A3QL-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-IG-A3QL-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_7_rg.sorted	TCGA-IG-A3QL-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_7_rg.sorted.bam	27.52	NA	0.15	58cfa832e4b0c9d6adf6d0cc	TCGA-IG-A3QL-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3QL-01A	0AC08ECF-4D70-48A4-9DFD-F44032551CB9	Primary Tumor	Illumina HiSeq	da10bdbe-12f7-41ed-b836-1689589d7ba2	Esophagus	54	D571A2B3-892B-46C4-883C-FDED4980492F	A48A75A1-B82B-4F4A-A04F-DFF6B1E801F1	TCGA-IG-A3QL-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3QL	TCGA-ESCA	NA	s1824	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T2	N0	Not available	Stage IIA	A248-26	TRUE
